SVM-light Version V5.01-TK-1.5
5 # kernel type
3 # kernel parameter -d 
1 # kernel parameter -g 
1 # kernel parameter -s 
1 # kernel parameter -r 
empty# kernel parameter -u 
0.4 # kernel parameter -L 
1 # kernel parameter -T 
S # kernel parameter -C 
1 # kernel parameter -F 
0 # kernel parameter -S 
0.400000 # kernel parameter -M 
3 # kernel parameter -N 
S # kernel parameter -V 
S # kernel parameter -W 
0 # kernel parameter -U 
5750 # highest feature index 
1647 # number of training documents 
371 # number of support vectors plus 1 
1.0004745 # threshold b, each following line is a SV (starting with alpha*y)
-0.00018108512185661083948584604286225  |BT| (FRAG (PP (IN (In))(NP (NN (LNCaP))(NN (cell))))(, (,))(NP (NP (JJ (caspase-mediated))(NN (apoptosis))(NN (induction))(NN (PGG)))(SBAR (S (NP (VBN (associated))(JJ (mediated))(JJ (major))(NN (part))(NN (activation))(NN (p53)))(VP (VBD (established))(NP (JJ (small))(VBG (interfering))(NN (RNA))(NN (knockdown))(JJ (dominant-negative))(JJ (mutant))(NN (approach)))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 41:A11 117:D13.150.650.700 133:D01.248.497.158.685.750.744.600 1367:D08.811.277.656.262.500.126  |ES| 2:1 12:1 19:1 89:1 94:1 169:1 225:1 244:1 413:1 437:1 451:1 462:1 464:1 515:1 736:1 750:1 811:1 911:1 2115:1 2660:1 3019:1 4904:1 4905:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (ADVP (RB (Intriguingly)))(, (,))(NP (NN (ZKSCAN3))(NN (protein)))(ADVP (RB (also)))(VP (VBD (expressed))(NP (NP (NP (NN (tumor))(JJ (wild-type))(NN (gene)))(PRN (-LRB- (-LRB-))(NP (NP (NN (APC)))(, (,))(NP (NN (p53)))(, (,))(NP (NN (K-Ras))))(-RRB- (-RRB-))))(RRC (ADVP (RB (commonly)))(NP (VBN (targeted))(NP (JJ (colorectal))(NN (cancer)))))))) |ET|  |BS| 1:G05.360.340.024.340.375.500.791.550 2:G05.360.340.024.340.375.249.385 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 7:D12.776 8:C04  |ES| 1:1 2:1 3:1 4:1 5:1 6:1 7:1 8:1 9:1 10:1 11:1 12:1 13:1 14:1 15:1 16:1 17:1 18:1 19:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NNS (CONCLUSIONS))(: (:)))(PP (IN (In))(NP (JJ (human))(NN (CRC))(NN (cell))))(, (,))(NP (NN (miR-221))(NN (miR-222)))(VP (VBP (act))(NP (JJ (positive))(NN (feedback))(NN (loop))(NN (increase))(NN (expression))(NN (level))(NN (RelA))(NN (STAT3))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 55:B01.050.150.900.649.801.400.112.400.400 81:E02.095.465.425.400.330.050.400 82:D12.644.360.024.342.300 83:L01.143.283.425  |ES| 2:1 19:1 36:1 40:1 94:1 104:1 115:1 140:1 141:1 233:1 239:1 244:1 245:1 246:1 247:1 248:1 249:1 250:1 251:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (PURPOSE))(: (:)))(NP (DT (The))(NN (MYC))(NN (oncogene)))(ADVP (RB (frequently)))(VP (VBN (overexpressed))(NP (NN (prostate))(NN (cancer))))) |ET| 18:1 19:1 24:1 25:1 77:1 104:1 472:1 687:1 691:1 698:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (JJ (Elevated))(NN (expression))(JJ (coactivator-associated))(NN (arginine))(NN (methyltransferase))(CD (1)))(VP (VBN (associated))(NP (JJ (early))(NN (hepatocarcinogenesis))))) |ET| 19:1 98:1 115:1 169:1 900:1 1128:1 1350:1 2655:1 3464:1 3465:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (SPDEF)))(VP (VP (VBD (inhibited))(NP (NN (expression))(JJ (beta-catenin-target))(NN (gene))(NN (mouse))(NN (colon))(NN (tumor))))(, (,))(VP (VBD (interacted))(NP (NP (NN (beta-catenin))(NN (block))(JJ (transcriptional))(NN (activity)))(NP (NN (CRC))(NN (cell))(NN (line))))(, (,))(S (VP (VBG (resulting))(NP (JJR (lower))(NN (level))(NN (cyclin))(NN (D1))(NN (c-MYC)))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 51:C04.588.274.476.411.307.180 94:A11.251.210 122:C14.280.383 155:G05.355.310 209:G02.111.087.847 215:D12.644.360.262.150.100  |ES| 2:1 7:1 9:1 19:1 52:1 60:1 94:1 113:1 115:1 117:1 245:1 249:1 264:1 365:1 384:1 399:1 559:1 625:1 739:1 740:1 741:1 742:1 743:1 744:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (DT (The))(NN (effect))(NN (folate))(NN (transporter))(NN (gene))(NN (ablation))(NN (colon))(NN (carcinogenesis)))(VP (VBD (evaluated))(NP (NP (CD (8))(CD (38))(NN (week)))(JJ (post-azoxymethane))(NN (injection))(JJ (wild-type))(JJ (heterozygous))(NN (mouse))))) |ET|  |BS| 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 157:G05.380.383 224:D03.438.733.631.400 225:E05.337 226:E02.319.267.530 227:D12.776.157.530  |ES| 8:1 9:1 19:1 52:1 75:1 91:1 113:1 207:1 691:1 778:1 779:1 780:1 781:1 782:1 783:1 784:1 785:1 786:1  |EV| 
-0.00030302255390179336919098673774897  |BT| (S (NP (NNS (CONCLUSIONS)))(: (:))(S (NP (DT (This))(NN (study)))(VP (VBZ (demonstrates))(NP (JJ (synergistic))(NN (antitumor))(NN (activity))(NN (combination))(NN (dovitinib))(NN (oxaliplatin))(NN (colon))(NN (cancer))(JJ (different))(NN (RAS-RAF))(NN (status)))))) |ET|  |BS| 1:G05.360.340.024.340.375.500.791.550  |ES| 18:1 19:1 104:1 113:1 131:1 239:1 399:1 414:1 416:1 530:1 807:1 2012:1 2244:1 2541:1 2542:1 2543:1 2544:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (ADVP (RB (Furthermore)))(, (,))(NP (NN (Cdx2)))(VP (VBD (decreased))(S (VP (VBG (knocking))(NP (NN (HNF4alpha))(JJ (human))(NN (colon))(NN (cancer))(NN (cell)))(S (VP (VBG (using))(NP (NN (siRNA))(NN (colon))(NN (mouse))))))))(S (ADVP (RB (conditionally)))(VP (VBD (knocked))(NP (NN (Hnf4alpha))(NN (gene))(JJ (adult))(NN (intestine)))(PRN (-LRB- (-LRB-))(NP (NP (NP (NN (Hnf4alpha)))(PRN (-LRB- (-LRB-))(NP (NN (f/f)))(-RRB- (-RRB-))))(: (;))(NP (NNP (VilCre))(-LRB- (-LRB-))(NN (ERT2))(-RRB- (-RRB-))(NN (mouse))))(-RRB- (-RRB-)))))) |ET|  |BS| 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 41:A11 46:A03.556.124.526.356 47:A03.556.124 55:B01.050.150.900.649.801.400.112.400.400 116:D08.811.913.696.620.682.700.567.249.750 117:D13.150.650.700 118:D01.248.497.158.380 119:M01.060.116  |ES| 2:1 9:1 10:1 14:1 18:1 19:1 36:1 52:1 94:1 113:1 123:1 202:1 213:1 217:1 334:1 349:1 350:1 351:1 352:1 353:1 354:1 355:1 356:1 357:1 358:1 359:1  |EV| 
-7.3157230365281664466459154994027e-05  |BT| (S (NP (NP (ADVP (RB (Surprisingly)))(, (,))(VBN (given))(VBN (proposed))(NN (role))(NN (loss))(NN (function))(NN (mutation))(NN (p53))(NN (gene))(NN (development)))(NP (JJ (human))(JJ (colorectal))(NN (cancer)))(, (,)))(VP (VBD (found))(NP (NP (NN (evidence)))(PP (CC (either))(NP (NP (NN (increase))(NN (rate))(NN (adenoma))(NN (formation))(NN (APC)))(CC (+))(: (/))(: (-))(, (,))(NP (NN (p53))(: (-)))(: (/))(FRAG (: (-))(NP (NP (NN (animal)))(, (,))(NP (NP (VBD (increased))(NN (rate))(NN (progression))(NN (malignancy)))(VP (VBN (compared))(NP (NP (NN (APC)))(NP (CC (+))(: (/))(: (-))(NN (p53))(CC (+))(FRAG (: (/))(CC (+))(NP (NN (mouse))))))))))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 13:D01.339.387 14:F01.525 15:F01.829.316.616 16:C23.550.291.656 17:C04.557.470.035 18:G05.365.590 19:B01.050 20:G03.495  |ES| 2:1 9:1 11:1 12:1 17:1 18:1 19:1 28:1 29:1 30:1 31:1 32:1 33:1 34:1 35:1 36:1 37:1 38:1 39:1 40:1 41:1 42:1 43:1 44:1 45:1 46:1 47:1 48:1 49:1 50:1 51:1 52:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NP (ADVP (RB (Surprisingly)))(, (,))(VBN (given))(VBN (proposed))(NN (role))(NN (loss))(NN (function))(NN (mutation))(NN (p53))(NN (gene))(NN (development)))(NP (JJ (human))(JJ (colorectal))(NN (cancer)))(, (,)))(VP (VBD (found))(NP (NP (NN (evidence)))(PP (CC (either))(NP (NP (NN (increase))(NN (rate))(NN (adenoma))(NN (formation))(NN (APC)))(CC (+))(: (/))(: (-))(, (,))(NP (NN (p53))(: (-)))(: (/))(FRAG (: (-))(NP (NP (NN (animal)))(, (,))(NP (NP (VBD (increased))(NN (rate))(NN (progression))(NN (malignancy)))(VP (VBN (compared))(NP (NP (NN (APC)))(NP (CC (+))(: (/))(: (-))(NN (p53))(CC (+))(FRAG (: (/))(CC (+))(NP (NN (mouse))))))))))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 13:D01.339.387 14:F01.525 15:F01.829.316.616 16:C23.550.291.656 17:C04.557.470.035 18:G05.365.590 19:B01.050 20:G03.495  |ES| 2:1 9:1 11:1 12:1 17:1 18:1 19:1 28:1 29:1 30:1 31:1 32:1 33:1 34:1 35:1 36:1 37:1 38:1 39:1 40:1 41:1 42:1 43:1 44:1 45:1 46:1 47:1 48:1 49:1 50:1 51:1 52:1  |EV| 
-0.0002630569695981277086871408243951  |BT| (S (NP (DT (The))(NN (effect))(NN (folate))(NN (transporter))(NN (gene))(NN (ablation))(NN (colon))(NN (carcinogenesis)))(VP (VBD (evaluated))(NP (NP (CD (8))(CD (38))(NN (week)))(JJ (post-azoxymethane))(NN (injection))(JJ (wild-type))(JJ (heterozygous))(NN (mouse))))) |ET|  |BS| 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 157:G05.380.383 224:D03.438.733.631.400 225:E05.337 226:E02.319.267.530 227:D12.776.157.530  |ES| 8:1 9:1 19:1 52:1 75:1 91:1 113:1 207:1 691:1 778:1 779:1 780:1 781:1 782:1 783:1 784:1 785:1 786:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (NP (NN (Cyclooxygenase-2)))(PRN (-LRB- (-LRB-))(NP (NN (COX-2)))(-RRB- (-RRB-))))(ADVP (RB (constitutively)))(VP (VBD (expressed))(NP (NP (NN (variety))(NN (tumor)))(PP (VBG (including))(NP (JJ (colorectal))(NN (cancer))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 24:D08.811.600.720.750  |ES| 6:1 7:1 10:1 14:1 17:1 18:1 19:1 76:1 196:1 561:1 952:1 1158:1  |EV| 
-0.00028371100423812967150638542079832  |BT| (S (NP (PRP (We)))(VP (VBD (observed))(NP (NP (JJ (similar))(NN (result))(JJ (cellular))(NN (model)))(JJ (hepatocellular))(NN (colon))(NN (cancer)))(, (,))(S (VP (VBG (indicating))(S (NP (JJ (doxorubicin-sensitizing))(NN (effect))(NN (miR-137))(NN (tumor)))(ADJP (JJ (type-specific)))))))) |ET|  |BS| 8:C04 41:A11 136:D02.455.426.559.847.562.050.200.175  |ES| 2:1 7:1 18:1 19:1 72:1 75:1 101:1 113:1 261:1 303:1 332:1 420:1 843:1 2236:1 3074:1 5749:1 5750:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (DT (This))(NN (study)))(VP (VBZ (provides))(SBAR (S (NP (NP (JJ (first))(JJ (quantitative))(NN (analysis))(JJ (discrete))(NN (CRKI))(NN (CRKII))(NN (protein))(NNS (isoforms)))(SBAR (S (NP (JJ (human))(NN (lung))(NN (tumor)))(VP (VBZ (provides))(NP (NN (evidence))(NN (C-CRK))(NN (proto-oncogene)))))))(VP (MD (may))(VP (VB (foment))(NP (JJ (aggressive))(NN (phenotype))(NN (lung))(NN (cancer))))))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400 80:G05.695 162:F01.145.126.125 235:G05.360.340.024.340.375.500.791 236:D12.644.360.024.318 237:C04.588.894.797.520 238:D12.776.800  |ES| 4:1 7:1 18:1 19:1 36:1 38:1 131:1 236:1 328:1 491:1 538:1 563:1 661:1 807:1 815:1 816:1 817:1 818:1 819:1 820:1 821:1 822:1 823:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NNS (Tumors)))(VP (VBD (graded))(NP (NP (NN (histology))(JJ (immunostained))(NN (p53)))(, (,))(NP (JJ (adenomatous))(NN (polyposis))(NN (coli)))(, (,))(NP (NN (beta-catenin)))(, (,))(NP (NP (NP (NN (cyclooxygenase-2))(-LRB- (-LRB-))(NN (Cox-2))(-RRB- (-RRB-))(JJ (inducible))(JJ (nitric))(NN (oxide))(NN (synthase)))(PRN (-LRB- (-LRB-))(NP (NN (iNOS)))(-RRB- (-RRB-))))(VBN (sequenced))(NN (p53))(NN (mutation)))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 3:C04.557.470.035.215.100 8:C04 18:G05.365.590 21:G05.360.340.024.340.375.249.050 22:D08.811.682.664.500.772.500 23:D12.776.091.249 24:D08.811.600.720.750 25:G02.111.570.080 26:G02.111.570.080 27:G02.111.570.080 28:H01.158.100.656  |ES| 2:1 10:1 12:1 14:1 19:1 34:1 53:1 54:1 55:1 56:1 57:1 58:1 59:1 60:1 61:1 62:1 63:1 64:1 65:1 66:1 67:1 68:1  |EV| 
0.00041788035725208173528158472898042  |BT| (FRAG (PP (TO (To))(NP (VB (investigate))(NP (NP (NN (role))(NN (KCNQ1))(JJ (human))(JJ (colorectal))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (CRC)))(-RRB- (-RRB-))))(, (,))(NP (NP (VBN (measured))(NN (protein))(NN (level))(NN (KCNQ1))(NN (immunohistochemistry))(NN (tissue))(NNS (microarrays)))(VP (VBG (containing))(NP (NP (NN (sample))(NN (CRC))(NN (patient))(NN (liver))(NN (metastasis)))(VP (VBN (undergone))(NP (JJ (hepatic))(NN (resection)))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 38:Z01.058.290.120.180 40:Z01.542.248.700 50:M01.643 55:B01.050.150.900.649.801.400.112.400.400 98:A10 113:C04.697.650 143:E01.370.225.500.607.512 228:E05.978 241:D12.776.157.530.400.600.900.124.249.500 242:A03.620  |ES| 2:1 4:1 10:1 14:1 17:1 18:1 19:1 31:1 36:1 120:1 128:1 245:1 249:1 272:1 286:1 459:1 789:1 791:1 806:1 828:1 833:1 834:1 835:1 836:1 837:1 838:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (DT (This))(NN (study)))(VP (VBP (show))(SBAR (S (NP (NN (c-Myc))(JJ (critical))(JJ (Apc-dependent))(JJ (intestinal))(NN (tumorigenesis))(NN (mouse)))(VP (VBZ (provides))(NP (JJ (potential))(JJ (therapeutic))(NN (target))(NN (treatment))(JJ (colorectal))(NN (cancer)))))))) |ET|  |BS| 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 47:A03.556.124 52:E02  |ES| 17:1 18:1 19:1 52:1 78:1 109:1 131:1 160:1 429:1 541:1 546:1 807:1 815:1 824:1 825:1 826:1 827:1  |EV| 
-0.00030166342045082755740637026065087  |BT| (S (SBAR (IN (Although))(S (NP (NP (NN (therapy)))(VP (VBG (targeting))(NP (JJ (high))(NN (EphA1))(NN (expression)))))(VP (VBP (seem))(NP (JJ (plausible))(NN (CRC))))))(, (,))(S (NP (NN (loss))(NN (expression)))(VP (VBD (advanced))(NP (NN (disease)))))(VP (VBZ (suggests))(SBAR (S (NP (NP (NP (JJ (potential))(NN (risk)))(VBN (targeted))(NN (therapy)))(, (,))(VP (VBG (selecting))(NP (NN (loss))(NN (expression))))(, (,)))(VP (MD (might))(VP (VB (contribute))(NP (NN (disease))(NN (progression))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 16:C23.550.291.656 38:Z01.058.290.120.180 40:Z01.542.248.700 52:E02 61:E05.318.740.600.800 288:C23.550.288  |ES| 2:1 16:1 19:1 32:1 48:1 107:1 115:1 130:1 171:1 178:1 245:1 331:1 450:1 616:1 798:1 827:1 994:1 995:1 996:1 997:1 998:1 999:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (PP (IN (As))(NP (JJ (key))(NN (molecule))(NN (drive))(NN (progression))(NN (chemoresistance))(JJ (gastrointestinal))(NN (cancer))))(, (,))(NP (NP (NP (JJ (epidermal))(NN (growth))(NN (factor))(NN (receptor)))(PRN (-LRB- (-LRB-))(NP (NN (EGFR)))(-RRB- (-RRB-))))(NN (HER2)))(VP (VBP (become))(NP (JJ (efficacious))(NN (drug))(NN (target))(NN (setting))))) |ET|  |BS| 16:C23.550.291.656 63:G05.360.340.024.340.375.500.791.295.305 64:D08.811.913.696.620.682.725.400.009.300 65:D08.811.913.696.620.682.725.400.009.400 66:F01.658.293 67:D26  |ES| 2:1 10:1 14:1 18:1 19:1 48:1 102:1 159:1 160:1 168:1 180:1 181:1 182:1 183:1 184:1 185:1 186:1 187:1 188:1 189:1 190:1 191:1 192:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (NP (NP (NNS (Mutations)))(NP (NP (NP (JJ (human))(NN (DNA))(NN (mismatch))(NN (repair)))(PRN (-LRB- (-LRB-))(NP (NN (MMR)))(-RRB- (-RRB-))))(NP (NP (NP (NN (gene))(NN (MLH1))(VBN (associated))(JJ (hereditary))(JJ (nonpolyposis))(JJ (colorectal))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NP (NNP (Lynch))(NN (syndrome)))(, (,))(NP (NN (HNPCC))))(-RRB- (-RRB-))))(NP (JJ (significant))(NN (proportion))(JJ (sporadic))(JJ (colorectal))(NN (cancer)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 174:G02.111.087.219.220 524:C04.588.274.476.411.307.190  |ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 36:1 135:1 169:1 513:1 584:1 666:1 723:1 725:1 1294:1 1410:1 1845:1 1846:1 1940:1 2134:1 2135:1 2136:1  |EV| 
-4.4127191695615198326757555591371e-06  |BT| (S (NP (NN (Curcumin)))(VP (VBZ (sensitizes))(NP (NP (JJ (human))(JJ (colorectal))(NN (cancer))(NN (xenograft))(JJ (nude))(NN (mouse))(NN (gamma-radiation)))(VP (VBG (targeting))(NP (JJ (nuclear))(JJ (factor-kappaB-regulated))(NN (gene))(NN (product))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 816:G01.358.500.505.300 973:E05.393.335  |ES| 9:1 17:1 18:1 19:1 36:1 52:1 265:1 266:1 616:1 675:1 1256:1 2062:1 3429:1 3430:1 3431:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (Downregulation))(NN (miR-610)))(VP (VBZ (promotes))(SBAR (S (NP (NN (proliferation))(NN (tumorigenicity)))(VP (VBZ (activates))(NP (NN (Wnt/beta-catenin))(NN (signaling))(JJ (human))(JJ (hepatocellular))(NN (carcinoma)))))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 104:C04.557.470.200.025.255 105:G02.149.115.800.925  |ES| 19:1 36:1 195:1 296:1 297:1 298:1 299:1 300:1 301:1 302:1 303:1 304:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (DT (These)))(VP (VBP (result))(VP (VBP (suggest))(NP (S (NP (NN (K-sam))(NN (overexpression)))(VP (VBN (associated))(NP (JJ (malignant))(NN (phenotype))(JJ (undifferentiated))(NN (type))(NN (stomach))(NN (cancer)))))(, (,))(NP (JJ (infiltrative))(NN (growth))(NN (metastasis))))))) |ET|  |BS| 45:G07.700.320.249 80:G05.695 113:C04.697.650 231:C04.557.465.625.600.380.590 232:D02.886.030.676.180  |ES| 2:1 18:1 19:1 101:1 102:1 152:1 169:1 236:1 543:1 792:1 796:1 801:1 802:1 803:1 804:1 805:1 806:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NN (Expression))(JJ (gut-enriched))(JJ (Kruppel-like))(NN (factor)))(FRAG (-LRB- (-LRB-))(NP (NP (JJ (Kruppel-like))(NN (factor))(CD (4))(-RRB- (-RRB-))(NN (gene)))(JJ (human))(ADJP (NN (colon))(NN (cancer))(NN (cell))(NN (line))(NN (RKO))(JJ (dependent)))(NN (CDX2))))) |ET|  |BS| 6:G05.360.340.024.340 9:G05.360.340.024.340.375.500 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210  |ES| 9:1 10:1 14:1 18:1 19:1 36:1 94:1 113:1 114:1 185:1 264:1 316:1 317:1 318:1 319:1 320:1 321:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (NP (NP (NP (DT (The))(NN (potency))(JJ (nifuroxazide))(NN (breast))(NN (cancer)))(VP (VBN (assessed))(ADVP (FW (vitro))(FW (vivo)))))) |ET| 18:1 19:1 23:1 216:1 378:1 691:1 2796:1 2820:1 3823:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (ADVP (RB (Furthermore)))(, (,))(NP (NP (JJ (stable))(NN (overexpression)))(VP (VBG (using))(NP (JJ (lentiviral))(NN (vector))(NN (NCI-H460))(NN (A549))(NN (cell)))))(VP (VBD (inhibited))(NP (NN (tumor))(NN (xenograft))(NN (growth))(JJ (immunodeficient))(NN (mouse)))(PRN (-LRB- (-LRB-))(NP (NP (CD (95))(ADJP (CD (50))(NN (%)))(NN (reduction)))(VP (VBN (compared))(NP (NN (control)))(, (,))(ADVP (RB (respectively)))(-RRB- (-RRB-))))(, (,))(PP (IN (whereas))(NP (NP (NP (NN (effect))(NN (mir-660))(NN (overexpression))(JJ (absent))(NN (H1299)))(, (,))(NP (NP (NN (lung))(NN (cancer))(NN (cell))(NN (line)))(VP (VBG (lacking))(NP (NN (p53))(NN (locus))))))(, (,))(NP (ADJP (FW (vitro))(FW (vivo)))(NN (assay)))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 8:C04 11:B01.050.150.900.649.865.635.505.500 41:A11 45:G07.700.320.249 92:E04.936.764 93:A01.941.875 94:A11.251.210 106:E05.091 120:I01.409.418.750.600.480.150 121:B04.820.650.589 122:C14.280.383 123:G05.360.337 124:C20.673  |ES| 2:1 7:1 10:1 12:1 14:1 18:1 19:1 50:1 52:1 75:1 94:1 102:1 152:1 216:1 264:1 265:1 289:1 310:1 328:1 334:1 350:1 360:1 361:1 362:1 363:1 364:1 365:1 366:1 367:1 368:1 369:1 370:1 371:1 372:1 373:1 374:1 375:1 376:1 377:1 378:1  |EV| 
-0.00011985672340244103023509936178925  |BT| (S (S (NP (NP (JJ (Low))(JJ (dietary))(NN (folate))(NN (intake)))(VP (VBN (associated))))(VP (VBD (increased))(NP (NN (risk))(NN (colon))(NN (cancer))))(: (;)))(S (ADVP (RB (however)))(, (,))(NP (JJ (relevant))(JJ (genetic))(NN (animal))(NN (model)))(VP (VBG (lacking))))) |ET|  |BS| 19:B01.050 61:E05.318.740.600.800 224:D03.438.733.631.400 285:E05.598 595:G07.203.650.240 1109:E05.599.395.397  |ES| 2:1 18:1 19:1 46:1 47:1 72:1 113:1 169:1 171:1 217:1 376:1 778:1 864:1 865:1 1387:1 2563:1 2594:1 3615:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (ADJP (RB (Here))(VBN (studied)))(NN (role))(NN (HNF4alpha))(NN (mechanism))(NN (deregulation))(NN (Cdx2))(NN (colon))(NN (cancer)))) |ET|  |BS| 15:F01.829.316.616  |ES| 18:1 19:1 31:1 113:1 123:1 162:1 213:1 400:1 401:1 402:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (DT (The))(NN (CDX2))(NN (expression))(JJ (gastric))(NN (cancer)))(ADVP (RB (also)))(ADVP (RB (inversely)))(VP (VBD (correlated))(NP (NN (expression))(JJ (gastric))(NN (mucin))))) |ET|  |BS| 72:D12.776.395.560.631.100  |ES| 5:1 18:1 19:1 86:1 114:1 115:1 209:1 418:1 446:1 691:1  |EV| 
-0.00015017486222773657189577534154523  |BT| (S (NP (DT (The))(JJ (anti-tumor))(NN (effect))(NN (thymoquinone)))(ADVP (RB (also)))(VP (VP (VBD (investigated))(NP (NN (tumor))(NN (xenograft))(NN (mouse))(NN (model))(NN (colon))))(, (,))(NP (NN (prostate))(, (,))(JJ (pancreatic))(NN (lung))(NN (cancer))))) |ET|  |BS| 8:C04 11:B01.050.150.900.649.865.635.505.500 34:A05.360.444.575 46:A03.556.124.526.356 92:E04.936.764 93:A01.941.875 608:A03.734  |ES| 2:1 5:1 7:1 18:1 19:1 52:1 72:1 75:1 77:1 113:1 265:1 328:1 403:1 467:1 691:1 3677:1 3796:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (Expression))(NN (KLK13))(NN (KLK14))(NN (gene)))(VP (VBN (examined))(NP (NP (NN (mRNA))(NN (protein))(NN (level))(NN (cohort))(CD (57))(NN (patient)))(NP (NP (JJ (non-small-cell))(NN (lung))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (NSCLC)))(-RRB- (-RRB-))))))) |ET|  |BS| 6:G05.360.340.024.340 50:M01.643 110:C04.588.894.797.520.109.220.249 111:D13.444.735.544 112:D12.776.097.820  |ES| 4:1 9:1 10:1 14:1 18:1 19:1 120:1 121:1 249:1 316:1 322:1 323:1 324:1 325:1 326:1 327:1 328:1 329:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (S (NP (NN (miR-137))(NN (overexpression)))(VP (VBD (resulted))(NP (NP (NN (downregulation))(NN (CAR))(NN (protein))(NN (mRNA)))(PRN (-LRB- (-LRB-))(PP (IN (via))(NP (NN (mRNA))(NN (degradation))))(-RRB- (-RRB-))))))(: (;))(S (VBN (sensitized))(NP (JJ (doxorubicin-resistant))(NN (cell))(NN (doxorubicin)))(-LRB- (-LRB-))(VP (VP (VBN (shown))(S (VP (VBN (reduced))(NP (NN (proliferation))))))(, (,))(VP (VBD (increased))(NP (NN (apoptosis))))(VP (VBD (increased))(NP (JJ (G2-phase))(NN (cell))(NN (cycle))(NN (arrest))))(SINV (-RRB- (-RRB-))(NP (VBD (reduced))(FW (vivo))(NN (growth))(NN (rate))(NN (neuroblastoma))(NN (xenograft))))))) |ET|  |BS| 7:D12.776 39:G04.299.139.160 41:A11 45:G07.700.320.249 85:G02.111.087.225 92:E04.936.764 93:A01.941.875 111:D13.444.735.544 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 139:J01.937.500.100 177:G04.299.134.109.500 178:G02.111.780  |ES| 2:1 4:1 10:1 14:1 19:1 41:1 47:1 89:1 94:1 102:1 152:1 217:1 237:1 265:1 299:1 325:1 378:1 420:1 421:1 423:1 424:1 452:1 594:1 595:1 596:1 597:1 598:1 599:1 600:1 601:1 602:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (NP (NP (NP (NN (KLF4)))(NP (ADVP (RB (therefore)))(NP (JJ (potential))(NN (mediator))(NN (antitumor))(NN (effect))(NN (Notch))(NN (inhibitor))(NN (dibenzazepine)))))) |ET| 19:1 75:1 218:1 256:1 380:1 827:1 1892:1 2244:1 3018:1 3351:1  |EV| 
-0.00040462668174228930140223781108944  |BT| (S (ADVP (RB (Thus)))(, (,))(NP (JJ (NAC1-mediated))(NN (autophagy)))(VP (MD (may))(VP (VBN (exploited))(NP (JJ (new))(NN (target))(VBG (enhancing))(NN (efficacy))(NN (cisplatin))(JJ (ovarian))(NN (cancer))(NN (type))(NN (malignancy)))))) |ET|  |BS| 390:G04.299.139.399 498:D01.210.375  |ES| 2:1 18:1 19:1 49:1 160:1 491:1 543:1 712:1 1317:1 1691:1 1760:1 1761:1 1763:1 2304:1 2527:1 3867:1  |EV| 
-1.1294591332136269534736072728265e-05  |BT| (NP (NP (NNS (CONCLUSIONS))(: (:)))(S (NP (NN (Expression))(NN (ra))(NN (protein))(NN (type))(CD (II))(JJ (alveolar))(NNS (pneumocytes))(NN (mutation))(NN (codon))(CD (12))(JJ (K-ras))(NN (gene))(NN (lung))(NN (tissue)))(VP (MD (may))(VP (VB (contribute))(NP (NN (induction))(NN (lung))(NN (carcinoma))(NN (patient))(NN (IPF))))))) |ET|  |BS| 18:G05.365.590 50:M01.643 98:A10 182:A04.411 265:C04.557.470.200 276:C08.381.483.487.500 334:D08.811.277.040.330.300.400.500 335:D13.444.735.544.355 336:A04.411.715.512 337:C08.381.765  |ES| 4:1 9:1 19:1 34:1 104:1 120:1 239:1 272:1 304:1 316:1 328:1 450:1 491:1 543:1 736:1 1115:1 1116:1 1117:1 1118:1 1119:1 1120:1 1121:1 1122:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (JJ (Ectopic))(NN (expression))(NN (miR-139-5p))(NN (colon))(NN (cancer))(NN (cell))(NN (line)))(VP (ADVP (RB (significantly)))(NP (VBD (suppressed))(NP (NP (NN (cell))(NN (growth))(VBN (evidenced))(NN (cell))(NN (viability))(NN (assay)))(PRN (-LRB- (-LRB-))(S (NP (NN (P)))(VP (JJR (<))(NP (CD (0.001)))))(-RRB- (-RRB-))))(NP (NP (NP (NN (colony))(NN (formation))(NN (assay)))(PRN (-LRB- (-LRB-))(NP (NP (NN (P)))(ADJP (JJR (<))(NP (CD (0.01)))))(-RRB- (-RRB-))))(NP (NP (NN (xenograft))(NN (tumor))(NN (growth))(JJ (nude))(NN (mouse)))(PRN (-LRB- (-LRB-))(NP (NP (NN (P)))(ADJP (JJR (<))(NP (CD (0.01)))))(-RRB- (-RRB-)))))))) |ET|  |BS| 8:C04 20:G03.495 45:G07.700.320.249 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 94:A11.251.210 106:E05.091 107:G05.355.315.202 108:G04.299.316 109:I01.696.116  |ES| 7:1 10:1 14:1 18:1 19:1 43:1 52:1 94:1 102:1 113:1 115:1 124:1 264:1 265:1 266:1 305:1 306:1 307:1 308:1 309:1 310:1 311:1 312:1 313:1 314:1 315:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (NP (NP (NP (VBN (Enhanced))(NN (sensitivity))(NN (celecoxib))(JJ (human))(NN (glioblastoma))(NN (cell)))(: (:))(NP (NP (NN (Induction))(NN (DNA))(NN (damage)))(VP (VBG (leading))(NP (JJ (p53-dependent))(NN (G1))(NN (cell))(NN (cycle))(NN (arrest))(NN (autophagy))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 41:A11 55:B01.050.150.900.649.801.400.112.400.400 86:D01.268.556.435 390:G04.299.139.399 526:G05.355.180 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247 1076:G04.299.134.109.249  |ES| 19:1 36:1 88:1 94:1 104:1 601:1 602:1 607:1 639:1 666:1 670:1 1317:1 1848:1 2020:1 2186:1 2807:1 3466:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NP (DT (The))(JJ (adenomatous))(NN (polyposis))(NN (coli))(-LRB- (-LRB-))(NN (APC))(-RRB- (-RRB-))(NN (gene))(NN (product)))(NP (VBN (mutated))(JJ (vast))(NN (majority))(JJ (human))(JJ (colorectal))(NN (cancer))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400 219:G05.360.340.024.340.375.249.320 220:D05.500.117.249  |ES| 9:1 10:1 11:1 14:1 17:1 18:1 19:1 36:1 57:1 58:1 59:1 198:1 229:1 675:1 691:1 752:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (DT (This)))(VP (VBD (led))(SBAR (S (NP (NN (u)))(VP (VBP (investigate))(SBAR (S (NP (NP (JJ (antitumor))(NN (growth)))(NP (JJ (antimetastatic))(NN (activity))(NN (alpha-mangostin))(JJ (immunocompetent))(NN (xenograft))(NN (model))(NN (mouse))(JJ (metastatic))(JJ (mammary))(NN (cancer))(NN (p53))(NN (mutation))))(VP (VBZ (induces))(NP (NP (JJ (metastatic))(NN (spectrum)))(NP (JJ (similar))(VBN (seen))(JJ (human))(NN (breast))(NN (cancer)))))))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 10:A01.236 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 86:D01.268.556.435 92:E04.936.764 93:A01.941.875 113:C04.697.650 213:F02.830.816.964 609:A01.236.249 610:G12.460  |ES| 12:1 18:1 19:1 23:1 34:1 36:1 52:1 72:1 102:1 214:1 265:1 332:1 337:1 399:1 459:1 724:1 807:1 2228:1 2243:1 2244:1 2245:1 2246:1 2247:1 2248:1 2249:1  |EV| 
-0.00039698482700542894741069233077724  |BT| (S (NP (NN (Magnolol)))(VP (MD (could))(ADVP (RB (potentially)))(NP (JJ (safe))(JJ (potent))(JJ (anticarcinogenic))(NN (agent))(NN (skin))(NN (cancer))))) |ET|  |BS| 778:D27.505.954.444  |ES| 18:1 19:1 22:1 333:1 728:1 773:1 908:1 2312:1 2319:1 2737:1  |EV| 
-0.00010031119169383317935029253931134  |BT| (S (NP (DT (A))(NN (relationship))(JJ (renal))(NN (tumor))(NN (ASPS)))(ADVP (RB (initially)))(VP (VBD (suggested))(NP (JJ (cytogenetic))(NN (finding))(JJ (balanced))(-LRB- (-LRB-))(NN (X))(: (;))(CD (17))(-RRB- (-RRB-))(-LRB- (-LRB-))(NN (p11))(NN (.2))(: (;)))(NP (CD (q25)))(-RRB- (-RRB-))(SBAR (S (NP (NP (CD (two))(NN (case)))(, (,))(NP (NN (ASPL-TFE3))(NN (fusion))(NN (transcript))))(VP (VBD (confirmed))(NP (JJ (reverse))(NN (transcriptase-polymerase))(NN (chain))(NN (reaction)))))))) |ET|  |BS| 272:E05.393.620.500.725 273:H01.158.273.343.180 274:C04.588.945.947.535 275:C23.888  |ES| 2:1 7:1 10:1 14:1 19:1 69:1 217:1 223:1 768:1 922:1 923:1 924:1 925:1 926:1 927:1 928:1 929:1 930:1 931:1 932:1 933:1 934:1 935:1 936:1 937:1 938:1 939:1 940:1 941:1  |EV| 
0.00041788035725208173528158472898042  |BT| (FRAG (NP (NNS (Results)))(VBP (show))(NP (NN (KLF9))(JJ (haploinsufficient))(NN (suppressor))(NN (colon))(NN (tumorigenesis))(NN (Apc)))(-LRB- (-LRB-))(NP (NP (NP (NP (NN (Min)))(: (/))(CC (+))(-RRB- (-RRB-))(NN (mouse))(NN (part)))(, (,))(NP (NP (NN (repression))(NN (ISG15))(NN (latter))(POS ('s)))(JJ (antiapoptotic))(NN (function)))))) |ET|  |BS| 3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 38:Z01.058.290.120.180 40:Z01.542.248.700 46:A03.556.124.526.356 207:G05.365.590.029.530.587 208:F01.393.821  |ES| 2:1 10:1 14:1 19:1 33:1 52:1 78:1 113:1 280:1 429:1 451:1 461:1 700:1 702:1 703:1 704:1 705:1 706:1 707:1 708:1 709:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (PP (IN (In))(NP (JJ (current))(NN (report))))(, (,))(VBN (used))(S (NP (NN (DLD-1))(JJ (colorectal))(NN (cancer))(NN (cell)))(ADVP (RB (stably)))(NP (VBN (transfected))(NP (NN (POX))(NN (gene))(NN (control))(JJ (tetracycline-inducible))(NN (promoter))))(VP (VBD (found))(SBAR (S (NP (CD (three))(NN (pathway))(NN (cross))(NN (talk)))(VP (VBD (downregulated))(NP (NP (NN (POX)))(: (:))(NP (NP (NP (NP (NN (cyclooxygenase-2)))(PRN (-LRB- (-LRB-))(NP (NN (COX-2)))(-RRB- (-RRB-))))(NN (pathway)))(, (,))(NP (NP (NP (JJ (epidermal))(NN (growth))(NN (factor))(NN (receptor)))(PRN (-LRB- (-LRB-))(NP (NN (EGFR)))(-RRB- (-RRB-))))(NN (pathway))(NN (Wnt/beta-catenin))(NN (pathway))))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 23:D12.776.091.249 24:D08.811.600.720.750 41:A11 64:D08.811.913.696.620.682.725.400.009.300 146:D02.455.426.559.847.562.900.875 147:G02.149.115.800.925 148:G12.425.143.281  |ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 37:1 61:1 76:1 83:1 94:1 102:1 104:1 175:1 184:1 185:1 186:1 187:1 244:1 289:1 302:1 383:1 417:1 426:1 476:1 477:1 478:1 479:1 480:1 481:1 482:1 483:1 484:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (Notch1)))(ADVP (RB (directly)))(VP (VBD (induced))(NP (NN (CD133))(NN (expression))(JJ (human))(JJ (diffuse))(NN (type))(JJ (gastric))(NN (cancer))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400  |ES| 18:1 19:1 36:1 86:1 115:1 412:1 543:1 621:1 651:1 652:1 653:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (ADVP (RB (Nevertheless)))(, (,))(NP (NN (extent))(NN (NAG-1))(NN (induction)))(VP (MD (could))(NP (VBN (altered))(NN (ERK))(NN (inhibitor))(NN (PD98059))))) |ET| 2:1 19:1 380:1 693:1 736:1 908:1 1662:1 4486:1 4968:1 5046:1 5047:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (NP (NP (JJ (Previous))(NN (study)))(VP (VBN (shown))(S (NP (NN (decorin))(NN (expression)))(VP (ADVP (RB (significantly)))(VBD (reduced))(NP (NP (JJ (colorectal))(NN (cancer))(NN (tissue))(NN (cancer))(NN (cell)))(, (,))(NP (JJ (genetic))(NN (deletion))(NN (decorin))(NN (gene))(JJ (sufficient))(NN (cause))(JJ (intestinal))(NN (tumor))(NN (formation))(NN (mouse)))(, (,))(VP (VBG (resulting))(NP (NN (downregulation))(NN (p21))))(, (,))(NP (NP (NN (p27)))(PRN (-LRB- (-LRB-))(NP (NN (kip1)))(-RRB- (-RRB-))))(FRAG (NP (NN (E-cadherin))(NN (upregulation))(NN (beta-catenin))(NN (signaling)))(-LRB- (-LSB-))(NP (NP (NN (Bi)))(, (,))(NP (NN (X)))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 20:G03.495 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 69:G02.111.087.800 85:G02.111.087.225 98:A10 102:C04.588.274.476.411 249:G05.355.315.800 338:D12.644.360.225.600 339:G02.111.087.880 549:G05.355.600.800.320 708:D12.776.395.650.750.625 820:D12.776.395.550.200.200  |ES| 2:1 7:1 9:1 10:1 14:1 17:1 18:1 19:1 43:1 52:1 60:1 94:1 109:1 115:1 124:1 131:1 195:1 237:1 242:1 272:1 384:1 452:1 595:1 864:1 929:1 1059:1 1124:1 1126:1 1135:1 1373:1 1779:1 2267:1 2900:1 2901:1 2902:1 2903:1  |EV| 
-4.6118725517123315693623908373411e-05  |BT| (S (NP (PRP$ (Our))(NNS (data)))(VP (VBP (suggest))(NP (JJ (important))(NP (NN (role))(NN (beta2-AR/STAT3/miR))(CD (-373))(NN (signaling))(NN (transformation))(JJ (gastric))(NN (cancer))(NN (cell)))))) |ET|  |BS| 12:Z01.542.049 15:F01.829.316.616 41:A11 69:G02.111.087.800 82:D12.644.360.024.342.300  |ES| 18:1 19:1 31:1 86:1 94:1 195:1 658:1 793:1 796:1 902:1 1384:1 2144:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NP (NN (Activation))(JJ (p53-dependent))(NN (apoptosis))(JJ (acute))(NN (ablation))(NN (glycogen))(NN (synthase))(NN (kinase-3beta)))(NP (JJ (colorectal))(NN (cancer))(NN (cell))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 41:A11  |ES| 17:1 18:1 19:1 66:1 87:1 88:1 89:1 90:1 91:1 92:1 93:1 94:1  |EV| 
-0.00035336699829374706993689869705122  |BT| (S (NP (DT (The))(NN (orphan))(NN (cotransport))(NN (protein)))(VP (VBD (expressed))(NP (NP (NP (NN (SLC5A8))(NN (gene))(VBN (shown))(NN (play))(NN (role)))(NP (VBG (controlling))(NN (growth))(NN (colon))(NN (cancer))))(, (,))(NP (NN (silencing))(NP (NN (gene))(JJ (common))(NP (JJ (early))(NN (event))(JJ (human))(NN (colon))(NN (neoplasia)))))))) |ET|  |BS| 6:G05.360.340.024.340 7:D12.776 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 42:G05.355.315.203.374 45:G07.700.320.249 51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693 604:M01.108  |ES| 2:1 4:1 6:1 9:1 18:1 19:1 31:1 36:1 100:1 102:1 113:1 205:1 237:1 238:1 640:1 655:1 691:1 1128:1 2217:1 2218:1 2219:1 2220:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (miR-490-3p)))(VP (VBD (exhibited))(NP (NP (JJ (progressive))(NN (downregulation))(NN (gastritis)))(, (,))(NP (JJ (intestinal))(NN (metaplasia)))(, (,))(NP (NN (adenocarcinoma))(NN (H)))))) |ET|  |BS| 47:A03.556.124 48:C23.550.589 84:C04.557.470.200.025 85:G02.111.087.225 175:J01.897.280.500.269 179:D01.248.497.300.459.700 180:C06.405.205.697  |ES| 2:1 19:1 109:1 110:1 255:1 595:1 608:1 609:1 610:1 611:1 612:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (NN (Coexpression))(NN (K-rasVal12))(NN (TAgWt)))(VP (VBP (produce))(NP (NN (dysplasia))))) |ET| 19:1 203:1 1565:1 5405:1 5406:1 5407:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NP (NN (Mutation))(NN (Pla2g2a)))(, (,))(NP (JJ (secretory))(NN (phospholipase))(NN (A))(-LRB- (-LRB-))(CD (2))(-RRB- (-RRB-)))(NP (NN (gene)))(, (,)))(VP (VP (ADVP (RB (dramatically)))(VB (increase))(NP (NN (number))(JJ (intestinal))(NN (polyp)))(VP (VB (develop))(NP (NP (NP (JJ (multiple))(JJ (intestinal))(NN (neoplasia)))(PRN (-LRB- (-LRB-))(NP (NN (Min)))(-RRB- (-RRB-))))(NN (mouse)))))(, (,))(NP (JJ (murine))(ADJP (NN (model))(JJ (adenomatous))(NN (polyposis))(NN (coli))(JJ (human)))))) |ET|  |BS| 3:C04.557.470.035.215.100 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 21:G05.360.340.024.340.375.249.050 55:B01.050.150.900.649.801.400.112.400.400 102:C04.588.274.476.411 192:D08.811.277.352.100.680.750.937.750 193:C23.300.825.411  |ES| 2:1 9:1 10:1 14:1 19:1 36:1 40:1 52:1 57:1 58:1 59:1 69:1 72:1 109:1 148:1 627:1 640:1 641:1 642:1 643:1 644:1 645:1 646:1 647:1 648:1 649:1 650:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NP (JJ (Antisense))(NNS (oligodeoxynucleotides))(JJ (human))(NN (superoxide))(NN (dismutase))(CD (2)))(CC (and/or))(NP (JJ (ectopic))(NN (bcl-2))(NN (overexpression))))(VP (VBD (avoided))(NP (NP (NNS (polyphenols)))(SBAR (S (NP (JJ (chemoradiotherapy-induced))(JJ (colorectal))(NN (cancer))(NN (elimination)))(VP (VBD (showed))(NP (NP (JJ (mangano-type))(NN (superoxide))(NN (dismutase))(NN (Bcl-2))(JJ (key))(NN (target))(JJ (molecular))(NN (mechanism)))(VP (VBN (activated))(NP (JJ (combined))(NN (application))(NN (t-PTER))(NNP (QUER))))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 56:D02.455.426.559.389.657.715 57:D13.695.578.424.450 58:D08.811.682.881 59:E02.186.079  |ES| 17:1 18:1 19:1 36:1 132:1 144:1 145:1 146:1 147:1 148:1 149:1 150:1 151:1 152:1 153:1 154:1 155:1 156:1 157:1 158:1 159:1 160:1 161:1 162:1 163:1 164:1 165:1 166:1 167:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (FRAG (PP (JJ (Molecular))(S (VP (VBG (targeting))(NP (NP (NP (NN (GSK3beta))(NN (overexpression))(NN (GSK3beta))(JJ (dominant-negative))(NN (mutant)))(, (,))(NP (JJ (acute-silencing))(NN (GSK3beta))(NN (RNA))(NN (interference)))(, (,)))(VBN (reproduced))(NN (induction)))(NP (ADJP (RB (transcriptionally))(JJ (active)))(NP (NN (p53))(JJ (colorectal))(NN (cancer))(NN (cell)))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 38:Z01.058.290.120.180 40:Z01.542.248.700 41:A11 156:G05.355.315.203.374.790  |ES| 2:1 12:1 17:1 18:1 19:1 94:1 152:1 197:1 515:1 516:1 616:1 736:1 811:1 1854:1 1894:1 2114:1 2115:1 2116:1 2117:1  |EV| 
-1.5700033827864556812414775777142e-07  |BT| (S (S (NP (NN (Resveratrol)))(VP (VBD (induced))(NP (NP (NN (cell))(NN (cycle))(NN (arrest)))(VP (VBG (up-regulating))(NP (NN (expression))(NN (p21/CIP1)))))))(, (,))(S (NP (NN (p27/KIP1)))(VP (VBG (inhibiting))(NP (NN (expression))(NN (cyclin))(NN (D1)))))) |ET|  |BS| 122:C14.280.383 150:Z01.542.248.960 215:D12.644.360.262.150.100 338:D12.644.360.225.600 773:G04.299.134.109  |ES| 2:1 19:1 94:1 115:1 412:1 601:1 602:1 743:1 744:1 880:1 1876:1 2946:1 5140:1 5141:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (NP (NP (ADJP (RB (Here))(VBN (studied)))(NN (role))(NN (HNF4alpha))(NN (mechanism))(NN (deregulation))(NN (Cdx2))(NN (colon))(NN (cancer)))) |ET|  |BS| 15:F01.829.316.616  |ES| 18:1 19:1 31:1 113:1 123:1 162:1 213:1 400:1 401:1 402:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (PRP (We)))(VP (VBD (investigated))(SBAR (IN (whether))(S (NP (NP (NN (rat))(NN (model)))(VP (VBG (carrying))(NP (JJ (knockout))(NN (allele))(NN (gatekeeper))(NN (gene))(NNP (Adenomatous))(NN (polyposis))(NN (coli))(-LRB- (-LRB-))(NN (Apc))(-RRB- (-RRB-)))))(VP (VBZ (recapitulates))(NP (NP (JJ (familial))(NN (colon))(NN (cancer)))(JJ (human))(S (ADVP (RB (closely)))(VP (VBG (existing))(NP (JJ (murine))(NN (model))))))))))) |ET|  |BS| 3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 21:G05.360.340.024.340.375.249.050 44:F01.829.263 55:B01.050.150.900.649.801.400.112.400.400 77:G05.360.340.024.340.030 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 247:G01.374.676.530 248:E05.393.335.750  |ES| 9:1 10:1 14:1 18:1 19:1 36:1 58:1 59:1 71:1 72:1 113:1 221:1 230:1 280:1 403:1 627:1 843:1 849:1 850:1 851:1 852:1 853:1 854:1 855:1 856:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (S (VP (TO (To))(VP (VB (determine))(SBAR (IN (whether))(S (NP (NP (NN (DAP))(NN (kinase))(NN (promoter)))(NN (methylation)))(VP (VBZ (contributes))(NP (NP (NN (TRAIL))(NN (resistance))(NN (NSCLC))(NN (cell)))(, (,))(NP (NP (VBN (measured))(NN (DAP))(NN (kinase))(NN (promoter))(NN (methylation))(NN (gene))(NN (expression))(NN (status)))(NP (CD (11))(NN (NSCLC))(NN (cell))(NN (line)))))))))))(VP (VBD (correlated))(NP (NN (methylation/expression))(NN (status))(NN (sensitivity))(NN (cell))(NN (TRAIL))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 36:G02.111.087.029.538 41:A11 94:A11.251.210 110:C04.588.894.797.520.109.220.249 155:G05.355.310 228:E05.978 474:D08.811.913.696.620.682.700.125.387  |ES| 2:1 9:1 19:1 74:1 81:1 83:1 94:1 115:1 221:1 264:1 329:1 416:1 446:1 470:1 607:1 789:1 828:1 845:1 1057:1 1094:1 1694:1 1695:1 1696:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (ADVP (RB (Moreover)))(, (,))(NP (NN (CDX2))(NN (expression)))(ADVP (RB (progressively)))(VP (VBD (reduced))(NP (JJ (gastric))(NN (dysplasia))(NN (cancer))))) |ET|  |BS| 70:A03.556.875.875  |ES| 2:1 18:1 19:1 86:1 114:1 115:1 201:1 203:1 452:1 622:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NP (NN (miRNA-141)))(, (,))(VP (VBD (downregulated))(NP (JJ (pancreatic))(NN (cancer))))(, (,)))(VP (VBZ (inhibits))(NP (NN (cell))(NN (proliferation))(NN (invasion)))(S (VP (ADVP (RB (directly)))(VBG (targeting))(NP (NN (MAP4K4))))))) |ET|  |BS| 122:C14.280.383 183:G04.299.233.750 184:D13.150.650.319  |ES| 2:1 18:1 19:1 94:1 299:1 426:1 465:1 467:1 615:1 616:1 619:1 620:1 621:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (ADVP (RB (However)))(, (,))(NP (JJ (combined))(NN (effect))(NN (mda-7))(NN (sulindac)))(ADVP (RB (previously)))(VP (VBN (tested)))) |ET|  |BS| 251:D02.455.426.559.847.486.875  |ES| 2:1 19:1 75:1 164:1 433:1 869:1 1527:1 2988:1 5657:1  |EV| 
-0.0001872271367056709684417725725325  |BT| (S (NP (NN (CONCLUSION))(: (:)))(VP (VP (VBN (Taken))(ADVP (RB (together))))(, (,))(SBAR (S (NP (NNS (data))(VBP (show))(NN (Akt))(NN (inhibitor))(NN (AZD5363)))(VP (VBZ (synergizes))(SBAR (S (NP (JJ (lysosomotropic))(NN (inhibitor))(NN (autophagy))(NN (chloroquine)))(VP (VBP (induce))(NP (NN (apoptosis))(NN (delay))(NN (tumor))(NN (progression))(NN (prostate))(NN (cancer))(NN (model))(JJ (resistant))(NN (monotherapy))(NN (AZD5363)))(, (,))(S (VP (VBG (providing))(NP (NP (JJ (new))(JJ (therapeutic))(NN (approach)))(RRC (ADVP (RB (potentially)))(NP (JJ (translatable))(NN (patient))))))))))))))) |ET|  |BS| 8:C04 16:C23.550.291.656 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 50:M01.643 52:E02 202:C04.588.945.440.770 390:G04.299.139.399 961:D03.438.810.050.180  |ES| 2:1 7:1 18:1 19:1 48:1 72:1 77:1 89:1 104:1 120:1 136:1 243:1 380:1 427:1 429:1 541:1 712:1 773:1 793:1 911:1 1289:1 1317:1 1537:1 1538:1 1882:1 3025:1 3375:1 3376:1 3377:1 3378:1 3379:1 3380:1  |EV| 
0.00041788035725208173528158472898042  |BT| (FRAG (PP (IN (In))(NP (JJ (adult))))(, (,))(NP (NP (JJ (Cdx1))(NN (Cdx2)))(, (,))(NP (NN (Cdx4)))(, (,))(NP (ADJP (RB (intensively))(VBN (explored)))(NN (function))(JJ (intestinal))(NN (tissue))(NN (homeostasis))(NN (pathogenesis))(JJ (gastrointestinal))(NN (cancer))))) |ET|  |BS| 47:A03.556.124 98:A10 119:M01.060.116 152:G07.700.345  |ES| 2:1 18:1 19:1 33:1 109:1 183:1 213:1 244:1 272:1 355:1 496:1 497:1 498:1 499:1 500:1 501:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (NP (NNP (Ling))(NN (extract)))(, (,))(NP (JJ (high))(NN (furanodiene))(NN (content)))(, (,)))(VP (VBD (showed))(NP (JJ (anti-cancer))(NN (effect))(NN (breast))(NN (cancer))(NN (cell))(NN (vitro))))) |ET|  |BS| 41:A11  |ES| 2:1 18:1 19:1 23:1 75:1 94:1 132:1 178:1 216:1 1112:1 1794:1 2496:1 3610:1 3611:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NP (NP (NN (Overexpression))(NN (progastrin)))(, (,))(NP (JJ (nonamidated))(ADJP (RB (incompletely))(VBN (processed)))(NN (product))(NN (gastrin))(NN (gene)))(, (,)))(VP (VBN (shown))(VP (VBP (induce))(NP (JJ (colonic))(NN (hyperproliferation))))))(VP (VBP (promote))(NP (NP (JJ (colorectal))(NN (cancer))(NN (mouse)))(, (,))(NP (NP (NN (mechanism))(NN (pathogenesis)))(VP (VBN (defined))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 199:D06.472.317.413 200:D06.472.317.413  |ES| 2:1 9:1 17:1 18:1 19:1 52:1 162:1 237:1 243:1 501:1 668:1 671:1 672:1 673:1 674:1 675:1 676:1 677:1 678:1 679:1 680:1  |EV| 
-0.00041724959759709308315667186661813  |BT| (NP (NP (JJ (Critical))(NN (function))(NN (ADAM9))(NN (mouse))(NN (prostate))(NN (cancer)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500  |ES| 18:1 19:1 33:1 52:1 77:1 3211:1 3415:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (JJ (Correlated))(NN (pattern)))(VP (VBN (observed))(NP (NP (NN (HNF4alpha))(NN (Cdx2))(JJ (several))(JJ (experimental))(NN (model))(JJ (human))(NN (colon))(NN (cancer))(NN (cell))(NN (line)))(: (:))(NP (NP (NN (xenograft))(JJ (nude))(NN (mouse)))(, (,))(NP (NN (wound))(NN (healing))(NN (glucose))(NN (starvation))))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 89:G16.100.856.891 90:C18.654.521.750 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 94:A11.251.210 95:E05.599  |ES| 2:1 18:1 19:1 36:1 52:1 72:1 94:1 104:1 113:1 123:1 213:1 259:1 260:1 261:1 262:1 263:1 264:1 265:1 266:1 267:1 268:1 269:1 270:1  |EV| 
-0.00018452939606816709527947750757448  |BT| (SINV (S (VP (TO (To))(VP (VB (determine))(NP (NP (JJ (genetic))(JJ (molecular))(JJ (characteristic))(NN (tumor)))(VP (VBG (carrying))(NP (NN (EGFR))(NN (gene))(NN (mutation))))))))(, (,))(VBD (investigated))(S (S (NP (NN (EGFR))(NN (gene))(NN (status))(NN (lung))(NN (adenocarcinoma)))(VP (VBD (evaluated))(NP (NN (association))(JJ (specific))(JJ (characteristic))(NN (patient))(NN (tumor)))))(, (,))(NP (NP (NP (NP (NX (NN (mutation))(NNP (KRAS))(NN (p53)))(, (,))(NN (EGFR))(NN (ErbB2))(NN (gene))(NN (amplification)))(, (,))(NP (NN (level))(NN (EGFR))(NN (HER2))(NN (protein)))(, (,)))(NN (level))(JJ (downstream))(NN (effector))(NN (EGFR)))(, (,))(NP (JJ (phospho-extracellular))(JJ (signal-regulated))(NN (kinase))(NN (phospho-S6))(NN (protein)))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 7:D12.776 8:C04 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 225:E05.337 247:G01.374.676.530 358:G05.360.340.024.340.375.500.791.295.300 386:F02.463.425.069 388:G05.360.340.024.340.375.500.791.550 392:G05.355.315.250 477:D08.811.913.696.620.682.700.567.249 478:D08.811.913.696.620.682.700.567  |ES| 2:1 4:1 7:1 9:1 12:1 19:1 34:1 74:1 120:1 161:1 187:1 188:1 249:1 255:1 328:1 336:1 403:1 416:1 470:1 540:1 560:1 570:1 780:1 828:1 850:1 864:1 921:1 1298:1 1305:1 1705:1 1706:1 1707:1 1708:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (DT (The))(NN (Tg737))(NN (gene)))(VP (VBD (found))(NP (NP (JJ (altered))(ADJP (QP (RB (approximately))(CD (40)))(NN (%)))(JJ (rodent))(JJ (chemically-induced))(NN (liver))(NN (tumor)))(, (,))(NP (NP (CD (40))(NN (%)))(JJ (human))(NN (liver))(NN (tumor)))(, (,))(NP (NN (liver)))(, (,))(NP (NN (kidney))(JJ (pancreatic))(JJ (human))(NN (tumor))(NN (cell))(NN (line)))))) |ET|  |BS| 6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 242:A03.620 485:A05.810.453 514:B01.050.150.900.649.865 515:C04.588.274.623 607:A11.251.210.190 608:A03.734  |ES| 2:1 7:1 9:1 19:1 36:1 37:1 94:1 264:1 369:1 467:1 582:1 691:1 693:1 836:1 1717:1 1805:1 1843:1 2173:1 2233:1  |EV| 
-0.0003466180303452809016717672818686  |BT| (S (ADVP (RB (Importantly)))(, (,))(NP (NN (cotreatment))(JJ (low))(NNS (dos))(NP (NP (NNS (oligoamines))(NN (DNA))(NN (methyltransferase))(NN (inhibitor)))(ADVP (RB (highly)))))(VP (VBZ (induces))(SBAR (S (NP (NN (reexpression)))(ADVP (RB (aberrantly)))(VP (VBD (silenced))(SBAR (S (NP (NN (SFRP2))(NN (gene)))(VP (VBP (result))(NP (NP (JJ (significant))(NN (inhibition))(NN (growth)))(VBN (established))(NN (tumor))(JJ (human))(NN (colon))(NN (tumor))(NN (model)))(FW (vivo)))))))))) |ET|  |BS| 6:G05.360.340.024.340 8:C04 43:F01.145.544 45:G07.700.320.249 51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 618:E02.186 746:D08.811.150.240  |ES| 2:1 7:1 9:1 19:1 36:1 72:1 101:1 102:1 103:1 113:1 135:1 214:1 378:1 380:1 531:1 626:1 666:1 2651:1 2652:1 2653:1 2654:1 2655:1 2656:1 2657:1 2658:1 2659:1 2660:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NN (INTRODUCTION)))(: (:))(NP (NP (NP (NP (JJ (Triple))(JJ (negative))(NN (breast))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (TNBC)))(-RRB- (-RRB-))))(NP (JJ (aggressive))(ADJP (RB (currently))(JJ (specific)))(JJ (therapeutic))(NN (target))))(, (,))(NP (NP (NN (hormone))(NN (receptor))(JJ (human))(JJ (epidermal))(NN (growth))(NN (factor))(NN (receptor))(NN (type))(CD (2)))(PRN (-LRB- (-LRB-))(NP (NN (HER2)))(-RRB- (-RRB-)))))(: (;))(ADVP (RB (therefore)))(, (,))(NP (NN (prognosis))(JJ (poor)))) |ET|  |BS| 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 159:I01.880.735.634 160:C04.588.180.788 161:D06.472 162:F01.145.126.125 163:E01.789  |ES| 2:1 10:1 14:1 18:1 19:1 23:1 36:1 102:1 104:1 148:1 160:1 184:1 185:1 186:1 188:1 217:1 218:1 449:1 535:1 536:1 537:1 538:1 539:1 540:1 541:1 542:1 543:1 544:1 545:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (DT (The))(NN (result)))(VP (VBP (demonstrate))(NP (NP (JJ (growth-promoting))(NN (property))(NN (periostin)))(, (,))(NP (NP (JJ (possible))(NN (role)))(VP (VBG (targeting))(NP (NN (protein))(JJ (therapeutic))(NN (option))(JJ (colorectal))(NN (cancer)))))))) |ET|  |BS| 4:C04.588.274.476.411.307 15:F01.829.316.616 45:G07.700.320.249 52:E02 112:D12.776.097.820  |ES| 2:1 4:1 17:1 18:1 19:1 31:1 101:1 502:1 541:1 616:1 691:1 841:1 1359:1 3512:1 3832:1 3833:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (S (NP (DT (This))(JJ (K-Ras))(NN (tumor))(NN (phenotype)))(VP (VBN (associated))(VP (VBD (attenuated))(NP (NN (signaling))(NN (MAPK))(NN (pathway))))))(, (,))(NP (JJ (human))(NN (colon))(NN (cancer))(NN (cell)))(VP (VBG (expressing))(NP (NP (JJ (mutant))(NN (K-Ras))(JJ (hypersensitive))(NN (inhibition))(NN (Raf)))(, (,))(NP (NN (Mek)))))) |ET|  |BS| 1:G05.360.340.024.340.375.500.791.550 8:C04 41:A11 43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 80:G05.695 233:D08.811.913.696.620.682.700.565 234:D08.811.913.696.620.682.700.565  |ES| 2:1 7:1 13:1 18:1 19:1 36:1 94:1 103:1 113:1 169:1 195:1 236:1 383:1 807:1 808:1 809:1 810:1 811:1 812:1 813:1 814:1  |EV| 
-0.00041777749719995593835619729361497  |BT| (NP (NP (JJ (Therapeutic))(NN (effect))(JJ (multi-targeted))(NN (imidazolium))(NN (compound))(JJ (hepatocellular))(NN (carcinoma)))) |ET|  |BS| 104:C04.557.470.200.025.255  |ES| 19:1 75:1 303:1 304:1 2433:1 2993:1 3034:1 3035:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NNS (METHODS))(: (:)))(S (NP (NN (Notch))(NN (status)))(VP (VBD (analysed))(S (VP (VBG (studying))(S (NP (NN (expression))(NN (Notch))(NN (effector))(NN (Hes1))(NN (Notch))(NNS (ligands/receptors)))(NP (JJ (human))(JJ (colorectal))(NP (NP (NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (CRC)))(-RRB- (-RRB-))))(NN (mouse))(NN (model))(NN (Apc))(NN (mutation))))))))) |ET|  |BS| 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 168:E05.581 169:D12.776.543.750.725 170:D27.720.470.480  |ES| 10:1 14:1 17:1 18:1 19:1 34:1 36:1 52:1 72:1 104:1 115:1 245:1 256:1 258:1 280:1 416:1 565:1 568:1 569:1 570:1 571:1  |EV| 
0.00041788035725208173528158472898042  |BT| (FRAG (PP (IN (In))(NP (NN (study))))(, (,))(NP (VBN (explored))(NN (role))(NN (miR-141))(JJ (pancreatic))(NN (cancer)))) |ET|  |BS| 15:F01.829.316.616  |ES| 2:1 18:1 19:1 31:1 131:1 244:1 463:1 467:1 499:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (DT (A))(NN (TRAMP/COX))(CD (-2))(JJ (knockout))(NN (mouse))(NN (model)))(ADVP (RB (also)))(VP (VBD (generated))(VP (VB (determine))(NP (NN (effect))(NN (loss))(NN (COX-2))(NN (gene))(NN (prostate))(NN (tumorigenesis))(NN (TRAMP))(NN (mouse)))))) |ET|  |BS| 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 34:A05.360.444.575  |ES| 5:1 9:1 19:1 32:1 52:1 69:1 70:1 71:1 72:1 73:1 74:1 75:1 76:1 77:1 78:1 79:1  |EV| 
-4.2106493022359137157195618783589e-05  |BT| (S (NP (NP (JJ (CRC-associated))(NN (symptom))(NN (patient)))(PP (VBG (including))(NP (JJ (intestinal))(NN (bleeding))(NN (anaemia)))))(ADVP (RB (faithfully)))(VP (VBD (mimicked))(NP (NP (NP (JJ (AOM-treated))(NN (MybER))(JJ (transgenic))(NN (mouse)))(VBN (implicated))(NN (hypoxia))(NN (vessel))(NN (leakage)))(VP (VBG (identifying))(NP (ADJP (ADJP (JJ (additional)))(ADJP (JJ (pathogenic))))(NN (role))(NN (Myb))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 15:F01.829.316.616 47:A03.556.124 50:M01.643 52:E02 99:B01.050.050.136.500 132:D02.172.080 327:G06.930 371:A07.231 1011:C23.888.852.079 1322:C15.378.071 1323:C23.550.414  |ES| 19:1 31:1 52:1 109:1 120:1 285:1 561:1 977:1 980:1 1698:1 2474:1 4710:1 4711:1 4712:1 4713:1 4714:1 4715:1 4716:1 4717:1 4718:1 4719:1 4720:1 4721:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NNS (RESULTS))(: (:)))(VP (ADVP (RB (Herein)))(VB (provide))(NP (JJ (new))(NP (NN (evidence))(JJ (transcriptional))(NN (regulation)))(NN (Notch))(NN (PEA3))(NN (breast))(NN (cancer))))) |ET|  |BS| 142:I01.880.604 209:G02.111.087.847  |ES| 18:1 19:1 23:1 38:1 104:1 256:1 428:1 438:1 559:1 710:1 711:1 712:1 713:1  |EV| 
-0.00029674089238878318449538218359862  |BT| (FRAG (NP (PRP (We)))(VBD (characterized))(SBAR (S (NP (NP (NN (effect))(JJ (gefitinib))(NN (EGFR)))(, (,))(NP (NN (HER2)))(, (,))(NP (NN (ErbB-3))(NN (phosphorylation))(NN (Western))(NN (blot))))(VP (VBD (determined))(NP (NN (effect))(JJ (downstream))(NN (signaling))(NN (growth))))))(, (,))(NP (NP (NN (survival)))(, (,))(NP (NN (stress))(NN (pathway))(NN (effect))(NN (proliferation)))(, (,))(NP (NN (cell))(NN (cycle)))(, (,))(NP (NN (apoptosis))))) |ET|  |BS| 39:G04.299.139.160 45:G07.700.320.249 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 69:G02.111.087.800 96:I03.784 255:E05.196.401.143 256:E05.196.401.143 353:G04.299.134 972:G02.111.087.677 1350:G05.360.340.024.340.375.500.791.295  |ES| 2:1 19:1 75:1 89:1 94:1 102:1 187:1 188:1 195:1 274:1 299:1 383:1 560:1 601:1 843:1 872:1 873:1 985:1 1582:1 2522:1 3310:1 3426:1 4818:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (DT (These))(NNS (data)))(VP (VP (VBP (provide))(NP (NN (evidence))(NN (Cdx2))(VP (VBZ (antagonizes))(NP (NN (process))(NN (tumor))(NN (cell))(NN (dissemination))))))(, (,))(VP (VBP (suggest))(SBAR (S (NP (NN (homeobox))(NN (gene)))(VP (MD (might))(VP (VB (represent))(NP (JJ (new))(JJ (therapeutic))(NN (target))(JJ (metastatic))(NN (spreading))(NN (colon))(NN (cancer)))))))))) |ET|  |BS| 8:C04 52:E02 229:G05.360.340.024.340.230.500 230:G04  |ES| 2:1 7:1 9:1 18:1 19:1 38:1 94:1 113:1 160:1 213:1 337:1 541:1 638:1 711:1 712:1 792:1 793:1 794:1 795:1 796:1 797:1 798:1 799:1 800:1  |EV| 
-0.00027853541668662086527863408491612  |BT| (S (ADVP (RB (Moreover)))(, (,))(NP (NN (silencing))(NN (IGFBP1))(NN (gene)))(VP (VBD (blunted))(NP (JJ (emodin-induced))(NN (inhibition))(NN (cell))(NN (growth))(NN (cell))(NN (cycle))(NN (arrest))))) |ET|  |BS| 41:A11 42:G05.355.315.203.374 43:F01.145.544 45:G07.700.320.249 773:G04.299.134.109 1327:D12.776.157.420.250 1518:D02.455.426.559.847.117.159.205.400  |ES| 2:1 9:1 19:1 94:1 100:1 102:1 103:1 601:1 602:1 622:1 5201:1 5613:1 5690:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (ADVP (RB (Moreover)))(, (,))(VP (VBD (identified))(SBAR (S (NP (NN (Usp28))(NN (c-MYC))(NN (target))(NN (gene)))(ADVP (RB (highly)))(VBD (expressed))(NP (JJ (murine))(JJ (human))(JJ (intestinal))(NN (cancer)))(, (,))(VP (VBZ (indicates))(SBAR (S (NP (NN (USP28))(NN (c-MYC))(NN (form))(JJ (positive))(NN (feedback))(NN (loop)))(VP (VBZ (maintains))(NP (JJ (high))(NN (c-MYC))(NN (protein))(NN (level))(NN (tumor))))))))))) |ET|  |BS| 8:C04 11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 83:L01.143.283.425 101:C04.588.274.476.411 185:G05.360.340.024.340.375.500.791.420 186:G05.360.340.024.340.375.500.791.420 187:D08.622.705 188:N02.628 189:V02.460  |ES| 2:1 4:1 6:1 7:1 9:1 18:1 19:1 36:1 109:1 160:1 178:1 233:1 247:1 248:1 249:1 622:1 623:1 624:1 625:1 626:1 627:1 628:1 629:1 630:1 631:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (PRP (We)))(VP (VBD (wanted))(VP (VB (determine))(SBAR (IN (whether))(S (NP (NP (JJ (genetic))(NN (defect))(JJ (relevant))(JJ (colorectal))(NN (cancer)))(, (,))(NP (NN (Msh2))(NN (p53))(NN (deficiency)))(, (,)))(VP (MD (would))(VP (VB (influence))(NP (NN (efficiency))(NN (sulindac))(NN (chemoprevention))(NN (increase))(NN (side))(NN (effect)))))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 87:C18.654.521 251:D02.455.426.559.847.486.875 252:F02.784.692.351 253:E02.319.162 254:C16.131  |ES| 2:1 12:1 17:1 18:1 19:1 40:1 74:1 75:1 221:1 253:1 585:1 588:1 843:1 863:1 864:1 865:1 866:1 867:1 868:1 869:1 870:1 871:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (PRP$ (Our))(NP (NP (JJ (recent))(JJ (global))(NN (analysis))(NN (CpG))(NN (island))(NN (hypermethylation))(NN (gene))(NN (expression))(JJ (colorectal))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (CRC)))(-RRB- (-RRB-))))(NN (cell))(NN (line)))(VP (VBD (revealed))(S (NP (NN (SOX17))(NN (gene))(NN (silencing)))(NP (VBN (associated))(NN (DNA))(NN (hypermethylation))(NN (CpG))(NN (island))(NN (promoter))(NN (region)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 42:G05.355.315.203.374 94:A11.251.210 155:G05.355.310 195:G02.111.570.080.380.160 196:G02.111.570.080.689.675 197:A01.456.505.420 198:D13.444.308  |ES| 9:1 10:1 14:1 17:1 18:1 19:1 83:1 94:1 100:1 115:1 169:1 245:1 264:1 275:1 658:1 659:1 660:1 661:1 662:1 663:1 664:1 665:1 666:1 667:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (Western))(NN (blot)))(VP (VBD (revealed))(NP (NP (NN (overexpression))(NN (beta-catenin)))(, (,))(NP (NP (NN (c-Myc)))(, (,))(NP (NN (cyclin))(NN (D1)))(, (,))(NP (JJ (inducible))(JJ (nitric))(NN (oxide))(NN (synthase)))(NP (NN (cyclooxygenase-2))(NN (colon))(NN (tumor))(NN (sample))))))) |ET|  |BS| 22:D08.811.682.664.500.772.500 23:D12.776.091.249 24:D08.811.600.720.750 51:C04.588.274.476.411.307.180 215:D12.644.360.262.150.100 255:E05.196.401.143  |ES| 2:1 7:1 19:1 60:1 61:1 63:1 64:1 65:1 66:1 113:1 152:1 275:1 743:1 744:1 824:1 835:1 872:1 873:1  |EV| 
-0.00012924564501393131805279113066831  |BT| (S (NP (NN (K-Ras))(NN (mutation))(NN (treatment))(NN (outcome))(JJ (colorectal))(NN (cancer))(NN (patient)))(VP (VBG (receiving))(NP (JJ (exclusive))(NN (fluoropyrimidine))(NN (therapy))))) |ET|  |BS| 1:G05.360.340.024.340.375.500.791.550 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 50:M01.643 52:E02 164:E01.789.800  |ES| 13:1 17:1 18:1 19:1 34:1 120:1 130:1 546:1 547:1 548:1 549:1 550:1  |EV| 
-2.1065152450892854485431371358573e-05  |BT| (NP (NP (JJ (Epigenetic))(NN (inactivation))(JJ (paired))(NN (box))(NN (gene))(CD (5)))(, (,))(NP (JJ (novel))(NN (tumor))(NN (suppressor))(NN (gene)))(, (,))(NP (NP (JJ (direct))(NN (upregulation))(NN (p53)))(NP (VBN (associated))(NN (prognosis))(JJ (gastric))(NN (cancer))(NN (patient))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 42:G05.355.315.203.374 50:M01.643 163:E01.789 206:G05.360.340.024.340.375.249 249:G05.355.315.800 259:D12.776.395.240.150.500 339:G02.111.087.880  |ES| 2:1 7:1 9:1 12:1 18:1 19:1 86:1 120:1 169:1 544:1 578:1 700:1 790:1 891:1 1126:1 1201:1 1314:1 1891:1 1918:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (ADJP (RB (Here))(VBN (investigated)))(NP (NN (role))(NN (Bcl-3))(NN (azoxymethane/dextran))(NN (sulfate))(NN (sodium)))(PRN (-LRB- (-LRB-))(NP (NN (AOM/DSS)))(-RRB- (-RRB-))))(: (-))(VP (VBN (induced))(NP (NP (NN (colon))(NN (tumor)))(, (,))(NP (NN (mouse))(NN (model))(JJ (colitis-associated))(JJ (colorectal))(NN (cancer)))(JJ (human))))) |ET|  |BS| 4:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 51:C04.588.274.476.411.307.180 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 131:D09.698.365.272.300 132:D02.172.080  |ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 31:1 36:1 52:1 72:1 113:1 400:1 403:1 404:1 405:1 406:1 407:1 408:1 409:1 410:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (NP (NP (NP (DT (The))(JJ (adenomatous))(NN (polyposis))(NN (coli))(-LRB- (-LRB-))(NN (APC))(-RRB- (-RRB-))(NN (gene))(NN (product)))(NP (VBN (mutated))(JJ (vast))(NN (majority))(JJ (human))(JJ (colorectal))(NN (cancer))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400 219:G05.360.340.024.340.375.249.320 220:D05.500.117.249  |ES| 9:1 10:1 11:1 14:1 17:1 18:1 19:1 36:1 57:1 58:1 59:1 198:1 229:1 675:1 691:1 752:1  |EV| 
-3.2959746043559334793826565146446e-17  |BT| (S (PP (IN (In))(NP (NN (study))))(, (,))(VP (VBD (identified))(NP (NP (JJ (novel))(NN (CEBPD))(NN (activator)))(, (,))(NP (NP (LST (LS (1))(: (-)))(-LRB- (-LRB-))(JJ (2-hydroxy-5-methylphenyl))(-RRB- (-RRB-))(NN (-3-phenyl-1,3-propanedione)))(PRN (-LRB- (-LRB-))(NP (NN (HMDB)))(-RRB- (-RRB-))))))) |ET|  |BS| 259:D12.776.395.240.150.500  |ES| 2:1 10:1 14:1 19:1 131:1 244:1 623:1 861:1 891:1 5667:1 5668:1 5669:1 5670:1 5671:1  |EV| 
-0.00027251118897220205639086998417042  |BT| (NP (NP (NNS (METHODS)))(: (:))(S (NP (NP (NP (JJ (Stable))(JJ (transient))(NN (RNA))(NN (silencing))(NN (GAST))(NN (gene)))(VP (VBD (induced))(NP (NP (JJ (human))(NN (tumor))(NN (cell))(NN (mouse)))(VP (VBG (carrying))(NP (NP (JJ (heterozygous))(NN (Apc))(NN (mutation)))(PRN (-LRB- (-LRB-))(NP (NN (APCDelta14)))(-RRB- (-RRB-))))))))(, (,))(VP (VBP (overexpress))(NP (NN (progastrin)))))(VP (VBD (amidated))(NP (JJ (glycine-extended))(NN (gastrin)))))) |ET|  |BS| 3:C04.557.470.035.215.100 6:G05.360.340.024.340 8:C04 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 41:A11 42:G05.355.315.203.374 55:B01.050.150.900.649.801.400.112.400.400 156:G05.355.315.203.374.790 157:G05.380.383 168:E05.581 199:D06.472.317.413 200:D06.472.317.413 247:G01.374.676.530 1003:D12.125.481 1422:D13.444.735  |ES| 2:1 7:1 9:1 10:1 14:1 19:1 34:1 36:1 52:1 94:1 100:1 104:1 280:1 412:1 515:1 565:1 671:1 676:1 745:1 786:1 850:1 2513:1 5677:1 5678:1 5679:1 5680:1 5681:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (Notch-1))(NN (Notch-4))(JJ (potent))(NN (breast))(NN (oncogene)))(VP (VBN (overexpressed))(NP (JJ (triple-negative))(NNS (subtypes))(NN (breast))(NN (cancer))))) |ET|  |BS| 9:G05.360.340.024.340.375.500 10:A01.236  |ES| 18:1 19:1 20:1 21:1 22:1 23:1 24:1 25:1 26:1 27:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (ADVP (RB (Importantly)))(, (,))(NP (NN (cotreatment))(JJ (low))(NNS (dos))(NP (NP (NNS (oligoamines))(NN (DNA))(NN (methyltransferase))(NN (inhibitor)))(ADVP (RB (highly)))))(VP (VBZ (induces))(SBAR (S (NP (NN (reexpression)))(ADVP (RB (aberrantly)))(VP (VBD (silenced))(SBAR (S (NP (NN (SFRP2))(NN (gene)))(VP (VBP (result))(NP (NP (JJ (significant))(NN (inhibition))(NN (growth)))(VBN (established))(NN (tumor))(JJ (human))(NN (colon))(NN (tumor))(NN (model)))(FW (vivo)))))))))) |ET|  |BS| 6:G05.360.340.024.340 8:C04 43:F01.145.544 45:G07.700.320.249 51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 618:E02.186 746:D08.811.150.240  |ES| 2:1 7:1 9:1 19:1 36:1 72:1 101:1 102:1 103:1 113:1 135:1 214:1 378:1 380:1 531:1 626:1 666:1 2651:1 2652:1 2653:1 2654:1 2655:1 2656:1 2657:1 2658:1 2659:1 2660:1  |EV| 
-3.2937018894160785542624125810107e-06  |BT| (S (NP (PRP (We)))(ADVP (RB (previously)))(VP (VBD (showed))(SBAR (S (NP (NN (embelin)))(VP (VBZ (inhibits))(NP (NN (growth))(NN (colon))(NN (cancer))(NN (cell))(NN (vitro))))))(, (,))(VP (ADVP (RB (effectively)))(VBZ (suppresses))(NP (JJ (1,2-dimethylhydrazine))(JJ (dihydrochloride-induced))(NN (colon))(NN (carcinogenesis))(NN (mouse)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 122:C14.280.383  |ES| 2:1 18:1 19:1 52:1 94:1 102:1 113:1 132:1 207:1 216:1 615:1 686:1 843:1 1527:1 2642:1 2889:1 2977:1 3145:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (JJ (Sonic))(NN (hedgehog))(NN (inhibitor)))(VP (VBP (prevent))(NP (JJ (colitis-associated))(NN (cancer)))(FRAG (IN (via))(NP (VBN (orchestrated))(NN (mechanism))(NN (IL-6)))(: (/))(NP (NP (NN (gp130))(NN (inhibition)))(, (,))(NP (NN (15-PGDH))(NN (induction)))(, (,))(NP (NN (Bcl-2))(NN (abrogation)))(, (,))(NP (NN (tumorsphere))(NN (inhibition))))))) |ET|  |BS| 43:F01.145.544 53:C06.405.205.265 54:G05.360.340.024.340.375.500.791.150 201:D12.644.276.374.465.224 214:B01.050.150.900.649.473.376  |ES| 2:1 18:1 19:1 103:1 133:1 158:1 162:1 380:1 410:1 596:1 731:1 732:1 733:1 734:1 735:1 736:1 737:1 738:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (DT (The))(NN (Tg737))(NN (gene)))(VP (VBD (investigated))(NP (JJ (gross))(NN (alteration))(NN (series))(NN (rodent/human))(NN (liver))(NN (tumor))(JJ (human))(JJ (tumorigenic))(NN (cell))(NN (line))))) |ET|  |BS| 6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 514:B01.050.150.900.649.865 515:C04.588.274.623  |ES| 7:1 9:1 19:1 36:1 94:1 264:1 403:1 691:1 836:1 951:1 1805:1 1806:1 1807:1 1808:1 1809:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (Penta-1,2,3,4,6-O-galloyl-beta-D-glucose)))(VP (VP (VBZ (induces))(SBAR (S (NP (NN (p53)))(VP (VBZ (inhibits))(NP (NN (STAT3))(NN (prostate))(NN (cancer))(NN (cell))(NN (vitro)))))))(VP (VBZ (suppresses))(NP (NN (prostate))(NN (xenograft))(NN (tumor))(NN (growth)))(FW (vivo))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 41:A11 45:G07.700.320.249 82:D12.644.360.024.342.300 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 122:C14.280.383 202:C04.588.945.440.770  |ES| 7:1 12:1 18:1 19:1 77:1 94:1 102:1 214:1 216:1 251:1 265:1 378:1 615:1 685:1 686:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NNS (CONCLUSIONS))(: (:)))(NP (NP (JJ (Gastric))(NN (expression))(NN (Cdx2)))(ADJP (RB (alone))(JJ (sufficient))))(VP (VBP (induce))(NP (JJ (intestinal))(NN (metaplasia))(NN (mouse))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 48:C23.550.589 70:A03.556.875.875  |ES| 19:1 52:1 104:1 109:1 110:1 115:1 213:1 239:1 240:1 241:1 242:1 243:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (S (NP (JJ (Regular))(NN (aspirin))(NN (use))(NN (diagnosis)))(VP (VBD (associated))(NP (JJR (lower))(NN (risk))(JJ (colorectal))(JJ (cancer-specific))(NN (mortality)))(PP (IN (among))(NP (NP (NN (participant))(JJ (primary))(NN (tumor))(JJ (overexpressed))(NN (COX-2)))(PRN (-LRB- (-LRB-))(NP (NP (JJ (multivariate))(NN (HR)))(, (,))(NP (CD (0.39)))(: (;))(NP (NP (ADJP (CD (95))(NN (%)))(NN (CI)))(, (,))(NP (CD (0.20-0.76)))))(-RRB- (-RRB-)))))))(, (,))(IN (whereas))(S (NP (NN (aspirin))(NN (use)))(VP (VBD (associated))(NP (JJR (lower))(NN (risk)))(PP (IN (among))(NP (NP (JJ (primary))(NN (tumor))(JJ (weak))(JJ (absent))(NN (expression)))(PRN (-LRB- (-LRB-))(NP (NP (JJ (multivariate))(NN (HR)))(, (,))(NP (CD (1.22)))(: (;))(NP (NP (ADJP (CD (95))(NN (%)))(NN (CI)))(, (,))(NP (CD (0.36-4.18)))))(-RRB- (-RRB-)))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 61:E05.318.740.600.800 263:E01 670:D02.455.426.559.389.657.410.595.176 695:E05.318.308.985.550 828:Z01.107.757.235  |ES| 2:1 7:1 10:1 14:1 17:1 19:1 25:1 76:1 115:1 117:1 169:1 171:1 217:1 338:1 344:1 367:1 369:1 372:1 374:1 1037:1 1372:1 1659:1 2487:1 2508:1 2509:1 2511:1 2923:1 2924:1 2925:1 2926:1 2927:1 2928:1 2929:1 2930:1  |EV| 
-0.00036532756435716552678716340096798  |BT| (S (NP (NN (Astrocyte))(JJ (elevated))(NN (gene-1))(NN (c-Myc)))(VP (VBP (cooperate))(VP (VBP (promote))(NP (NN (hepatocarcinogenesis))(NN (mouse)))))) |ET|  |BS| 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 529:A08.637.200  |ES| 19:1 52:1 474:1 679:1 756:1 824:1 900:1 1858:1 1859:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (NN (Induction))(NN (p53)))(VP (VBP (render))(NP (JJ (ATM-deficient))(NN (mouse))(JJ (refractory))(NN (hepatocarcinogenesis))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500  |ES| 12:1 19:1 52:1 900:1 2020:1 2021:1 2022:1 2023:1  |EV| 
-6.1166675303314654854602849809453e-05  |BT| (S (PP (IN (In))(NP (JJ (present))(NN (study))))(, (,))(VP (VBN (investigated))(S (NP (NP (NN (role))(NN (IDO))(NN (diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-))))(: (-))(VP (VBN (induced))(NP (NN (hepatocarcinogenesis)))(S (VP (VBG (using))(NP (NP (NP (NN (IDO-knockout)))(PRN (-LRB- (-LRB-))(NP (NN (KO)))(-RRB- (-RRB-))))(NN (mouse))))))))) |ET|  |BS| 15:F01.829.316.616 29:B01.050.050.136.500.500 554:D02.654.442.200  |ES| 2:1 10:1 14:1 19:1 31:1 52:1 131:1 244:1 350:1 403:1 409:1 900:1 1307:1 1875:1 1952:1 2849:1 4243:1 4244:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (UCP (S (NP (DT (The))(NN (miR-122))(JJ (regulatory))(NN (circuitry))(NN (implication))(NN (hepatocarcinogenesis)))(VP (VBN (identified))(S (VP (VBG (using))(NP (NN (liver))(JJ (different))(NN (development))(NN (stage)))))))(, (,))(NP (NP (NP (NP (JJ (human))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(NP (NN (tissue))(NN (cell))(NN (line)))(, (,))(NP (NP (NN (aflatoxin))(NN (B)))(-LRB- (-LRB-))(CD (1))(-RRB- (-RRB-))(-LRB- (-LRB-))(NN (AFB))(LST (-LRB- (-LRB-))(CD (1))(-RRB- (-RRB-))(-RRB- (-RRB-)))))(: (-))(NP (VBN (transformed))(NN (cell))))) |ET|  |BS| 41:A11 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 98:A10 104:C04.557.470.200.025.255 242:A03.620 603:D03.383.663.283.119.075  |ES| 2:1 10:1 14:1 19:1 35:1 36:1 85:1 94:1 98:1 264:1 272:1 303:1 304:1 350:1 414:1 441:1 623:1 691:1 763:1 836:1 900:1 1129:1 1789:1 1817:1 1818:1 2214:1 2215:1 2216:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (Sil))(NN (gene))(NN (expression))(NN (lung))(NN (cancer)))(VP (VBD (correlated))(NP (NN (expression))(JJ (several))(NN (kinetochore))(NN (check-point))(NN (gene))(JJ (histopathologic))(JJ (mitotic))(NN (index))))) |ET|  |BS| 155:G05.355.310 211:A11.284.430.106.279.345.190.160.165.500 212:E01.370.225.500.385.500  |ES| 9:1 18:1 19:1 115:1 262:1 328:1 446:1 716:1 717:1 718:1 719:1 720:1 721:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (JJ (Intestinal))(NN (metaplasia))(NN (dysplasia))(JJ (low))(NN (expression))(NN (CDX2)))(VP (MD (may))(VP (VB (serve))(NP (JJ (predictive))(NN (marker))(JJ (gastric))(NN (cancer)))))) |ET|  |BS| 47:A03.556.124 48:C23.550.589 158:D23.101  |ES| 18:1 19:1 86:1 110:1 114:1 115:1 203:1 204:1 491:1 531:1 532:1 533:1 534:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (Wnt/beta-catenin))(NN (signaling))(JJ (critical))(JJ (intestinal))(NN (cell))(NN (proliferation)))(, (,))(VP (VBD (decreased))(NP (NN (CDX2))(NN (expression))(NN (influence))(NN (Wnt))(JJ (signaling-related))(NN (gene))(NN (progression))(JJ (colorectal))(NN (cancer))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 16:C23.550.291.656 47:A03.556.124 69:G02.111.087.800 105:G02.149.115.800.925 183:G04.299.233.750  |ES| 2:1 9:1 17:1 18:1 19:1 48:1 94:1 109:1 114:1 115:1 195:1 202:1 299:1 302:1 825:1 867:1 877:1 878:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (JJ (Isogenic))(JJ (LKB1-knockdown))(NN (breast))(NN (cancer))(NN (cell))(NN (line))(NN (pair)))(VP (VBD (developed)))) |ET|  |BS| 94:A11.251.210  |ES| 18:1 19:1 23:1 94:1 264:1 1165:1 2035:1 2036:1 2037:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NP (NN (CDX2)))(, (,))(NP (NN (master))(NN (regulator))(JJ (intestinal))(NN (phenotype)))(, (,)))(VP (VBN (shown))(NP (NN (play))(JJ (tumor-suppressive))(NN (role))(NN (colon))(NN (cancer))))) |ET|  |BS| 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 51:C04.588.274.476.411.307.180 79:I03.450.642.693 80:G05.695  |ES| 2:1 18:1 19:1 31:1 109:1 113:1 114:1 177:1 234:1 235:1 236:1 237:1 238:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (Silencing))(NN (MLH1)))(VP (ADVP (RB (frequently)))(VBN (seen))(S (NP (JJ (sporadic))(JJ (colorectal))(NN (cancer)))))) |ET|  |BS| 4:C04.588.274.476.411.307 213:F02.830.816.964  |ES| 17:1 18:1 19:1 698:1 722:1 723:1 724:1 725:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (DT (The))(JJ (apoptosis-inducing))(NN (effect))(NN (gastrin))(JJ (colorectal))(NN (cancer))(NN (cell)))(VP (VBZ (relates))(NP (NP (VBN (increased))(NP (NN (IEX-1)))(NN (expression)))(VP (VBG (mediating))(NP (NP (NN (NF-kappa))(NN (B)))(NN (inhibition))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 41:A11 43:F01.145.544 199:D06.472.317.413 200:D06.472.317.413 210:D12.776.260.600  |ES| 17:1 18:1 19:1 47:1 75:1 94:1 103:1 115:1 676:1 691:1 758:1 759:1 760:1 761:1 762:1 763:1  |EV| 
-9.9582845788426244126867459272034e-05  |BT| (S (PP (IN (In))(NP (NN (aggregate))))(, (,))(VP (VBP (conclude))(NP (NP (NP (NN (Let-7))(NN (depletion))(NN (drive))(NN (stem))(NN (cell))(NN (phenotype)))(NN (development))(JJ (intestinal))(NN (cancer)))(, (,))(PP (ADVP (RB (primarily)))(IN (via))(NP (NN (Hmga2))))))) |ET|  |BS| 66:F01.658.293 80:G05.695 101:C04.588.274.476.411 283:D12.776.260.312.937 308:A11.872 557:D02.241.081.069.600.150  |ES| 2:1 18:1 19:1 35:1 94:1 109:1 181:1 236:1 244:1 596:1 1106:1 1613:1 1967:1 1968:1 1969:1 1970:1 1971:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (ADVP (RB (Interestingly)))(, (,))(NP (NP (NP (JJ (gastric))(NN (adenocarcinoma)))(ADJP (RB (significantly))(JJ (frequent)))(NN (Pdx-1-Cre)))(: (;))(NP (NN (Smad4))(-LRB- (-LRB-))(NN (F/F))(-RRB- (-RRB-)))(: (;))(NP (NN (Trp53))(-LRB- (-LRB-))(NN (F/F))(-RRB- (-RRB-)))(: (;))(NP (NP (NP (NN (Cdh1))(-LRB- (-LRB-))(NN (F))(-RRB- (-RRB-)))(PRN (-LRB- (-LRB-))(: (/))(CC (+))(-RRB- (-RRB-))))(NN (mouse))(NN (Pdx-1-Cre)))(: (;))(NP (NN (Smad4))(-LRB- (-LRB-))(NN (F/F))(-RRB- (-RRB-)))(: (;))(NP (NN (Trp53))(-LRB- (-LRB-))(NN (F/F))(-RRB- (-RRB-)))(: (;))(NP (NN (Cdh1))(PRN (-LRB- (-LRB-))(CC (+))(: (/))(CC (+))(-RRB- (-RRB-)))(NN (mouse)))(, (,))(S (NP (VBG (demonstrating))(NN (Cdh1))(NN (heterozygosity)))(VP (VBZ (accelerates))(NP (NN (development))(NN (progression))(JJ (gastric))(NN (adenocarcinoma)))))(, (,))(NP (NN (combination))(NN (loss))(NN (Smad4))(NN (p53)))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 70:A03.556.875.875 84:C04.557.470.200.025 118:D01.248.497.158.380 157:G05.380.383  |ES| 2:1 10:1 12:1 14:1 19:1 32:1 35:1 48:1 51:1 52:1 86:1 124:1 217:1 255:1 518:1 519:1 520:1 521:1 522:1 523:1 524:1 525:1 526:1 527:1 528:1 529:1 530:1  |EV| 
-1.9296473573889982161544409677845e-05  |BT| (S (NP (NN (CRC))(NN (xenograft)))(VP (VBD (differed))(NP (NP (NP (NP (NN (p53))(NN (status)))(PRN (-LRB- (-LRB-))(NP (JJ (wt))(NN (muf)))(-RRB- (-RRB-))))(NN (microsatellite))(NN (instability))(NN (phenotype)))(PRN (-LRB- (-LRB-))(NP (NP (NN (MSI)))(CC (+))(NP (JJ (altered))))(-RRB- (-RRB-)))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 80:G05.695 92:E04.936.764 93:A01.941.875 538:C23.550.362.590  |ES| 10:1 12:1 14:1 19:1 236:1 245:1 265:1 416:1 693:1 1299:1 1332:1 1901:1 1902:1 1903:1 1904:1  |EV| 
-9.316471092095379713526881459984e-05  |BT| (SINV (NP (NP (JJ (Hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(NP (CD (one))(JJ (common))(NN (cancer)))(ADVP (RB (worldwide)))(, (,))(VP (VBD (caused)))(NP (NP (NP (NNP (Hepatitis))(NNP (C))(NN (virus)))(PRN (-LRB- (-LRB-))(NP (NN (HCV)))(-RRB- (-RRB-))))(NN (hepatotoxin)))) |ET|  |BS| 104:C04.557.470.200.025.255 550:B04.450.410  |ES| 2:1 10:1 14:1 18:1 19:1 304:1 441:1 655:1 1010:1 1422:1 1938:1 1954:1 1955:1 2151:1 2506:1 3987:1 3988:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (ADVP (RB (Similarly)))(, (,))(NP (NN (treatment))(JJ (human))(NN (colon))(NN (cancer))(NN (cell))(NN (line))(NN (hypomethylating))(NN (agent)))(VP (VBZ (induces))(NP (NP (JJ (differentiation-related))(NN (gene)))(, (,))(PP (VBG (including))(NP (NN (CDX1))))))) |ET|  |BS| 6:G05.360.340.024.340 52:E02 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 94:A11.251.210  |ES| 2:1 9:1 18:1 19:1 36:1 94:1 113:1 214:1 264:1 546:1 561:1 726:1 727:1 728:1 729:1 730:1  |EV| 
-0.0003692824855528985261710062104612  |BT| (S (NP (JJ (Knock-down))(NN (TnC))(NN (gene)))(VP (VBD (increased))(NP (NN (susceptibility))(JJ (DSS-induced))(NN (colitis)))(, (,))(S (VP (VBN (compared))(S (NP (NP (NN (TnC)))(PRN (-LRB- (-LRB-))(CC (+))(: (/))(CC (+))(-RRB- (-RRB-))))(NP (NNS (littermates)))))))) |ET|  |BS| 53:C06.405.205.265 400:E05.393.335.500 401:C23.550.291.687  |ES| 2:1 9:1 10:1 14:1 19:1 47:1 50:1 51:1 143:1 1343:1 1352:1 1353:1 1354:1 1355:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NP (CD (One))(JJ (common))(JJ (rate-limiting))(NN (mutation)))(JJ (human))(NN (CRC)))(VP (VBZ (occurs))(NP (JJ (adenomatous))(NN (polyposis))(NN (coli))(-LRB- (-LRB-))(NN (APC))(-RRB- (-RRB-))(NN (gene))))) |ET|  |BS| 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 21:G05.360.340.024.340.375.249.050 55:B01.050.150.900.649.801.400.112.400.400 194:G05.355.044.250.750  |ES| 9:1 10:1 11:1 14:1 19:1 34:1 36:1 57:1 58:1 59:1 245:1 654:1 655:1 656:1 657:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NP (NP (JJ (Human))(NN (CRC))(NN (tissue)))(NP (JJR (higher))(NN (level))(NN (miR-221))(NN (miR-222))(JJ (nontumor))(NN (colon))(NN (tissue))))(: (;))(NP (NN (increase)))(VP (VBD (correlated))(NP (VBN (increased))(NN (level))(NN (RelA))(NN (STAT3))(NNS (mRNAs)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 82:D12.644.360.024.342.300 98:A10 111:D13.444.735.544  |ES| 19:1 40:1 47:1 113:1 140:1 141:1 170:1 217:1 245:1 249:1 250:1 251:1 272:1 444:1 445:1 446:1 447:1  |EV| 
-5.000804197583322285858287159499e-06  |BT| (S (NP (JJ (Transgenic))(NN (mouse))(VBG (expressing))(NN (cyclooxygenase-2))(NNS (hepatocytes)))(VP (VBP (reveal))(NP (JJ (minor))(NN (contribution))(NN (enzyme))(NN (chemical))(NN (hepatocarcinogenesis))))) |ET|  |BS| 24:D08.811.600.720.750 99:B01.050.050.136.500 262:A11.436.348 730:D08.811 1108:M01.416  |ES| 19:1 52:1 61:1 810:1 894:1 900:1 1360:1 1670:1 2124:1 2388:1 3880:1 3881:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (ADJP (QP (IN (About))(CD (80)))(NN (%)))(JJ (gastric))(NN (cancer)))(VP (VBD (showed))(NP (JJ (high))(NN (level))(NN (expression))(NN (cyclooxygenase))(CD (2)))(, (,))(S (NP (NN (subset))(NN (case)))(VP (VBP (express))(PP (IN (without))(NP (JJ (unknown))(NN (reason)))))))) |ET|  |BS| 24:D08.811.600.720.750  |ES| 2:1 18:1 19:1 86:1 115:1 132:1 148:1 178:1 208:1 249:1 369:1 573:1 934:1 1195:1 1285:1 2182:1 3180:1 3257:1 3258:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NNS (CONCLUSIONS))(: (:)))(UCP (PP (IN (In))(NP (NN (mouse))))(, (,))(NP (NP (NN (fucosylation))(NN (deficiency))(NN (lead))(NN (colitis))(NN (adenocarcinoma)))(, (,))(NP (NN (loss))(NN (Notch))(NN (activation)))(, (,))(NP (NN (down-regulation))(NN (Hes1)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 53:C06.405.205.265 84:C04.557.470.200.025 85:G02.111.087.225 86:D01.268.556.435 87:C18.654.521  |ES| 2:1 19:1 32:1 52:1 104:1 143:1 225:1 239:1 244:1 252:1 253:1 254:1 255:1 256:1 257:1 258:1  |EV| 
-0.00034111837555078627914895150752272  |BT| (S (NP (NN (Penta-O-galloyl-beta-D-glucose)))(VP (VBZ (induces))(NP (NN (G1))(NN (arrest))(NN (DNA))(JJ (replicative))(NN (S-phase))(NN (arrest)))(NP (NP (ADJP (RB (independently))(JJ (cyclin-dependent)))(NN (kinase))(NN (inhibitor))(NN (1A)))(, (,))(NP (JJ (cyclin-dependent))(NN (kinase))(NN (inhibitor))(NN (1B))(NN (P53))(JJ (human))(NN (breast))(NN (cancer))(NN (cell)))(NP (RB (orally))(JJ (active))(JJ (triple))(JJ (negative))(NN (xenograft))(NN (growth)))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 122:C14.280.383 198:D13.444.308 338:D12.644.360.225.600 1299:D12.644.360.225.500 1404:G02.111.087.222.880  |ES| 2:1 18:1 19:1 23:1 36:1 94:1 102:1 197:1 214:1 265:1 380:1 449:1 470:1 602:1 666:1 670:1 1503:1 1916:1 2052:1 2149:1 4226:1 4546:1 5097:1 5098:1 5099:1 5100:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (ADVP (RB (Herein)))(, (,))(VP (VBD (investigated))(NP (NP (ADJP (FW (vitro))(FW (vivo)))(JJ (anticancer))(NN (effect)))(NP (VBN (associated))(NN (mechanism))(NN (wogonin))(JJ (human))(NN (breast))(NN (cancer)))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400  |ES| 2:1 18:1 19:1 23:1 36:1 75:1 162:1 169:1 216:1 378:1 403:1 428:1 1880:1 2444:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (Animal))(NN (breast))(NN (colon))(NN (tumor))(NN (therapy))(NN (study)))(VP (VBD (showed))(SBAR (S (NP (JJ (15-PGDH))(NN (gene))(NN (therapy)))(VP (VBD (produced))(NP (JJ (significant))(NN (delay))(NN (2LMP))(NN (LS174T))(NN (tumor))(NN (growth)))))))) |ET|  |BS| 8:C04 10:A01.236 19:B01.050 45:G07.700.320.249 51:C04.588.274.476.411.307.180 52:E02  |ES| 7:1 9:1 19:1 23:1 102:1 113:1 129:1 130:1 131:1 132:1 133:1 134:1 135:1 136:1 137:1 138:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (NP (CD (One))(JJ (common))(JJ (rate-limiting))(NN (mutation)))(JJ (human))(NN (CRC)))(VP (VBZ (occurs))(NP (JJ (adenomatous))(NN (polyposis))(NN (coli))(-LRB- (-LRB-))(NN (APC))(-RRB- (-RRB-))(NN (gene))))) |ET|  |BS| 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 21:G05.360.340.024.340.375.249.050 55:B01.050.150.900.649.801.400.112.400.400 194:G05.355.044.250.750  |ES| 9:1 10:1 11:1 14:1 19:1 34:1 36:1 57:1 58:1 59:1 245:1 654:1 655:1 656:1 657:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (NN (17-Allylamino-17-demethoxygeldanamycin)))(VP (VBZ (overcomes))(NP (NN (TRAIL))(NN (resistance))(NN (colon))(NN (cancer))(NN (cell))(NN (line))))) |ET|  |BS| 94:A11.251.210  |ES| 18:1 19:1 94:1 113:1 264:1 1094:1 1695:1 3238:1 3239:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (YY1)))(VP (VBZ (promotes))(NP (NP (NN (colon))(NN (cancer))(NN (growth)))(VP (VBG (inhibiting))(NP (NP (NN (p53)))(S (VP (VBG (promoting))(NP (NN (Wnt))(NN (signaling))(NN (pathway))(NN (serf))(JJ (independent))(JJ (prognostic))(NN (biomarker))(NN (CRC))(NN (patient)))))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 45:G07.700.320.249 50:M01.643 122:C14.280.383 147:G02.149.115.800.925 158:D23.101 258:D12.776.260.235.875  |ES| 12:1 18:1 19:1 102:1 113:1 120:1 195:1 245:1 298:1 383:1 877:1 879:1 880:1 881:1 882:1 883:1 884:1 885:1  |EV| 
-7.5645809245035618151309364520785e-05  |BT| (S (NP (DT (All))(NN (fusion)))(VP (VBD (identified))(SBAR (S (NP (NP (NNP (RET))(NN (KIF5B))(NN (gene)))(, (,))(NP (NP (NNP (RET))(NN (fusion))(NN (CCDC6))(NN (NCOA4))(NN (gene)))(, (,))(NP (JJ (characteristic))(NN (thyroid))(NN (cancer)))(, (,))))(VP (VBD (identified))(NP (JJ (irradiated))(NN (lung))(NN (cell)))))))) |ET|  |BS| 6:G05.360.340.024.340 13:D01.339.387 41:A11 182:A04.411 281:E02.815  |ES| 2:1 9:1 18:1 19:1 94:1 328:1 336:1 623:1 936:1 956:1 965:1 966:1 967:1 968:1 969:1 970:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (ADVP (RB (Moreover)))(, (,))(NP (JJ (gastric))(NN (cancer))(JJ (human)))(ADVP (RB (often)))(VP (VBD (preceded))(NP (NP (JJ (intestinal))(NN (metaplasia)))(, (,))(NP (NN (phenotype))))(S (VP (VBD (described))(SBAR (S (ADVP (RB (strongly)))(VP (VBZ (suggests))(NP (NP (NN (involvement))(NN (Cdx2))(NN (initiation))(NN (process)))(VBG (leading))(JJ (intestinal))(NN (neoplasia))(JJ (gastric))(NN (mucosa)))))))))) |ET|  |BS| 47:A03.556.124 48:C23.550.589 55:B01.050.150.900.649.801.400.112.400.400 80:G05.695 86:D01.268.556.435 190:C04.588.274.476.767 191:A03.556.124.369  |ES| 2:1 18:1 19:1 36:1 86:1 109:1 110:1 213:1 236:1 331:1 579:1 622:1 632:1 633:1 634:1 635:1 636:1 637:1 638:1 639:1 640:1  |EV| 
-1.3767629767824293707256799734751e-06  |BT| (FRAG (SBAR (IN (Although))(S (NP (NP (NP (JJ (additional))(NN (study))(NN (animal))(NN (model)))(VP (VBN (needed))(, (,))))(VP (VBG (finding))(VP (VBP (suggest))(S (VP (VBG (targeting))(NP (NN (HMGA2))))))))(VP (MD (could))(SBAR (S (NP (RB (therapeutically))(JJ (beneficial))(NN (lung))(NN (cancer))(NN (cancer)))(VP (VBD (characterized))(NP (VBN (increased))(NN (HMGA2))(NN (expression)))))))))) |ET|  |BS| 283:D12.776.260.312.937 284:N03.349.380.420 285:E05.598  |ES| 2:1 18:1 19:1 46:1 47:1 72:1 107:1 115:1 131:1 328:1 616:1 796:1 908:1 927:1 980:1 981:1 982:1 983:1 984:1 985:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (NP (NP (NP (NNS (CONCLUSIONS))(: (:)))(S (NP (JJ (Acute))(NN (ablation))(NN (GSK3beta))(JJ (colorectal))(NN (cancer))(NN (cell)))(VP (VBZ (activates))(NP (JJ (p53-dependent))(NN (apoptosis)))))(SBAR (S (VP (VBZ (antagonizes))(NP (NN (tumor))(NN (growth)))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 39:G04.299.139.160 41:A11 45:G07.700.320.249  |ES| 7:1 17:1 18:1 19:1 88:1 89:1 91:1 94:1 102:1 104:1 239:1 301:1 794:1 1893:1 1894:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (LINE-1))(NN (methylation)))(VP (VBD (decreased))(SBAR (S (NP (NN (transition))(JJ (intestinal))(NN (metaplasia))(JJ (gastric))(NN (adenoma))(NN (decrease)))(VP (VBD (occurred))(NP (NN (transition))(JJ (gastric))(NN (adenoma))(NN (GC)))))))) |ET|  |BS| 17:C04.557.470.035 36:G02.111.087.029.538 47:A03.556.124 48:C23.550.589 70:A03.556.875.875  |ES| 19:1 42:1 81:1 86:1 109:1 110:1 202:1 295:1 551:1 552:1 553:1 554:1  |EV| 
0.00041788035725208173528158472898042  |BT| (FRAG (NP (S (NP (NP (NNS (Mice))(NN (mutation))(NN (mismatch))(NN (repair))(NN (gene)))(, (,))(NP (NN (Msh2))(NN (Mlh1)))(, (,)))(VP (VBP (exhibit))(S (NP (NN (mismatch))(NN (repair))(NN (defect)))(VP (VBN (predisposed))(S (VP (VBG (developing))(NP (JJ (gastrointestinal))(NN (cancer)))))))))(, (,))(NN (lymphoma))(NN (tumor))(NN (organ))(NN (system)))) |ET|  |BS| 6:G05.360.340.024.340 8:C04 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 174:G02.111.087.219.220 175:J01.897.280.500.269 176:C04.557.386  |ES| 2:1 7:1 9:1 18:1 19:1 34:1 183:1 513:1 583:1 584:1 585:1 586:1 587:1 588:1 589:1 590:1 591:1 592:1 593:1  |EV| 
-0.00040815028093276264908872974501719  |BT| (NP (NP (DT (The))(JJ (K-rasVal12-augmented))(NN (apoptosis))(JJ (unrelated))(NN (dysplasia)))(: (;))(S (NP (VBN (enhanced))(NN (apoptosis)))(ADVP (RB (also)))(VP (VBD (observed))(SBAR (S (NP (NN (cycling))(JJ (nondysplastic))(NNS (enterocytes)))(VP (VBP (produce))(NP (NN (K-rasVal12))(NN (TAg))(JJ (COOH-terminal))(NN (truncation))))))))) |ET|  |BS| 39:G04.299.139.160 1475:A03.556.124.369.290  |ES| 5:1 19:1 89:1 203:1 217:1 261:1 385:1 691:1 1565:1 5362:1 5406:1 5508:1 5535:1 5536:1 5537:1 5538:1 5539:1 5540:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NP (NN (Immunohistochemistry))(NN (beta-catenin)))(, (,))(NP (NN (c-myc)))(, (,))(NP (NP (NN (Ki-67))(NN (TUNEL-staining)))(VP (VBN (performed))(VP (VBP (investigate))(NP (NP (NN (TQ))(POS ('s)))(NN (effect))(JJ (major))(JJ (colorectal))(NN (cancer))(NN (pathway)))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 143:E01.370.225.500.607.512 144:E05.393.475  |ES| 2:1 17:1 18:1 19:1 60:1 75:1 383:1 454:1 455:1 456:1 457:1 458:1 459:1 460:1 461:1 462:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (ADVP (RB (Herein)))(, (,))(VP (VBP (show))(SBAR (S (NP (NNP (NANOG)))(VP (VBD (expressed))(NP (NP (NN (NANOG1))(NN (NANOGP8))(JJ (human))(JJ (colorectal))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (CRC)))(-RRB- (-RRB-))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400  |ES| 2:1 6:1 10:1 14:1 17:1 18:1 19:1 36:1 245:1 428:1 429:1 430:1 431:1 432:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (PP (IN (In))(NP (NN (study))))(, (,))(VP (VBP (demonstrate))(S (NP (NP (NP (NN (histone))(NN (deacetylase))(NN (inhibitor)))(PRN (-LRB- (-LRB-))(NP (NN (HDACi)))(-RRB- (-RRB-))))(NN (vorinostat))(NN (LBH589)))(VP (ADVP (RB (significantly)))(VBP (downregulate))(NP (NN (TS))(NN (gene))(NN (expression))(NN (panel))(NN (colon))(NN (cancer))(NN (cell))(NN (line))))))) |ET|  |BS| 94:A11.251.210 153:D27.505.519.389.360 154:Z01.058.266.887 155:G05.355.310  |ES| 2:1 9:1 10:1 14:1 18:1 19:1 94:1 113:1 115:1 124:1 131:1 244:1 264:1 380:1 502:1 503:1 504:1 505:1 506:1 507:1 508:1 509:1 510:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (NN (K-Ras))(NN (mutation))(NN (treatment))(NN (outcome))(JJ (colorectal))(NN (cancer))(NN (patient)))(VP (VBG (receiving))(NP (JJ (exclusive))(NN (fluoropyrimidine))(NN (therapy))))) |ET|  |BS| 1:G05.360.340.024.340.375.500.791.550 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 50:M01.643 52:E02 164:E01.789.800  |ES| 13:1 17:1 18:1 19:1 34:1 120:1 130:1 546:1 547:1 548:1 549:1 550:1  |EV| 
-0.00041787912499419155309965390188154  |BT| (NP (NP (NN (Protein))(NN (kinase))(JJ (potential))(JJ (chemotherapeutic))(NN (target))(JJ (colorectal))(NN (cancer)))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 151:E02.319 823:D08.811.913.696.620.682.700.150.125  |ES| 17:1 18:1 19:1 160:1 470:1 827:1 1762:1 2911:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (PRP (We)))(VP (VBD (investigated))(SBAR (IN (whether))(S (NP (NN (microRNA))(NN (miR-221))(NN (miR-222)))(VP (VBP (regulate))(NP (NP (NP (NN (NF-kappaB))(NN (signal))(NN (transducer))(NN (activator))(NN (transcription))(CD (3)))(PRN (-LRB- (-LRB-))(NP (NN (STAT3)))(-RRB- (-RRB-))))(NP (NN (activation))(JJ (human))(NN (CRC))(NN (cell))(NN (line))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 184:D13.150.650.319 210:D12.776.260.600 249:G05.355.315.800 250:E07.305.812  |ES| 10:1 14:1 19:1 36:1 94:1 140:1 141:1 221:1 225:1 245:1 251:1 264:1 403:1 487:1 714:1 843:1 857:1 858:1 859:1 860:1 861:1 862:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (NP (PRP$ (Our))(VBN (integrated))(NN (microRNA)))(VP (VBG (profiling))(NP (NN (approach)))))(VP (VBD (identified))(S (NP (NN (miR-195-5p)))(ADVP (RB (independently)))(VP (VBN (associated))(NP (NN (prognosis))(NN (CRC))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 163:E01.789 184:D13.150.650.319  |ES| 19:1 169:1 245:1 271:1 544:1 623:1 658:1 857:1 911:1 2147:1 2148:1 2149:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (S (S (VP (TO (To))(VP (VB (understand))(NP (NN (miR-141))))))(VP (VBZ (mediates))(NP (NN (phenotype))(JJ (pancreatic))(NN (cancer))(NN (cell)))))(S (, (,))(NP (NNS (bioinformatics))(NN (tool)))(VP (VBN (used))(VP (VBP (identify))(NP (NN (MAP4K4))(JJ (potential))(NN (target))(NN (miR-141))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 80:G05.695 239:F02.463.188.357 240:H01.158.273.180  |ES| 2:1 18:1 19:1 94:1 160:1 236:1 463:1 465:1 467:1 476:1 755:1 827:1 828:1 829:1 830:1 831:1 832:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NP (NN (Germline))(JJ (somatic))(NN (mutation))(NN (BER))(NN (gene)))(, (,))(NP (NP (NN (MutY))(NN (Homolog)))(PRN (-LRB- (-LRB-))(NP (NN (MUTYH/MYH)))(-RRB- (-RRB-))))(NP (NP (JJ (DNA-directed))(NN (polymerase)))(PRN (-LRB- (-LRB-))(NP (NN (POLB)))(-RRB- (-RRB-))))(, (,)))(NP (VBN (associated))(VBN (increased))(NN (risk))(JJ (colorectal))(NN (cancer)))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 61:E05.318.740.600.800 127:D08.811.913.696.445.308.300 128:E02.095.301 129:G02.111.087.219 130:A05.360.490  |ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 34:1 47:1 169:1 171:1 387:1 388:1 389:1 390:1 391:1 392:1 393:1 394:1 395:1  |EV| 
-9.7162647703528861459210119733143e-07  |BT| (S (S (NP (NN (Rimonabant)))(VP (VBZ (inhibits))(NP (JJ (human))(NN (colon))(NN (cancer))(NN (cell))(NN (growth)))))(VP (VBZ (reduces))(NP (NN (formation))(JJ (precancerous))(NN (lesion))(NN (mouse))(NN (colon))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 20:G03.495 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 122:C14.280.383 341:C04.834  |ES| 18:1 19:1 36:1 43:1 52:1 94:1 102:1 113:1 142:1 615:1 1130:1 1131:1 2949:1  |EV| 
-7.4775785940287692321604140488489e-05  |BT| (S (PP (IN (In))(NP (JJ (present))(NN (study))))(, (,))(NP (NP (NN (report))(NN (vitro))(NN (treatment))(JJ (primary))(NN (hepatoma)))(, (,))(NP (NP (NN (HepG2)))(PRN (-LRB- (-LRB-))(NP (JJ (wild-type))(NN (p53)))(-RRB- (-RRB-))))(, (,))(NP (NP (NN (PLC/PRF/5)))(PRN (-LRB- (-LRB-))(NP (NN (p53-mutant)))(-RRB- (-RRB-))))(, (,))(NP (NP (NN (Hep3B)))(PRN (-LRB- (-LRB-))(ADJP (JJ (p53-deleted)))(-RRB- (-RRB-))))(NP (NP (NN (cell))(NN (2-chloroethyl-3-sarcosinamide-1-nitrosourea)))(PRN (-LRB- (-LRB-))(NP (NN (SarCNU)))(-RRB- (-RRB-)))))(VP (VBD (resulted))(NP (NP (NN (upregulation))(NN (p53))(, (,))(NN (p21))(-LRB- (-LRB-))(NN (Cip1/Waf1))(-RRB- (-RRB-)))(, (,))(NP (NP (VBN (phosphorylated))(NN (cdc-2))(NN (Tyr15))(JJ (wild-type))(NN (p53))(NN (cell))(NN (phosphorylation))(NN (cdc-2))(NN (Tyr15)))(NP (JJ (p53-mutant))(NP (JJ (p53-deleted))(NN (hepatoma))(NN (cell)))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 41:A11 52:E02 104:C04.557.470.200.025.255 249:G05.355.315.800 339:G02.111.087.880 515:C04.588.274.623 972:G02.111.087.677 1371:I01.409.418.750.600.650.225  |ES| 2:1 8:1 10:1 12:1 14:1 19:1 94:1 131:1 216:1 244:1 344:1 417:1 546:1 594:1 1126:1 1135:1 1307:1 3426:1 3481:1 3896:1 4502:1 4924:1 4925:1 4926:1 4927:1 4928:1 4929:1 4930:1 4931:1 4932:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NP (NN (Overexpression))(NN (miR-141))(JJ (pancreatic))(NN (cancer))(NN (cell)))(VBD (inhibited))(NP (NN (cell))(NN (proliferation)))(, (,))(NP (NP (NN (clonogenicity)))(, (,))(NP (NN (invasion)))(: (;))(NP (VBN (induced))(NN (G1))(NN (arrest))(NN (apoptosis)))(: (;))(NP (VBN (enhanced))(NN (chemosensitivity)))))) |ET|  |BS| 39:G04.299.139.160 41:A11 122:C14.280.383 183:G04.299.233.750  |ES| 2:1 18:1 19:1 89:1 94:1 217:1 299:1 365:1 385:1 386:1 412:1 463:1 467:1 602:1 620:1 668:1 669:1 670:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (gamma-Secretase))(NN (inhibitor)))(VP (VBP (abrogate))(NP (NP (JJ (oxaliplatin-induced))(NN (activation))(NN (Notch-1))(NN (signaling))(NN (pathway))(NN (colon))(NN (cancer))(NN (cell)))(VP (VBG (resulting))(NP (VBN (enhanced))(NN (chemosensitivity))))))) |ET|  |BS| 41:A11 69:G02.111.087.800 125:D08.811.277.656.300.032 126:G02.111.087.800  |ES| 18:1 19:1 20:1 94:1 113:1 195:1 225:1 379:1 380:1 381:1 382:1 383:1 384:1 385:1 386:1  |EV| 
-0.00015050676227661597284673833385682  |BT| (S (NP (NP (NP (NNP (Administration))(NN (acetaminophen))(NN (Jnk)))(PRN (-LRB- (-LRB-))(NP (NN (Deltahepa)))(-RRB- (-RRB-))))(NN (mouse)))(VP (VBD (produced))(NP (NP (JJR (greater))(NN (level))(NN (liver))(NN (injury)))(VBN (observed))(NP (NP (NN (Jnk1)))(PRN (-LRB- (-LRB-))(NP (NN (Deltahepa)))(-RRB- (-RRB-))))(NN (control))(NN (mouse)))(, (,))(NP (VBN (based))(NN (level))(NN (serum))(NN (marker))(JJ (microscopic))(JJ (histologic))(NN (analysis))(NN (liver))(NN (tissue))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 98:A10 242:A03.620 333:D01.045 426:E01.370.350.515 661:D02.065.199.092.040 1176:D23.101  |ES| 2:1 10:1 14:1 19:1 52:1 134:1 249:1 261:1 272:1 289:1 534:1 661:1 836:1 1992:1 2204:1 2346:1 2412:1 2414:1 2415:1 2416:1 2741:1 4069:1 4070:1 4071:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (DT (This))(NN (study)))(VP (VBP (show))(SBAR (S (NP (NN (c-Myc))(JJ (critical))(JJ (Apc-dependent))(JJ (intestinal))(NN (tumorigenesis))(NN (mouse)))(VP (VBZ (provides))(NP (JJ (potential))(JJ (therapeutic))(NN (target))(NN (treatment))(JJ (colorectal))(NN (cancer)))))))) |ET|  |BS| 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 47:A03.556.124 52:E02  |ES| 17:1 18:1 19:1 52:1 78:1 109:1 131:1 160:1 429:1 541:1 546:1 807:1 815:1 824:1 825:1 826:1 827:1  |EV| 
-0.00036084384559492699295901729783509  |BT| (S (NP (NP (NNP (PIRC))(NN (rat)))(PRN (-LRB- (-LRB-))(NP (NP (NN (F344/NTac-Apc)))(PRN (-LRB- (-LRB-))(NP (NN (am1137)))(-RRB- (-RRB-))))(-RRB- (-RRB-))))(NP (VBN (mutated))(NN (Apc))(NN (gene)))(ADVP (RB (spontaneously)))(VP (VB (develop))(NP (NN (colon)))(NP (NN (tumor)))(ADVP (RB (thus)))(VP (NP (VBG (mimicking))(JJ (familial))(NP (NP (JJ (adenomatous))(NN (polyposis))(-LRB- (-LRB-))(NN (FAP))(-RRB- (-RRB-))(JJ (sporadic))(JJ (colorectal))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (CRC)))(-RRB- (-RRB-))))(RB (closely))(JJ (Apc-based))(JJ (rodent))(NN (model)))(S (VP (VBG (developing))(NP (NP (NN (tumor)))(ADJP (RB (mostly))(JJ (small)))(NN (intestine)))))))) |ET|  |BS| 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 21:G05.360.340.024.340.375.249.050 51:C04.588.274.476.411.307.180 102:C04.588.274.476.411 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 333:D01.045 514:B01.050.150.900.649.865 590:B01.050.050.199.520.760.200  |ES| 7:1 9:1 10:1 14:1 17:1 18:1 19:1 57:1 58:1 72:1 113:1 229:1 245:1 280:1 356:1 590:1 648:1 725:1 750:1 849:1 854:1 855:1 1334:1 1506:1 2133:1 2168:1 2169:1 2170:1 2171:1 2172:1 2173:1 2174:1  |EV| 
0.00041788035725208173528158472898042  |BT| (FRAG (PP (IN (As))(NP (NP (JJ (incomplete))(JJ (intestinal))(NN (metaplasia)))(VP (VBN (associated))(NP (NP (JJR (higher))(NN (risk))(JJ (gastric))(NN (cancer)))(, (,))(NP (JJR (lower))(NN (CDX2))(NN (expression)))(VP (VBD (compared))(NP (NP (JJ (complete))(JJ (intestinal))(NN (metaplasia))(JJ (normal))(NN (colon))(NN (epithelium)))(VP (VBN (resolved))(NP (NP (JJ (current))(NN (contradiction))(JJ (tumor-suppressive))(NN (role)))(NN (CDX2))(NN (colon))(JJ (high))(NN (prevalence))(NN (CDX2))(JJ (intestinal))(NN (metaplasia))))))))))) |ET|  |BS| 8:C04 15:F01.829.316.616 46:A03.556.124.526.356 47:A03.556.124 48:C23.550.589 60:E05.318.308.985.525.750 61:E05.318.740.600.800 62:A10.272  |ES| 2:1 18:1 19:1 31:1 50:1 86:1 108:1 109:1 110:1 113:1 114:1 115:1 117:1 118:1 168:1 169:1 170:1 171:1 172:1 173:1 174:1 175:1 176:1 177:1 178:1 179:1  |EV| 
-2.8450020117531948926625773310661e-12  |BT| (S (NP (NN (Iso-3)))(VP (VBD (induced))(NP (NP (NP (NN (growth))(NN (arrest))(NN (cancer))(NN (cell))(NN (G0/G1)))(JJ (concomitant)))(SBAR (S (NP (VBN (increased))(NN (p21))(NN (p27))(NN (expression)))(VP (VBD (reduced))(NP (NP (NN (cyclin))(NN (E1)))(, (,))(NP (NN (PCNA))(NN (c-myc))(NN (level)))))))))) |ET|  |BS| 41:A11 45:G07.700.320.249 768:D12.776.660.740  |ES| 2:1 18:1 19:1 47:1 94:1 102:1 115:1 249:1 412:1 452:1 455:1 602:1 743:1 1124:1 1135:1 1580:1 1681:1 2698:1 5666:1 5673:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (PP (IN (In))(NP (NN (addition))))(, (,))(NP (NN (PIM))(NN (kinase)))(VP (VBP (activate))(S (NP (NN (MYC))(NN (signaling))(NN (mRNA))(NN (translation))(NN (prostate))(NN (cancer)))(VP (VBP (cooperate))(S (NP (NN (MYC)))(VP (VB (accelerate))(NP (NN (tumorigenesis))))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 69:G02.111.087.800 145:G02.111.087.675.871  |ES| 2:1 18:1 19:1 77:1 78:1 195:1 244:1 325:1 468:1 469:1 470:1 471:1 472:1 473:1 474:1 475:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (DT (This)))(VP (VBD (led))(SBAR (S (NP (NN (u)))(VP (VBP (investigate))(SBAR (S (NP (NP (JJ (antitumor))(NN (growth)))(NP (JJ (antimetastatic))(NN (activity))(NN (alpha-mangostin))(JJ (immunocompetent))(NN (xenograft))(NN (model))(NN (mouse))(JJ (metastatic))(JJ (mammary))(NN (cancer))(NN (p53))(NN (mutation))))(VP (VBZ (induces))(NP (NP (JJ (metastatic))(NN (spectrum)))(NP (JJ (similar))(VBN (seen))(JJ (human))(NN (breast))(NN (cancer)))))))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 10:A01.236 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 86:D01.268.556.435 92:E04.936.764 93:A01.941.875 113:C04.697.650 213:F02.830.816.964 609:A01.236.249 610:G12.460  |ES| 12:1 18:1 19:1 23:1 34:1 36:1 52:1 72:1 102:1 214:1 265:1 332:1 337:1 399:1 459:1 724:1 807:1 2228:1 2243:1 2244:1 2245:1 2246:1 2247:1 2248:1 2249:1  |EV| 
-0.00041788020158833871775527768477332  |BT| (NP (NP (NP (NNP (Gemcitabine)))(, (,))(NP (JJ (current))(JJ (standard-of-care))(NN (chemotherapy))(JJ (pancreatic))(NN (cancer)))(, (,))(NP (JJ (limited))(JJ (clinical))(NN (benefit))))) |ET|  |BS| 151:E02.319  |ES| 2:1 18:1 19:1 84:1 175:1 467:1 495:1 2131:1 2617:1 2618:1 2619:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (NP (NP (NN (Beta-catenin/T-cell))(NN (factor)))(PRN (-LRB- (-LRB-))(NP (NN (Tcf)))(-RRB- (-RRB-))))(NN (signaling)))(NP (RB (constitutively))(JJ (active))(NN (majority))(JJ (human))(JJ (colorectal))(NN (cancer)))(, (,))(VP (VBG (accompanying))(NP (NN (change))(NN (Bcl-2))(NN (expression))))) |ET|  |BS| 4:C04.588.274.476.411.307 23:D12.776.091.249 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 68:A11.118.637.555.567.569 69:G02.111.087.800  |ES| 2:1 10:1 14:1 17:1 18:1 19:1 36:1 115:1 158:1 185:1 193:1 194:1 195:1 196:1 197:1 198:1 199:1 200:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (JJ (Aberrant))(NN (methylation))(NN (SPARC))(NN (gene))(NN (promoter))(JJ (clinical))(NN (implication))(JJ (gastric))(NN (cancer)))) |ET|  |BS| 35:G02.111.570.080.689.675 36:G02.111.087.029.538 37:D12.776.157.125.715  |ES| 9:1 18:1 19:1 80:1 81:1 82:1 83:1 84:1 85:1 86:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (K-Ras))(NN (mutation))(NN (treatment))(NN (outcome))(JJ (colorectal))(NN (cancer))(NN (patient)))(VP (VBG (receiving))(NP (JJ (exclusive))(NN (fluoropyrimidine))(NN (therapy))))) |ET|  |BS| 1:G05.360.340.024.340.375.500.791.550 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 50:M01.643 52:E02 164:E01.789.800  |ES| 13:1 17:1 18:1 19:1 34:1 120:1 130:1 546:1 547:1 548:1 549:1 550:1  |EV| 
0.00041788035725208173528158472898042  |BT| (FRAG (ADVP (RB (Furthermore)))(, (,))(NP (NP (JJ (high))(NN (uniform))(NN (expression))(NN (CDX2)))(NP (NP (JJ (characteristic))(JJ (metastatic))(JJ (colorectal))(NN (cancer)))(, (,))(NP (ADJP (ADJP (JJ (weak)))(CC (and/or))(ADJP (JJ (focal))))(NN (CDX2))(NN (expression))(JJ (alert))(JJ (surgical))(NN (pathologist))(NN (possibility))(JJ (primary))(NN (lung))(NN (adenocarcinoma)))(, (,))(NP (ADVP (RB (especially)))(NN (presence))(NN (goblet))(NN (cell))(NN (morphology)))))) |ET|  |BS| 113:C04.697.650 114:J01.637.215 115:E04  |ES| 2:1 17:1 18:1 19:1 94:1 114:1 115:1 149:1 178:1 255:1 328:1 334:1 335:1 336:1 337:1 338:1 339:1 340:1 341:1 342:1 343:1 344:1 345:1 346:1 347:1 348:1  |EV| 
-0.00017219398670487162661402180674486  |BT| (S (VP (ADVP (RB (Here)))(VBP (show))(SBAR (S (NP (NP (JJ (ATP-binding))(NN (cassette))(NN (member))(NN (B5)))(PRN (-LRB- (-LRB-))(NP (NN (ABCB5)))(-RRB- (-RRB-))))(VP (VBZ (identifies))(NP (NP (JJ (therapy-refractory))(NN (tumor))(NN (cell))(JJ (colorectal))(NN (cancer))(NN (patient)))(PP (VBG (following))(NP (NP (NN (fluorouracil)))(PRN (-LRB- (-LRB-))(NP (NN (5-FU)))(-RRB- (-RRB-)))))))))(: (-))(S (NP (VBN (based))(NN (chemoradiation))(NN (therapy)))(VP (VBP (provide))(NP (NP (NN (evidence)))(JJ (functional))(NN (role))(NN (ABCB5))(JJ (colorectal))(NN (cancer))(NN (5-FU))(NN (resistance))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 15:F01.829.316.616 50:M01.643 52:E02 59:E02.186.079 333:D01.045 560:D03.383.742.698.875.404 1004:E02.095.147  |ES| 7:1 10:1 14:1 17:1 18:1 19:1 31:1 38:1 94:1 120:1 130:1 400:1 415:1 429:1 711:1 769:1 1094:1 1610:1 2308:1 2895:1 2919:1 3505:1 3506:1 3507:1 3508:1 3509:1 3510:1 3511:1  |EV| 
-3.6685561858214310593240270463866e-06  |BT| (NP (NNS (Mutations))(NP (NP (NN (APC))(NN (gene))(NN (play))(JJ (critical))(NN (role)))(JJ (sporadic))(JJ (familial))(NN (form))(JJ (colorectal))(NN (cancer)))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 18:G05.365.590 21:G05.360.340.024.340.375.249.050 44:F01.829.263 79:I03.450.642.693 189:V02.460  |ES| 9:1 11:1 17:1 18:1 19:1 31:1 238:1 630:1 725:1 825:1 854:1 1410:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (ADVP (RB (However)))(, (,))(NP (NP (JJ (molecular))(NN (detail)))(VP (VBG (underlying))(NP (NP (NN (miR-146a))(JJ (mediated))(NN (regulation))(NN (target))(NN (gene))(JJ (precise))(JJ (biological))(NN (function))(NN (cancer)))(, (,))(NP (NP (RB (especially))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-)))))))(VP (VBZ (remains))(ADJP (JJ (unclear))))) |ET|  |BS| 104:C04.557.470.200.025.255 140:G05.355.315 141:G16.100  |ES| 2:1 9:1 10:1 14:1 18:1 19:1 33:1 160:1 161:1 303:1 304:1 345:1 433:1 434:1 435:1 436:1 437:1 438:1 439:1 440:1 441:1 442:1 443:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (S (NP (NN (CRC))(NN (patient)))(VP (VBD (decreased))(NP (NN (level))(NN (miR-195-5p))(NN (tumor))(NN (tissue))))(S (ADVP (RB (significantly)))(VP (VBD (shortened))(SBAR (S (NP (NN (survival)))(VP (VBD (revealed))(NP (NP (NP (NN (TCGA))(NN (colon))(NN (adenocarcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (COAD)))(-RRB- (-RRB-))))(NN (dataset))(NN (CRC))(NN (cohort)))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 46:A03.556.124.526.356 50:M01.643 84:C04.557.470.200.025 96:I03.784 97:V02.302 98:A10  |ES| 7:1 10:1 14:1 19:1 113:1 120:1 121:1 124:1 202:1 245:1 249:1 255:1 271:1 272:1 273:1 274:1 275:1 276:1 277:1 278:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (JJ (Microsomal))(NN (prostaglandin))(NN (E))(NN (synthase-1)))(VP (VBN (involved))(NP (JJ (multiple))(NN (step))(NN (colon))(NN (carcinogenesis))))) |ET|  |BS| 33:C04.697.098 46:A03.556.124.526.356  |ES| 19:1 113:1 207:1 649:1 774:1 2083:1 2084:1 2085:1 2086:1 2087:1  |EV| 
-0.0001426840806299373154431009425025  |BT| (S (ADVP (RB (Here)))(, (,))(NP (NN (report))(NNP (MPA)))(ADVP (RB (also)))(VP (VBZ (induces))(NP (NP (NN (differentiation))(JJ (androgen-independent))(NN (prostate))(NN (cancer)))(NP (VBN (derived))(NN (cell))(NN (line))(NN (DU145)))))) |ET|  |BS| 74:G04.299.151 94:A11.251.210 852:C04.588.945.440.770.500  |ES| 2:1 5:1 18:1 19:1 77:1 94:1 214:1 215:1 264:1 400:1 417:1 1721:1 3423:1 3519:1 3520:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (DT (The))(NN (role))(NN (KCNQ1))(NN (mouse))(JJ (human))(JJ (gastrointestinal))(NN (cancer)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 55:B01.050.150.900.649.801.400.112.400.400  |ES| 18:1 19:1 31:1 36:1 52:1 183:1 691:1 791:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (miR-137)))(VP (VBZ (regulates))(SBAR (S (NP (JJ (constitutive))(NN (androstane))(NN (receptor)))(VP (VBZ (modulates))(NP (NN (doxorubicin))(NN (sensitivity))(JJ (parental))(JJ (doxorubicin-resistant))(NN (neuroblastoma))(NN (cell)))))))) |ET|  |BS| 41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320  |ES| 19:1 94:1 186:1 420:1 422:1 423:1 424:1 599:1 603:1 604:1 605:1 606:1 607:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (DT (The))(NNP (Ron))(NN (receptor))(NN (tyrosine))(NN (kinase)))(VP (VBD (overexpressed))(NP (ADJP (RB (approximately))(JJ (half)))(JJ (human))(NN (colon))(NN (cancer))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400  |ES| 18:1 19:1 25:1 36:1 113:1 186:1 470:1 691:1 1843:1 2341:1 3853:1 3854:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (HDAC8))(NN (STAT3)))(VP (VBP (repress))(NP (NN (BMF))(NN (gene))(NN (activity))(NN (colon))(NN (cancer))(NN (cell))))) |ET|  |BS| 6:G05.360.340.024.340 9:G05.360.340.024.340.375.500 41:A11 46:A03.556.124.526.356 82:D12.644.360.024.342.300  |ES| 9:1 18:1 19:1 94:1 113:1 251:1 396:1 397:1 398:1 399:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NP (NN (PURPOSE))(: (:)))(NN (IFITM3))(, (,))(JJ (IFN-inducible))(NN (gene)))(, (,))(NP (VBN (overexpressed))(JJ (human))(JJ (colorectal))(NN (cancer)))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400  |ES| 2:1 9:1 17:1 18:1 19:1 25:1 36:1 104:1 687:1 696:1 697:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (DT (A))(NP (JJ (pivotal))(NN (signaling))(NN (network))(JJ (colorectal))(NN (cancer))(NN (cell))))(VP (VBZ (involves))(NP (NP (NP (NN (glycogen))(NN (synthase))(NN (kinase-3beta)))(PRN (-LRB- (-LRB-))(NP (NN (GSK3beta)))(-RRB- (-RRB-))))(, (,))(NP (NP (JJ (multifunctional))(NN (kinase)))(SBAR (WHNP (WP$ (whose))(NN (role))(NN (tumor))(NN (cell))(NN (survival)))(S (VP (VBN (defined))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 15:F01.829.316.616 69:G02.111.087.800 108:G04.299.316 469:D08.811.913.696 588:I01.880.853.500.600  |ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 31:1 66:1 69:1 92:1 93:1 94:1 195:1 274:1 470:1 680:1 919:1 1673:1 1878:1 1894:1 2154:1 3248:1  |EV| 
-9.0714532015062632197555103630293e-05  |BT| (S (NP (NP (JJ (Kruppel-like))(NN (factor))(CD (9)))(PRN (-LRB- (-LRB-))(NP (NN (KLF9)))(-RRB- (-RRB-))))(VP (VBZ (prevents))(NP (JJ (colorectal))(NN (cancer))(NN (inhibition))(JJ (interferon-related))(NN (signaling))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 69:G02.111.087.800 617:D12.644.276.374.440 774:D12.776.124.125.375  |ES| 10:1 14:1 17:1 18:1 19:1 103:1 185:1 195:1 318:1 703:1 2717:1 2718:1 2719:1  |EV| 
-7.8260389267555824366340289088839e-05  |BT| (S (NP (NN (Cooperativity))(NN (E-cadherin))(NN (Smad4))(NN (loss)))(VP (VBP (promote))(NP (JJ (diffuse-type))(JJ (gastric))(NN (adenocarcinoma))(NN (metastasis))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 70:A03.556.875.875 84:C04.557.470.200.025 113:C04.697.650 613:D12.776.395.550.200.200 968:F01.145.813.115  |ES| 19:1 32:1 86:1 255:1 521:1 679:1 806:1 2267:1 3411:1 3412:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (S (NP (NN (Mouse))(NN (strain)))(VP (VBD (disrupted))(S (NP (NP (NN (sPLA)))(-LRB- (-LRB-))(CD (2))(-RRB- (-RRB-))(NN (gene))(JJ (susceptible))(NN (Min))(NN (phenotype)))(VP (VBP (develop))(NP (JJ (numerous))(JJ (intestinal))(NN (polyp))))))(, (,)))(IN (whereas))(S (NP (NP (NN (mouse))(JJ (normal))(NN (sPLA)))(PRN (-LRB- (-LRB-))(NP (CD (2)))(-RRB- (-RRB-))))(VP (VBP (develop))(NP (JJ (limited))(NN (number))(NN (polyp)))))) |ET|  |BS| 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 80:G05.695 192:D08.811.277.352.100.680.750.937.750 193:C23.300.825.411 444:C23.300.825  |ES| 2:1 9:1 10:1 14:1 19:1 52:1 109:1 118:1 148:1 236:1 372:1 646:1 647:1 648:1 650:1 899:1 2039:1 2127:1 2128:1 2129:1 2130:1 2131:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (PP (IN (In))(NP (NN (summary))))(, (,))(NP (NN (colon))(NN (cancer))(NN (cell)))(VP (MD (may))(VP (VB (up-regulate))(NP (NN (Notch-1))(JJ (protective))(NN (mechanism))(NN (response))(NN (chemotherapy)))))) |ET|  |BS| 41:A11 150:Z01.542.248.960 151:E02.319  |ES| 2:1 18:1 19:1 20:1 94:1 113:1 162:1 244:1 490:1 491:1 492:1 493:1 494:1 495:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (NP (JJ (Hypoxia-inducible))(NN (factor)))(PRN (-LRB- (-LRB-))(NP (NNS (HIFs)))(-RRB- (-RRB-))))(VP (VBP (accumulate))(NP (NP (JJ (neoplastic))(JJ (inflammatory))(NN (cell)))(PP (IN (within))(NP (NN (tumor))(NN (microenvironment))(NN (impact))(NN (progression))(NN (variety))(NN (disease))))(, (,))(PP (VBG (including))(NP (JJ (colorectal))(NN (cancer))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 16:C23.550.291.656 41:A11 1011:C23.888.852.079 1012:G04.366.500  |ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 48:1 94:1 185:1 561:1 893:1 952:1 998:1 2122:1 2430:1 3537:1 3538:1 3539:1 3540:1 3541:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NP (ADJP (RB (Little))(VBN (known)))(JJ (biological))(NN (significance))(NN (ELK1)))(, (,))(NP (JJ (transcriptional))(NN (factor))))(VP (VBZ (activates))(NP (NP (JJ (downstream))(NN (target)))(PP (VBG (including))(NP (NP (NN (c-fos))(NN (proto-oncogene)))(, (,))(NP (NN (bladder))(NN (cancer)))))))) |ET|  |BS| 165:G05.360.340.024.340.375.500.791.330 166:D12.776.930 167:H01.158.273  |ES| 2:1 18:1 19:1 160:1 185:1 301:1 440:1 555:1 556:1 557:1 558:1 559:1 560:1 561:1 562:1 563:1 564:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (DT (The))(NN (adhesion))(NN (molecule))(NN (L1CAM)))(VP (VBZ (mediates))(S (NP (NN (chemoresistance))(NN (migration))(NN (tumor))(NN (cell))(JJ (elevated))(NN (CRC))(NN (tissue)))(NP (VBN (associated))(JJ (metastatic))(NN (spread))(JJ (poor))(NN (prognosis))(NN (patient)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 98:A10 113:C04.697.650 159:I01.880.735.634 163:E01.789 221:D12.776.395.550.200.250.520.578 222:D12.776.395.550.200  |ES| 7:1 19:1 94:1 120:1 169:1 180:1 182:1 245:1 272:1 337:1 514:1 544:1 545:1 691:1 753:1 754:1 755:1 756:1 757:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (NP (NP (NNS (Mutations))(NP (NP (NN (APC))(NN (gene))(JJ (responsible))(JJ (familial))(JJ (adenomatous))(NN (polyposis)))(PRN (-LRB- (-LRB-))(NP (NN (FAP)))(-RRB- (-RRB-))))(NN (majority))(JJ (sporadic))(JJ (colorectal))(NN (cancer)))) |ET|  |BS| 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 18:G05.365.590 21:G05.360.340.024.340.375.249.050  |ES| 9:1 10:1 11:1 14:1 17:1 18:1 19:1 57:1 58:1 198:1 725:1 854:1 1410:1 2132:1 2133:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (JJ (Stable))(NN (transfection))(NN (Ha-ras))(JJ (human))(NN (colon))(NN (cancer))(NN (line))(NN (CaCo2)))(VP (VBP (result))(NP (JJ (morphologic))(NN (differentiation))(JJ (small))(NN (bowel))(NN (phenotype))))) |ET|  |BS| 1:G05.360.340.024.340.375.500.791.550 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 80:G05.695 216:Z01.107.084.900.425 217:E05.393.350.810 218:A03.556.124.684  |ES| 18:1 19:1 36:1 101:1 113:1 215:1 236:1 264:1 745:1 746:1 747:1 748:1 749:1 750:1 751:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (NN (ESE-1))(: (/))(NN (EGR-1))(NN (pathway)))(VP (VBP (play))(NP (NN (role)))(NP (ADJP (JJ (tolfenamic))(JJ (acid-induced)))(NP (NN (apoptosis))(JJ (colorectal))(NN (cancer))(NN (cell)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 39:G04.299.139.160 41:A11 79:I03.450.642.693  |ES| 17:1 18:1 19:1 31:1 89:1 94:1 238:1 383:1 2597:1 2598:1 2599:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (NP (NP (NP (NNS (Tumors)))(VP (VBG (lacking))(S (NP (NN (DNA))(NN (mismatch))(NN (repair))(NN (activity))(-LRB- (-LRB-))(NN (MMR))(-RRB- (-RRB-))(NN (patient)))(NP (NP (NP (JJ (Hereditary))(NN (Nonpolyposis))(JJ (Colorectal))(NN (Cancer)))(PRN (-LRB- (-LRB-))(NP (NN (HNPCC)))(-RRB- (-RRB-))))(SBAR (S (NP (JJ (sporadic))(JJ (colorectal))(NN (cancer)))(VP (VBD (identified))(NP (NP (NN (presence))(JJ (high))(NN (level))(NN (instability))(JJ (repetitive))(NN (sequence)))(VP (VBN (known))(NP (NP (NNS (microsatellites)))(PRN (-LRB- (-LRB-))(NP (NN (MSI)))(-RRB- (-RRB-)))))))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 50:M01.643 174:G02.111.087.219.220 394:G02.111.570.080.708.800.500 524:C04.588.274.476.411.307.190 538:C23.550.362.590 612:G02.111.570.080.708  |ES| 10:1 14:1 17:1 18:1 19:1 53:1 120:1 178:1 249:1 293:1 346:1 376:1 399:1 513:1 556:1 584:1 623:1 666:1 725:1 1299:1 1919:1 2134:1 2136:1 2260:1 2261:1 2262:1 2263:1 2264:1 2265:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (DT (The))(NN (ECM-modulator))(NN (inter)))(: (-))(S (NP (NP (NN (alpha-trypsin))(NN (inhibitor))(JJ (heavy))(NN (chain))(NN (family))(NN (member)))(CD (five))(-LRB- (-LRB-))(NN (ITIH5))(-RRB- (-RRB-)))(ADVP (RB (recently)))(VP (VBD (identified))(NP (NP (NN (tumor))(NN (suppressor)))(VP (ADVP (RB (potentially)))(VP (VBN (involved))(NP (NP (VBG (impairing))(NN (breast))(NN (cancer))(NN (progression))(JJ (molecular))(NN (mechanism)))(VP (VBG (underlying))(S (NP (NN (function)))(ADJP (ADVP (RB (still)))(JJ (elusive)))))))))))) |ET|  |BS| 16:C23.550.291.656 44:F01.829.263 206:G05.360.340.024.340.375.249 223:A11.284.295.310  |ES| 7:1 10:1 14:1 18:1 19:1 23:1 33:1 48:1 97:1 161:1 162:1 380:1 435:1 623:1 691:1 700:1 764:1 765:1 766:1 767:1 768:1 769:1 770:1 771:1 772:1 773:1 774:1 775:1 776:1 777:1  |EV| 
-0.00010553394123079089250705209224179  |BT| (S (NP (NN (Overexpression))(NN (glutamine))(NN (synthetase)))(VP (VBN (associated))(NP (NNS (beta-catenin-mutations))(NN (mouse))(NN (liver))(NN (tumor))(NN (promotion))(NN (hepatocarcinogenesis))(NN (phenobarbital))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 515:C04.588.274.623 756:D03.383.742.698.253.650 1057:D08.811.464.259.200.600  |ES| 7:1 19:1 52:1 169:1 668:1 836:1 900:1 2337:1 2685:1 3691:1 3692:1 3693:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (S (NP (NN (Cdx2)))(VP (VBZ (induces))(NP (NN (differentiation))(JJ (intestinal))(JJ (epithelial))(NN (cell))(NN (vitro)))))(: (;))(S (ADVP (RB (therefore)))(, (,))(VP (VBD (sought))(VP (VB (establish))(SBAR (IN (whether))(S (NP (JJ (causal))(NN (relationship)))(VP (VBZ (exists))(NP (NN (Cdx2))(NN (activation))(JJ (intestinal))(NN (metaplasia)))))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 48:C23.550.589 73:N05.715.350.200 74:G04.299.151 75:A11.436  |ES| 2:1 19:1 94:1 109:1 110:1 127:1 213:1 214:1 215:1 216:1 217:1 218:1 219:1 220:1 221:1 222:1 223:1 224:1 225:1  |EV| 
-5.5289560169320683957749906767276e-05  |BT| (S (S (NP (PRP (We)))(ADVP (RB (also)))(VP (VBD (found))(SBAR (S (NP (NN (pectolinarigenin)))(ADVP (RB (significantly)))(VP (VBD (suppressed))(NP (NN (osteosarcoma))(NN (cell))(NN (proliferation))))))))(, (,))(VP (VBD (induced))(NP (NP (NP (NP (NP (NN (apoptosis)))(VP (VBN (reduced))(NP (NN (level))(NN (STAT3))(JJ (downstream))(NN (protein))(NN (cyclin))(NN (D1)))))(, (,))(NP (NN (Survivin)))(, (,)))(NP (NP (NN (B-cell))(NN (lymphoma))(CD (2)))(PRN (-LRB- (-LRB-))(NP (NN (Bcl-2)))(-RRB- (-RRB-)))))(, (,))(NP (NP (NP (NN (B-cell))(NN (lymphoma))(NN (extra-large)))(PRN (-LRB- (-LRB-))(NP (NN (Bcl-xl)))(-RRB- (-RRB-))))(NP (NP (JJ (myeloid))(NN (cell))(NN (leukemia))(CD (1)))(PRN (-LRB- (-LRB-))(NP (NN (Mcl-1)))(-RRB- (-RRB-)))))))) |ET|  |BS| 39:G04.299.139.160 41:A11 82:D12.644.360.024.342.300 183:G04.299.233.750 215:D12.644.360.262.150.100 361:C04.557.337 447:C04.557.450.565.575.650 1424:C04.557.386.480.150 1455:A11.148.378.590 1456:C04.557.337.539 1457:A11.627  |ES| 2:1 4:1 5:1 10:1 14:1 19:1 37:1 89:1 94:1 98:1 124:1 148:1 158:1 249:1 251:1 299:1 307:1 412:1 452:1 560:1 591:1 743:1 744:1 843:1 1562:1 2199:1 2785:1 3779:1 5187:1 5312:1 5343:1 5344:1 5345:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (CDX2))(NN (expression)))(ADVP (RB (progressively)))(VP (VBD (decreased))(NP (NP (JJ (human))(JJ (gastric))(JJ (intestinal))(NN (metaplasia)))(, (,))(NP (NN (dysplasia))(NN (cancer)))))) |ET|  |BS| 47:A03.556.124 48:C23.550.589 55:B01.050.150.900.649.801.400.112.400.400 70:A03.556.875.875  |ES| 2:1 18:1 19:1 36:1 86:1 109:1 110:1 114:1 115:1 201:1 202:1 203:1  |EV| 
-0.00011532968146197794534479896810808  |BT| (S (NP (PRP (We)))(VP (VBP (hypothesize))(SBAR (S (NP (NP (NN (NF-kappaB))(NN (suppression))(JJ (novel))(NN (inhibitor))(NN (dimethylaminoparthenolide)))(PRN (-LRB- (-LRB-))(NP (NN (DMAPT)))(-RRB- (-RRB-))))(VP (MD (may))(VP (VB (enhance))(NP (NN (effect))(NN (gemcitabine))(JJ (pancreatic))(NN (cancer))))))))) |ET|  |BS| 210:D12.776.260.600 259:D12.776.395.240.150.500  |ES| 10:1 14:1 18:1 19:1 75:1 380:1 467:1 491:1 714:1 843:1 891:1 1690:1 2453:1 2504:1 2505:1 3141:1 3142:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (ADVP (RB (Here)))(, (,))(VP (VBD (investigated))(NP (NP (NN (cell))(NN (death))(NN (signaling))(NN (mechanism)))(VP (VBD (induced))(NP (NN (PGG))(JJ (human))(NN (prostate))(NN (cancer))(NN (cell))(JJ (different))(NN (p53))(JJ (functional))(NN (status))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 41:A11 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 133:D01.248.497.158.685.750.744.600 134:G04.299.139 135:C23.550.260  |ES| 2:1 12:1 18:1 19:1 36:1 77:1 94:1 162:1 195:1 400:1 403:1 411:1 412:1 413:1 414:1 415:1 416:1  |EV| 
-0.00018004915093826692751299844985624  |BT| (S (NP (PRP (We)))(VP (VBD (hypothesized))(SBAR (S (NP (NNP (BIM))(NN (intron))(CD (2))(NN (deletion))(NN (polymorphism))(NN (increase))(NN (lung))(NN (cancer))(NN (risk)))(VP (VBZ (predicts))(NP (NP (NP (JJ (poor))(NN (prognosis))(JJ (non-small))(NN (lung))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (NSCLC)))(-RRB- (-RRB-))))(NN (patient)))))))) |ET|  |BS| 50:M01.643 61:E05.318.740.600.800 159:I01.880.735.634 163:E01.789 305:G05.360.340.024.220.400 306:G05.355.600.800 307:G05.365.795  |ES| 10:1 14:1 18:1 19:1 40:1 120:1 148:1 171:1 328:1 329:1 544:1 545:1 694:1 843:1 1058:1 1059:1 1060:1 1633:1 1750:1 1751:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (PRP (We)))(VP (VBD (aimed))(VP (VB (investigate))(SBAR (IN (whether))(S (NP (NN (Notch1))(NN (signaling)))(VP (VBZ (contributes))(NP (NN (carcinogenesis))(JJ (gastric))(NN (cancer))(NN (CD133))(NN (induction))))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 69:G02.111.087.800  |ES| 18:1 19:1 86:1 195:1 207:1 221:1 459:1 651:1 652:1 736:1 843:1 844:1 845:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (PRP (We)))(VP (VBD (tested))(S (NP (NP (NP (NN (role))(JJ (basic))(NN (fibroblast))(NN (growth))(NN (factor)))(PRN (-LRB- (-LRB-))(NP (NN (bFGF)))(-RRB- (-RRB-))))(NP (JJ (vascular))(NP (NP (JJ (endothelial))(NN (growth))(NN (factor)))(PRN (-LRB- (-LRB-))(NP (NN (VEGF)))(-RRB- (-RRB-))))))(VP (VBP (switch))(NP (JJ (angiogenic))(NN (phenotype)))(NP (CD (35))(NN (patient))(JJ (colorectal))(NN (cancer))(JJ (different))(NN (stage))(NN (disease))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 80:G05.695 288:C23.550.288 371:A07.231 1067:D12.644.276.624.120 1130:D12.644.276.390  |ES| 10:1 14:1 17:1 18:1 19:1 31:1 102:1 120:1 185:1 236:1 414:1 843:1 998:1 1129:1 1251:1 2066:1 2213:1 2709:1 2988:1 3092:1 3733:1 3790:1 3947:1 3948:1  |EV| 
0.00041788035725208173528158472898042  |BT| (FRAG (NP (NP (DT (The))(NN (level))(NN (miR-221))(NN (miR-222)))(RRC (ADVP (RB (well)))(NP (NP (NN (RelA)))(, (,))(NP (NN (STAT3)))(, (,))(NP (NP (NN (PDLIM2))(NNS (mRNAs)))(VP (VBN (measured))(NP (CD (57))(JJ (paired))(NN (CRC))(JJ (adjacent))(JJ (nontumor))(NN (tissue))(NN (patient))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 82:D12.644.360.024.342.300 98:A10 111:D13.444.735.544 228:E05.978  |ES| 2:1 19:1 120:1 126:1 140:1 141:1 245:1 249:1 250:1 251:1 272:1 326:1 445:1 447:1 691:1 787:1 788:1 789:1 790:1  |EV| 
-0.0001494399863181611678997207093289  |BT| (S (NP (JJ (Great))(NN (interest)))(VP (VBD (focused))(NP (NN (chemoprevention))(JJ (colonic))(NN (carcinogenesis))(JJ (oral))(NN (administration)))(NP (NP (NP (JJ (ursodeoxycholic))(NN (acid)))(PRN (-LRB- (-LRB-))(NP (NN (UDCA)))(-RRB- (-RRB-))))(NN (administration)))(VP (ADVP (RB (reportedly)))(VBZ (reduces))(NP (NN (incidence))(NN (colon))(NN (cancer))(NN (animal))(NN (experiment)))))) |ET|  |BS| 33:C04.697.098 38:Z01.058.290.120.180 40:Z01.542.248.700 46:A03.556.124.526.356 253:E02.319.162 434:E05.318.308.985.525.375 737:D04.808.105.225.272.962 738:E05.017 739:E02.319.267.100  |ES| 10:1 14:1 18:1 19:1 46:1 113:1 142:1 207:1 677:1 870:1 1051:1 1275:1 1511:1 2310:1 2311:1 2575:1 2628:1 2629:1 2630:1 2631:1 2632:1  |EV| 
-0.00040180913697299147635533245193074  |BT| (S (NP (PRP$ (Our))(JJ (recent))(NN (study)))(VP (VBZ (indicates))(SBAR (S (NP (NNS (AR)))(VP (VBZ (upregulates))(NP (NP (NN (expression))(NN (tumor))(NN (suppressor))(NN (gene))(NN (PTEN))(NN (promoter)))(NN (activation))(NN (breast))(NN (cancer)))))))) |ET|  |BS| 155:G05.355.310 206:G05.360.340.024.340.375.249  |ES| 7:1 9:1 18:1 19:1 23:1 83:1 115:1 131:1 225:1 628:1 658:1 659:1 700:1 1936:1 2152:1 2153:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NN (Methylation))(NN (rate))(NN (SPARC))(NN (gene)))(NP (NP (CD (80))(NN (%)))(NP (CD (ten))(JJ (gastric))(NN (cancer))(NN (cell))(NN (line)))(NP (NP (CD (74))(NN (%)))(PRN (-LRB- (-LRB-))(NP (CD (163))(CD (220)))(-RRB- (-RRB-))))(NP (JJ (primary))(NN (tumor))))(, (,))(NP (NP (ADJP (CD (5))(NN (%)))(JJ (normal))(JJ (gastric))(NN (mucosa)))(PRN (-LRB- (-LRB-))(S (NP (NN (n)))(VP (JJ (=))(NP (CD (40)))))(-RRB- (-RRB-))))) |ET|  |BS| 8:C04 36:G02.111.087.029.538 37:D12.776.157.125.715 94:A11.251.210 171:E05.318.308.985.775.500 172:A03.556.875.875.440 173:C07.465.864.500  |ES| 2:1 7:1 9:1 10:1 14:1 18:1 19:1 41:1 82:1 86:1 94:1 118:1 264:1 344:1 369:1 572:1 573:1 574:1 575:1 576:1 577:1 578:1 579:1 580:1 581:1 582:1  |EV| 
-0.00014173311331457983958809210278673  |BT| (S (NP (DT (These)))(VP (VBP (result))(VP (VBP (suggest))(SBAR (S (NP (NN (inflexinol)))(VP (VBZ (inhibits))(NP (NN (colon))(NN (cancer))(NN (cell))(NN (growth)))(PP (IN (via))(NP (NP (NN (induction)))(NP (NP (JJ (apoptotic))(NN (cell))(NN (death))(NN (inactivation))(NN (NF-kappaB)))(NP (NP (JJ (direct))(NN (modification))(NN (cysteine))(NN (residue)))(NP (NN (p50))(NN (subunit))(NN (NF-kappaB))))))))))))) |ET|  |BS| 38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 45:G07.700.320.249 46:A03.556.124.526.356 122:C14.280.383 210:D12.776.260.600 583:D12.776.813 643:D02.886.030.230  |ES| 18:1 19:1 94:1 101:1 102:1 113:1 411:1 596:1 615:1 714:1 736:1 792:1 796:1 1314:1 1891:1 2110:1 2223:1 2373:1 2374:1 2375:1 2376:1 2377:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (DT (The))(NN (analysis))(JJ (clinical))(JJ (characteristic)))(VP (VBD (showed))(SBAR (S (NP (NN (miR-141)))(ADVP (RB (significantly)))(VP (VBD (downregulated))(NP (NN (tissue))(NN (cell))(NN (line))(JJ (pancreatic))(NN (cancer)))))))) |ET|  |BS| 94:A11.251.210 98:A10  |ES| 18:1 19:1 84:1 94:1 124:1 132:1 264:1 272:1 336:1 426:1 463:1 467:1 661:1 691:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (NP (NP (NNP (UNLABELLED)))(: (:))(NP (NP (NP (NN (Loss))(NN (E-cadherin)))(PRN (-LRB- (-LRB-))(NP (NN (CDH1)))(-RRB- (-RRB-))))(, (,))(NP (NN (Smad4)))(, (,))(NP (NP (NN (p53))(VBN (shown))(NN (play))(JJ (integral))(NN (role)))(ADJP (JJ (gastric))))(, (,))(NP (JJ (intestinal))(, (,))(NN (breast))(NN (cancer))(NN (formation))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 12:Z01.542.049 15:F01.829.316.616 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 70:A03.556.875.875 79:I03.450.642.693 613:D12.776.395.550.200.200  |ES| 2:1 10:1 12:1 14:1 18:1 19:1 23:1 31:1 43:1 86:1 104:1 109:1 237:1 238:1 521:1 1788:1 2266:1 2267:1 2268:1 2269:1  |EV| 
0.00041788035725208173528158472898042  |BT| (FRAG (NP (ADVP (FW (In))(FW (vitro)))(PRN (, (,))(NP (NP (VBN (forced))(NN (expression))(NN (Cdx2))(JJ (human))(NN (colon))(NN (cancer))(NN (cell))(NN (line)))(SBAR (S (NP (VBN (retarded))(NN (wound))(NN (repair)))(VP (VBD (reduced))(NP (NN (migration)))))))(, (,))))(SBAR (IN (whereas))(S (NP (NN (inhibition))(NN (Cdx2))(NN (expression))(NN (RNA))(NN (interference)))(VP (VBD (enhanced))(NP (NN (migration))))))) |ET|  |BS| 43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 89:G16.100.856.891 94:A11.251.210 122:C14.280.383 156:G05.355.315.203.374.790  |ES| 2:1 18:1 19:1 36:1 94:1 103:1 113:1 115:1 213:1 216:1 244:1 264:1 267:1 372:1 385:1 452:1 511:1 512:1 513:1 514:1 515:1 516:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NP (NP (NN (Beta-catenin/T-cell))(NN (factor)))(PRN (-LRB- (-LRB-))(NP (NN (Tcf)))(-RRB- (-RRB-))))(NN (signaling)))(NP (RB (constitutively))(JJ (active))(NN (majority))(JJ (human))(JJ (colorectal))(NN (cancer)))(, (,))(VP (VBG (accompanying))(NP (NN (change))(NN (Bcl-2))(NN (expression))))) |ET|  |BS| 4:C04.588.274.476.411.307 23:D12.776.091.249 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 68:A11.118.637.555.567.569 69:G02.111.087.800  |ES| 2:1 10:1 14:1 17:1 18:1 19:1 36:1 115:1 158:1 185:1 193:1 194:1 195:1 196:1 197:1 198:1 199:1 200:1  |EV| 
-1.0832679695863835743485648066553e-05  |BT| (S (NP (PRP (We)))(ADVP (RB (previously)))(VP (VBD (demonstrated))(SBAR (S (NP (NN (simvastatin)))(VP (VBZ (inhibits))(NP (NP (NN (NF-kappaB)))(SBAR (S (NP (NN (signaling))(JJ (human))(JJ (intestinal))(JJ (epithelial))(NN (cell)))(VP (VBZ (ameliorates))(NP (JJ (acute))(JJ (murine))(NN (colitis)))))))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 47:A03.556.124 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 75:A11.436 122:C14.280.383 210:D12.776.260.600 754:D02.455.426.559.847.638.400.900  |ES| 19:1 36:1 90:1 94:1 109:1 127:1 143:1 195:1 615:1 627:1 714:1 843:1 1175:1 1527:1 2679:1 2877:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NP (NN (Incubation))(NN (CRC))(NN (cell))(NN (miR-221))(NN (miR-222))(NN (inhibitor)))(SBAR (S (NP (VBD (reduced))(NN (proliferation))(NN (colony))(NN (formation)))(VP (VBN (compared))(NP (NN (control))(NN (cell)))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 20:G03.495 41:A11 109:I01.696.116  |ES| 19:1 43:1 50:1 94:1 140:1 141:1 245:1 289:1 299:1 314:1 380:1 452:1 517:1  |EV| 
-0.00010908474710783302476235778755154  |BT| (S (ADVP (RB (Here)))(, (,))(NP (NN (report))(NN (level))(NN (MT-1))(NN (MT-2A)))(ADVP (RB (drastically)))(VP (VBD (reduced))(NP (JJ (primary))(NP (NP (JJ (human))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NNS (HCCs)))(-RRB- (-RRB-))))(JJ (diethylnitrosamine-induced))(NN (liver))(NN (tumor))(NN (mouse)))(, (,))(NP (ADVP (RB (primarily)))(JJ (due))(NP (JJ (transcriptional))(NN (repression)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 208:F01.393.821 209:G02.111.087.847 515:C04.588.274.623 554:D02.654.442.200  |ES| 2:1 7:1 10:1 14:1 19:1 36:1 52:1 249:1 303:1 304:1 344:1 400:1 417:1 452:1 559:1 706:1 836:1 1132:1 1970:1 2732:1 2851:1 4203:1 4204:1 4205:1  |EV| 
-0.00037160441487154053860630931183096  |BT| (S (NP (NN (DEPDC1)))(VP (VBD (required))(NP (NN (cell))(NN (cycle))(NN (progression))(NN (motility))(JJ (nasopharyngeal))(NN (carcinoma))))) |ET|  |BS| 16:C23.550.291.656 353:G04.299.134  |ES| 19:1 48:1 94:1 304:1 601:1 1174:1 1176:1 1177:1 1178:1  |EV| 
-0.00032016432761207348940690753380522  |BT| (SINV (PP (IN (By))(NP (NN (sequencing))(NN (Apc))(NN (Ctnnb1))(NN (gene))))(, (,))(VBD (found))(S (S (NP (JJ (PhIP-induced))(JJ (small))(JJ (intestinal))(NN (tumor))(JJ (obese))(NN (mouse)))(VP (VBD (carried))(NP (JJ (single))(JJ (heterozygous))(NN (mutation))(NN (Apc)))(PP (IN (By))(NP (JJ (bisulfite-sequencing))(NN (CpG))(NN (island))(NN (Apc))))))(, (,))(VP (VBD (found))(NP (NP (NN (DNA))(NN (hypermethylation))(NN (CpG))(NN (cluster))(JJ (located))(NN (transcription))(NN (initiation))(NN (site)))(, (,))(SBAR (S (ADVP (JJ (likely)))(VP (VBD (caused))(NP (NN (inactivation))(JJ (wild-type))(NN (Apc))(NN (allele)))))))))) |ET|  |BS| 3:C04.557.470.035.215.100 6:G05.360.340.024.340 8:C04 18:G05.365.590 23:D12.776.091.249 25:G02.111.570.080 26:G02.111.570.080 27:G02.111.570.080 38:Z01.058.290.120.180 40:Z01.542.248.700 77:G05.360.340.024.340.030 157:G05.380.383 195:G02.111.570.080.380.160 198:D13.444.308 218:A03.556.124.684 247:G01.374.676.530 765:B01.050.150.900.649.865.635.505.500.550.530 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 1515:G05.360.340.024.340.137.750.840 1516:G02.111.570.080.380.160  |ES| 2:1 7:1 8:1 9:1 19:1 34:1 37:1 52:1 109:1 230:1 280:1 487:1 637:1 662:1 663:1 664:1 666:1 750:1 786:1 1003:1 1314:1 1328:1 1839:1 1868:1 2205:1 2468:1 2506:1 2846:1 4032:1 4435:1 5580:1 5581:1 5582:1  |EV| 
-0.00041208610995574490587500804394949  |BT| (NP (NP (NP (NP (JJ (Altered))(NN (expression))(JJ (human))(NN (enhancer))(NN (filamentation))(CD (1)))(PRN (-LRB- (-LRB-))(NP (NP (NN (HEF1)))(: (;))(NP (ADJP (RB (also))(VBN (known)))(NN (NEDD9))(NN (Cas-L))))(-RRB- (-RRB-))))(NP (VBN (implicated))(NN (progression))(NN (melanoma))(, (,))(NN (breast))(, (,))(NN (CRC))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 10:A01.236 15:F01.829.316.616 16:C23.550.291.656 32:C04.697.098.500 33:C04.697.098 55:B01.050.150.900.649.801.400.112.400.400 142:I01.880.604 239:F02.463.188.357 282:C04.557.465.625.650.510  |ES| 2:1 5:1 10:1 14:1 19:1 23:1 31:1 36:1 48:1 78:1 98:1 115:1 217:1 245:1 433:1 438:1 556:1 889:1 971:1 972:1 973:1 974:1 975:1 976:1 977:1 978:1 979:1  |EV| 
-5.7898148931992410304303575685481e-05  |BT| (S (NP (NN (CRC)))(VP (VBD (initiated))(NP (NP (NN (mutation))(NN (tumor))(NN (suppressor))(NN (gene)))(, (,))(NP (JJ (adenomatous))(NN (polyposis))(NN (coli))(-LRB- (-LRB-))(NN (APC))(-RRB- (-RRB-))))(, (,))(NP (NN (beta-catenin))(NN (gene))))) |ET|  |BS| 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 18:G05.365.590 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 206:G05.360.340.024.340.375.249  |ES| 2:1 7:1 9:1 10:1 11:1 14:1 19:1 34:1 57:1 58:1 59:1 60:1 245:1 700:1 1900:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (S (VP (VBG (Crossing))(NP (NP (NP (NN (Apc)))(PRN (-LRB- (-LRB-))(NP (NN (Delta14)))(: (/))(CC (+))(-RRB- (-RRB-))))(NP (NP (NN (mouse))(JJ (prone))(JJ (spontaneous))(JJ (intestinal))(NN (tumor))(NN (development))(NN (pCdx2-9LacZ)))(NP (JJ (transgenic))(NN (mouse))(S (VP (VBG (containing))(NP (NN (LacZ))(NN (reporter))(NN (control))(JJ (9.3-kb))(NN (Cdx2))(NN (promoter))))))))))(VP (VBD (showed))(SBAR (S (NP (NN (promoter))(NN (segment)))(VP (VBZ (contains))(NP (NP (NN (sequence)))(VP (VBG (recapitulating))(NP (NN (decrease))(NN (Cdx2))(NN (expression))(JJ (intestinal))(NN (cancer)))))))))) |ET|  |BS| 3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 26:G02.111.570.080 99:B01.050.050.136.500 100:G05.360.340.024.686.545 101:C04.588.274.476.411 102:C04.588.274.476.411 103:G11.427.695.525  |ES| 7:1 10:1 14:1 18:1 19:1 35:1 52:1 83:1 109:1 115:1 132:1 213:1 279:1 280:1 281:1 282:1 283:1 284:1 285:1 286:1 287:1 288:1 289:1 290:1 291:1 292:1 293:1 294:1 295:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (CDX2))(NN (expression)))(ADVP (RB (progressively)))(VP (VBD (decreased))(NP (NP (JJ (human))(JJ (gastric))(JJ (intestinal))(NN (metaplasia)))(, (,))(NP (NN (dysplasia))(NN (cancer)))))) |ET|  |BS| 33:C04.697.098 47:A03.556.124 48:C23.550.589 55:B01.050.150.900.649.801.400.112.400.400 70:A03.556.875.875  |ES| 2:1 18:1 19:1 36:1 86:1 109:1 110:1 114:1 115:1 159:1 201:1 202:1 203:1 204:1 205:1 206:1 207:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (PRP (We)))(VP (VBD (examined))(NP (NN (apobec-1))(NN (gene))(NN (expression))(JJ (human))(JJ (gastrointestinal))(NN (tumor))(NN (colon))(JJ (cancer-derived))(NN (cell))(NN (line))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 155:G05.355.310 244:C04.588.274.476  |ES| 7:1 9:1 19:1 36:1 94:1 113:1 115:1 183:1 264:1 324:1 843:1 847:1 848:1  |EV| 
-0.00039197507493191063865367596008582  |BT| (S (NP (NN (Liver))(NN (tumor)))(VP (VBD (induced))(NP (NP (JJ (male))(NNP (Fischer))(NN (F344))(NN (rat))(NN (diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-)))))) |ET|  |BS| 515:C04.588.274.623 554:D02.654.442.200 590:B01.050.050.199.520.760.200  |ES| 7:1 10:1 14:1 19:1 412:1 849:1 1402:1 1875:1 1952:1 2721:1 3185:1 4288:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (JJ (Aldo-keto))(NN (reductase))(NN (family))(CD (1))(NN (B10))(NN (gene))(NN (silencing)))(VP (VBP (result))(NP (NP (NN (growth))(NN (inhibition))(JJ (colorectal))(NN (cancer))(NN (cell)))(: (:))(NP (NP (NN (Implication))(NN (cancer)))(NN (intervention)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 42:G05.355.315.203.374 43:F01.145.544 44:F01.829.263 45:G07.700.320.249  |ES| 9:1 17:1 18:1 19:1 94:1 95:1 96:1 97:1 98:1 99:1 100:1 101:1 102:1 103:1 104:1 105:1 106:1  |EV| 
-5.453616852990877256202040257449e-05  |BT| (NP (NP (NNS (RESULTS))(: (:)))(S (NP (NN (Nestin))(NN (expression)))(ADVP (RB (significantly)))(VP (VBD (associated))(NP (NP (JJ (poor))(NN (survival))(NN (patient))(JJ (triple-negative))(NN (breast))(NN (cancer)))(PRN (-LRB- (-LRB-))(S (NP (NN (P)))(VP (JJ (=))(NP (CD (0.01)))))(-RRB- (-RRB-))))))) |ET|  |BS| 50:M01.643 96:I03.784 159:I01.880.735.634 160:C04.588.180.788 1047:D05.750.078.593.540  |ES| 10:1 14:1 18:1 19:1 23:1 26:1 104:1 115:1 120:1 124:1 169:1 274:1 311:1 315:1 545:1 581:1 710:1 3650:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (NP (JJ (Combined))(NN (treatment))(NN (EPLE))(NN (5-fluorouracil)))(, (,))(NP (JJ (first-line))(NN (chemotherapy))(NN (CRC))(NN (patient)))(, (,)))(VP (VBD (achieved))(NP (JJ (synergistic))(NN (effect))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 151:E02.319 560:D03.383.742.698.875.404 618:E02.186  |ES| 2:1 19:1 75:1 120:1 245:1 495:1 546:1 2012:1 2307:1 2488:1 2489:1 2490:1 2491:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (PP (IN (In))(NP (JJ (particular))))(, (,))(NP (NP (NN (expression))(JJ (intestine-specific))(NN (transcription))(NN (factor))(NN (Cdx2)))(, (,))(NP (JJ (key))(NN (gene))(JJ (intestinal))(NN (identity)))(VP (VBD (downregulated))(NP (NP (JJ (invasive))(NN (cancer))(NN (cell)))(, (,))(VP (VBD (reduced))(NP (NN (wound))(NN (healing))(NN (vitro))))))))) |ET|  |BS| 41:A11 47:A03.556.124 89:G16.100.856.891 149:G05.360.340.024.340.364.875.890  |ES| 2:1 9:1 18:1 19:1 94:1 109:1 115:1 159:1 185:1 213:1 216:1 244:1 267:1 268:1 426:1 452:1 485:1 486:1 487:1 488:1 489:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (Mir-660)))(VP (VBD (downregulated))(SBAR (S (NP (NN (lung))(NN (cancer))(NN (patient))(NN (replacement)))(VP (VBZ (inhibits))(NP (NP (NN (lung))(NN (tumorigenesis)))(VP (VBG (targeting))(NP (NN (MDM2-p53))(NN (interaction)))))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 32:C04.697.098.500 33:C04.697.098 50:M01.643 122:C14.280.383 181:E04.936.494 182:A04.411  |ES| 18:1 19:1 78:1 120:1 328:1 426:1 613:1 614:1 615:1 616:1 617:1 618:1  |EV| 
-0.0003653053628800972951751191430958  |BT| (S (NP (NN (Liver))(NN (fibrosis)))(VP (VBD (induced))(NP (NP (NN (carbon))(NN (tetrachloride)))(, (,))(NP (NN (bile))(NN (duct))(NN (ligation)))(, (,))(NP (NP (NN (disruption))(JJ (multidrug-resistance))(NN (transporter))(CD (2))(NN (gene)))(PRN (-LRB- (-LRB-))(NP (NN (Mdr2)))(-RRB- (-RRB-))))))) |ET|  |BS| 227:D12.776.157.530 676:C06.552.630 1220:D02.455.526.439.150 1221:G05.360.340.024.340.361 1222:A03.159.183 1223:E04.426  |ES| 2:1 9:1 10:1 14:1 19:1 148:1 412:1 779:1 949:1 1602:1 1621:1 1622:1 2721:1 4278:1 4279:1 4282:1 4283:1 4284:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (CDX2))(NN (expression)))(VP (ADVP (RB (significantly)))(VBD (decreased))(NP (NP (JJ (incomplete))(JJ (intestinal))(NN (metaplasia)))(, (,))(NP (VBP (express))(NP (NP (JJ (gastric))(NN (mucin)))(PRN (-LRB- (-LRB-))(NP (NN (MUC5AC))(NN (MUC6)))(-RRB- (-RRB-))))(JJ (intestinal))(NP (NP (NN (mucin)))(PRN (-LRB- (-LRB-))(NP (NN (MUC2)))(-RRB- (-RRB-)))))(, (,)))(VP (VBD (compared))(NP (JJ (complete))(JJ (intestinal))(NN (metaplasia))))(, (,))(S (VP (VBP (express))(NP (NP (JJ (intestinal))(NN (mucin)))(PRN (-LRB- (-LRB-))(NP (NN (MUC2)))(-RRB- (-RRB-)))))))) |ET|  |BS| 47:A03.556.124 48:C23.550.589 71:D12.776.395.560.631 72:D12.776.395.560.631.100  |ES| 2:1 10:1 14:1 19:1 50:1 86:1 108:1 109:1 110:1 114:1 115:1 124:1 172:1 202:1 208:1 209:1 210:1 211:1 212:1  |EV| 
-6.1413888752803735826546471798792e-06  |BT| (S (NP (NN (RT-PCR))(NN (Western))(NN (blot))(NN (assay)))(NP (VBN (detected))(NN (expression))(VBN (known))(NN (target))(NN (miR-372))(JJ (malignant))(NN (tumor)))(VP (VBD (found))(SBAR (S (NP (NP (NN (Cyclin))(NN (A1))(JJ (Cyclin-dependent))(NN (Kinase))(CD (2)))(PRN (-LRB- (-LRB-))(NP (NN (CDK2)))(-RRB- (-RRB-))))(VP (VBD (downregulated))(NP (NN (miR-372)))))))) |ET|  |BS| 255:E05.196.401.143 272:E05.393.620.500.725 1365:D08.811.913.696.620.682.700.646.500.750 1496:D12.644.360.262.100.100  |ES| 7:1 10:1 14:1 19:1 37:1 115:1 148:1 160:1 310:1 426:1 556:1 802:1 872:1 873:1 1007:1 1148:1 1543:1 2984:1 2992:1 4742:1 5511:1 5512:1  |EV| 
-0.00020908038150396768273253655934241  |BT| (S (S (VP (VBN (Taken))(ADVP (RB (together)))))(, (,))(NN (study))(VP (VBP (indicate))(SBAR (S (NP (VBN (upregulated))(NN (BYSL))(NN (expression)))(VP (VBP (play))(NP (NN (role))(NN (hepatocarcinogenesis)))))))) |ET|  |BS| 15:F01.829.316.616 79:I03.450.642.693  |ES| 2:1 19:1 31:1 115:1 125:1 131:1 238:1 900:1 1479:1 1537:1 1538:1 2196:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NN (PURPOSE))(CC (AND))(JJ (EXPERIMENTAL))(NN (DESIGN)))(: (:))(NP (NP (DT (The))(JJ (molecular))(NN (mechanism))(NN (p14ARF))(NN (gene)))(ADJP (JJ (altered))(SBAR (S (NP (NP (JJ (non-small))(NN (cell))(NN (lung))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (NSCLC)))(-RRB- (-RRB-))))(VP (NN (complex))(ADJP (JJ (unclear))))))))) |ET|  |BS| 110:C04.588.894.797.520.109.220.249 203:G05.360.340.024.340.375.249.375 204:E05.581.500 205:E05.581.500  |ES| 9:1 10:1 14:1 18:1 19:1 94:1 104:1 161:1 162:1 328:1 329:1 443:1 687:1 688:1 689:1 690:1 691:1 692:1 693:1 694:1 695:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (JJ (Further))(NN (decrease))(NN (CDX2))(NN (expression))(JJ (gastric))(NN (dysplasia))(NN (cancer)))(VP (VBZ (suggests))(NP (NP (NN (CDX2))(NN (play))(JJ (similar))(JJ (anticarcinogenic))(NN (role)))(JJ (intestinal))(NN (metaplasia))(NN (colon))))) |ET|  |BS| 15:F01.829.316.616 46:A03.556.124.526.356 47:A03.556.124 48:C23.550.589 70:A03.556.875.875 79:I03.450.642.693  |ES| 18:1 19:1 31:1 86:1 109:1 110:1 113:1 114:1 115:1 203:1 238:1 295:1 330:1 331:1 332:1 333:1  |EV| 
-0.00015747626040935394642339417714538  |BT| (S (NP (NNP (Lycopene))(JJ (active))(JJ (chemopreventive))(NN (agent))(NN (offer))(NN (protection))(JJ (DEN-induced))(NN (hepatocarcinogenesis)))(VP (VBG (inhibiting))(NP (NN (NF-kappaB))(NN (mTOR))(NN (pathway))))) |ET|  |BS| 122:C14.280.383 210:D12.776.260.600  |ES| 19:1 197:1 383:1 714:1 728:1 880:1 900:1 1042:1 1946:1 2733:1 2734:1 2735:1 2736:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (PP (IN (In))(NP (JJ (nude))(NN (mouse))(NN (xenograft))(NN (model))))(, (,))(NP (NN (overexpression))(NN (miR-141))(NN (knockdown))(NN (MAP4K4)))(ADVP (RB (significantly)))(VP (VBD (repressed))(NP (JJ (pancreatic))(NN (cancer))(NN (cell))(NN (growth))))) |ET|  |BS| 41:A11 45:G07.700.320.249 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875  |ES| 2:1 18:1 19:1 52:1 72:1 94:1 102:1 124:1 152:1 244:1 265:1 266:1 463:1 464:1 465:1 466:1 467:1  |EV| 
-3.4191404835404171080881496891379e-05  |BT| (S (NP (NN (AZD6244))(NN (doxorubicin)))(VP (VBP (induce))(NP (NN (growth))(NN (suppression))(NN (apoptosis))(NN (mouse))(NN (model))(JJ (hepatocellular))(NN (carcinoma))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 45:G07.700.320.249 104:C04.557.470.200.025.255 136:D02.455.426.559.847.562.050.200.175  |ES| 19:1 52:1 72:1 89:1 102:1 243:1 303:1 304:1 599:1 2452:1 2453:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (p53))(NN (activation))(NN (CRC))(NN (cell)))(VP (VBD (interfered))(NP (JJ (IL-6-induced))(NN (invasion))(NN (migration)))(PP (IN (via))(NP (JJ (miR-34a-dependent))(NN (downregulation))(NN (IL6R))(NN (expression)))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 85:G02.111.087.225 201:D12.644.276.374.465.224  |ES| 12:1 19:1 94:1 115:1 225:1 245:1 514:1 595:1 596:1 620:1 681:1 682:1 683:1 684:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NP (NP (NN (Western))(NN (blot))(JJ (quantitative))(JJ (real-time))(NN (PCR)))(PRN (-LRB- (-LRB-))(NP (NN (qRT-PCR)))(-RRB- (-RRB-))))(NN (analysis)))(VP (VBD (revealed))(SBAR (S (NP (NN (MAP4K4))(NN (expression)))(VP (ADVP (RB (inversely)))(VBD (correlated))(NP (NN (miR-141))(NN (expression))(JJ (pancreatic))(NN (cancer))(NN (sample))(NN (cell))(NN (line)))))))) |ET|  |BS| 94:A11.251.210 255:E05.196.401.143 256:E05.196.401.143 257:E05.393.620.500.706  |ES| 10:1 14:1 18:1 19:1 94:1 115:1 264:1 275:1 418:1 446:1 463:1 465:1 467:1 661:1 817:1 835:1 872:1 873:1 874:1 875:1 876:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (PRP (We)))(VP (VBD (examined))(NP (JJ (biological))(NN (function))(NP (NP (JJ (related))(JJ (molecular))(NN (mechanism))(NN (PAX5))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))))) |ET|  |BS| 104:C04.557.470.200.025.255 141:G16.100 243:D12.776.260.645.500  |ES| 10:1 14:1 19:1 33:1 161:1 162:1 303:1 304:1 324:1 419:1 440:1 441:1 843:1 846:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NP (NN (CDX2)))(, (,))(NP (NP (JJ (human))(NN (homologue)))(NP (FW (Drosophila))(FW (caudal))))(, (,)))(NP (VBN (mutated))(NN (allele))(NN (replication))(NN (error))(JJ (positive))(JJ (colorectal))(NN (cancer)))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 76:B01.050.500.131.617.289.310.250 77:G05.360.340.024.340.030 78:G02.111.087.222  |ES| 2:1 17:1 18:1 19:1 36:1 114:1 226:1 227:1 228:1 229:1 230:1 231:1 232:1 233:1  |EV| 
-0.00015594918837640026065827214551973  |BT| (NP (NP (NP (NN (Immunohistochemistry))(NN (beta-catenin)))(, (,))(NP (NN (c-myc)))(, (,))(NP (NP (NN (Ki-67))(NN (TUNEL-staining)))(VP (VBN (performed))(VP (VBP (investigate))(NP (NP (NN (TQ))(POS ('s)))(NN (effect))(JJ (major))(JJ (colorectal))(NN (cancer))(NN (pathway)))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 143:E01.370.225.500.607.512 144:E05.393.475  |ES| 2:1 17:1 18:1 19:1 60:1 75:1 383:1 454:1 455:1 456:1 457:1 458:1 459:1 460:1 461:1 462:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (NN (Inactivation))(NN (APC))(NN (gene)))(VP (VBN (considered))(S (VP (VBG (initiating))(NP (NN (event))(JJ (human))(JJ (colorectal))(NN (cancer))))))) |ET|  |BS| 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 42:G05.355.315.203.374 55:B01.050.150.900.649.801.400.112.400.400  |ES| 9:1 11:1 17:1 18:1 19:1 36:1 205:1 1061:1 2018:1 2019:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NP (JJ (Transient))(JJ (stable))(NN (overexpression))(NN (mir-660)))(S (VP (VBG (using))(S (NP (NN (miRNA)))(VP (VBP (mimic))(SBAR (S (NP (VBN (reduced))(NP (NN (migration)))(, (,))(NP (NN (invasion)))(, (,))(NP (NN (proliferation))(NN (property))))(VP (VBD (increased))(NP (NP (NN (apoptosis))(NN (p53))(JJ (wild-type))(NN (lung))(NN (cancer))(NN (cell)))(PRN (-LRB- (-LRB-))(NP (NP (NN (NCI-H460)))(, (,))(NP (NN (LT73)))(, (,))(NP (NN (A549))))(-RRB- (-RRB-))))))))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 120:I01.409.418.750.600.480.150 184:D13.150.650.319  |ES| 2:1 8:1 10:1 12:1 14:1 18:1 19:1 47:1 89:1 94:1 152:1 299:1 328:1 350:1 360:1 363:1 364:1 373:1 452:1 514:1 567:1 620:1 839:1 840:1 841:1 842:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (ADVP (RB (Furthermore)))(, (,))(NP (NN (UDCA)))(VP (VBD (inhibited))(NP (NP (NN (Cox-2))(NN (induction))(JJ (Ras-dependent)))(: (-))(NP (JJ (independent))(NN (mechanism)))))) |ET|  |BS| 1:G05.360.340.024.340.375.500.791.550 122:C14.280.383 737:D04.808.105.225.272.962  |ES| 2:1 19:1 62:1 162:1 334:1 365:1 736:1 2631:1 5425:1 5426:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NN (Regulation))(NN (tumor))(NN (suppressor))(NN (homeogene))(NN (Cdx2))(NN (HNF4alpha))(JJ (intestinal))(NN (cancer)))) |ET|  |BS| 38:Z01.058.290.120.180 40:Z01.542.248.700 101:C04.588.274.476.411 142:I01.880.604 206:G05.360.340.024.340.375.249  |ES| 7:1 18:1 19:1 109:1 123:1 213:1 699:1 700:1 701:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (NP (NP (NP (NN (METHODOLOGY/PRINCIPAL))(NNS (FINDINGS)))(: (:))(NP (NP (JJ (Pancreatic))(NN (cancer))(NN (cell))(NN (line)))(VP (VBN (treated))(NP (NN (resveratrol))))))) |ET|  |BS| 52:E02 94:A11.251.210  |ES| 18:1 19:1 94:1 104:1 264:1 1099:1 1213:1 1712:1 2748:1 2749:1  |EV| 
-0.0002882855289780849629421854984912  |BT| (S (NP (JJ (Nuclear))(NN (Maspin))(NN (expression)))(NP (ADJP (RB (highly))(JJ (predictive)))(NN (5-FU))(NN (chemotherapy))(NN (response))(NN (patient)))(VP (VBD (advanced))(NP (NN (stage))(NN (colon))(NN (cancer))))) |ET|  |BS| 50:M01.643 151:E02.319 560:D03.383.742.698.875.404  |ES| 18:1 19:1 113:1 115:1 120:1 494:1 495:1 533:1 626:1 997:1 1129:1 2308:1 2808:1 2809:1  |EV| 
-3.1374360674529117032349745386455e-05  |BT| (NP (NP (NP (NN (Cyclooxygenase))(CD (2))(NN (play))(JJ (critical))(NN (role))(NN (development))(JJ (gastrointestinal))(NN (cancer)))(NP (JJ (human))(NN (animal))(NN (model))))) |ET|  |BS| 15:F01.829.316.616 24:D08.811.600.720.750 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693 285:E05.598  |ES| 18:1 19:1 31:1 35:1 36:1 46:1 72:1 148:1 183:1 238:1 825:1 3432:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (Hypermethylation))(NN (miR-137))(NN (promoter))(JJ (negative))(NN (regulation))(NN (miR-137))(NN (CAR)))(VP (VP (VBP (contribute))(NP (NP (NN (part)))(VP (VBD (reduced))(NP (NN (miR-137))(NN (expression))))))(VP (VBD (increased))(NP (NN (CAR))(NN (MDR1))(NN (expression))(JJ (doxorubicin-resistant))(NN (neuroblastoma))(NN (cell)))))) |ET|  |BS| 41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 139:J01.937.500.100 142:I01.880.604  |ES| 19:1 47:1 83:1 94:1 115:1 420:1 421:1 423:1 424:1 438:1 448:1 449:1 450:1 451:1 452:1 453:1  |EV| 
-9.0732339279649132368632535872166e-05  |BT| (S (PP (IN (In))(NP (NN (summary))))(, (,))(NP (JJ (small))(NN (molecule))(NN (inhibitor))(NN (imatinib)))(VP (VP (VBZ (attenuates))(NP (JJ (stromal))(NN (cell))(NN (proliferation))(JJ (PDGF-C-induced))(NN (HCC))))(, (,))(VP (VBZ (coincides))(NP (NP (VBN (decreased))(NN (expression))(NN (CD34))(NN (PDGFRalpha)))(, (,))(NP (VBN (activated))(NN (Akt))))))) |ET|  |BS| 104:C04.557.470.200.025.255 183:G04.299.233.750 378:D08.811.913.696.620.682.700.755 1370:D08.811.913.696.620.682.725.400.900.500  |ES| 2:1 19:1 94:1 115:1 163:1 180:1 202:1 244:1 299:1 380:1 441:1 490:1 750:1 1289:1 2423:1 4916:1 4917:1 4918:1 4919:1 4920:1 4921:1  |EV| 
0.00041788035725208173528158472898042  |BT| (FRAG (ADVP (RB (Here)))(, (,))(NP (NP (NN (report))(ADJP (RB (inversely))(JJ (related)))(NN (expression))(NN (miR-137))(NN (CAR))(JJ (parental))(JJ (doxorubicin-resistant))(NN (neuroblastoma))(NN (cell)))(, (,))(SBAR (WHADVP (WRB (wherein)))(S (NP (NN (miR-137)))(VP (VBD (downregulated))(NP (JJ (resistant))(NN (cell)))))))) |ET|  |BS| 41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320 139:J01.937.500.100  |ES| 2:1 19:1 94:1 115:1 400:1 417:1 418:1 419:1 420:1 421:1 422:1 423:1 424:1 425:1 426:1 427:1  |EV| 
-0.00024045435003959558795116890905774  |BT| (S (NP (NN (Vitamin))(NN (E))(NN (succinate)))(VP (VBZ (induces))(NP (NN (NAG-1))(NN (expression))(NN (p38))(JJ (kinase-dependent))(NN (mechanism))))) |ET|  |BS| 469:D08.811.913.696 1452:D03.383.663.283.909.750.249  |ES| 19:1 115:1 162:1 214:1 1662:1 1666:1 1667:1 2085:1 3665:1 5332:1  |EV| 
-0.00031245575691300764287205993241514  |BT| (S (S (NP (JJS (Most))(JJ (human))(JJ (colorectal))(NN (cancer)))(VP (VB (arise))(NP (NN (accumulation))(NN (series))(JJ (genetic))(NN (alteration))(NN (point))(NN (mutation)))(PP (IN (within))(NP (JJ (Ki-ras))(NN (p53))(NN (gene))))))(, (,))(NP (NN (chemical))(NN (carcinogen)))(VP (MD (may))(VP (VBN (implicated))(NP (NN (event))(ADJP (RB (still))(JJ (unidentified))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100 438:G05.365.590.675  |ES| 2:1 9:1 12:1 17:1 18:1 19:1 34:1 36:1 205:1 491:1 776:1 864:1 951:1 977:1 1807:1 2118:1 2119:1 2120:1 2121:1 2122:1 2123:1 2124:1 2125:1 2126:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NNS (RESULTS))(: (:)))(S (PP (IN (In))(NP (NN (CRC))(NN (cell))(NN (line))))(, (,))(VP (VBP (mimic))(NP (NN (miR-221))(NN (miR-222))(VBD (activated))(NN (NF-kappaB))(NN (STAT3)))(, (,))(NP (VBG (increasing))(NN (expression))(NN (miR-221))(NN (miR-222)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 82:D12.644.360.024.342.300 94:A11.251.210 210:D12.776.260.600  |ES| 2:1 19:1 94:1 104:1 115:1 140:1 141:1 163:1 244:1 245:1 251:1 264:1 567:1 710:1 714:1 715:1  |EV| 
0.00041788035725208173528158472898042  |BT| (NP (NP (NNS (METHODS))(: (:)))(NP (NP (NP (NN (CRC))(NN (cell))(NN (line)))(PRN (-LRB- (-LRB-))(NP (NN (HCT116))(NN (RKO)))(-RRB- (-RRB-))))(VP (VBN (transfected))(S (NP (NN (miR-221))(NN (miR-222)))(VP (VBP (mimic))(NP (NN (inhibitor)))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 94:A11.251.210 168:E05.581  |ES| 10:1 14:1 19:1 94:1 104:1 140:1 141:1 245:1 264:1 320:1 380:1 479:1 565:1 566:1 567:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (Antagonism))(NN (miR-221))(NN (miR-222)))(VP (VBZ (reduces))(NP (NN (growth))(NN (colon))(NN (tumor))(NN (mouse))(NN (colitis))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 51:C04.588.274.476.411.307.180 53:C06.405.205.265  |ES| 7:1 19:1 52:1 102:1 113:1 139:1 140:1 141:1 142:1 143:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (FRAG (PP (IN (In))(NP (JJ (present))(NN (study))))(, (,))(NP (VBD (investigated))(NP (JJ (anticancer))(NN (activity))(JJ (tolfenamic))(NN (acid))(JJ (human))(JJ (colorectal))(NN (cancer))(NN (cell))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 55:B01.050.150.900.649.801.400.112.400.400  |ES| 2:1 17:1 18:1 19:1 36:1 94:1 131:1 244:1 399:1 403:1 1275:1 1307:1 1880:1 2598:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (PP (IN (In))(NP (NN (study))))(, (,))(VP (VBP (demonstrate))(S (NP (NP (NP (NN (histone))(NN (deacetylase))(NN (inhibitor)))(PRN (-LRB- (-LRB-))(NP (NN (HDACi)))(-RRB- (-RRB-))))(NN (vorinostat))(NN (LBH589)))(VP (ADVP (RB (significantly)))(VBP (downregulate))(NP (NN (TS))(NN (gene))(NN (expression))(NN (panel))(NN (colon))(NN (cancer))(NN (cell))(NN (line))))))) |ET|  |BS| 94:A11.251.210 153:D27.505.519.389.360 154:Z01.058.266.887 155:G05.355.310  |ES| 2:1 9:1 10:1 14:1 18:1 19:1 94:1 113:1 115:1 124:1 131:1 244:1 264:1 380:1 502:1 503:1 504:1 505:1 506:1 507:1 508:1 509:1 510:1  |EV| 
-9.2812665195188270850223943853052e-05  |BT| (S (PP (IN (In))(NP (NN (conclusion))))(, (,))(VP (VBP (suggest))(SBAR (S (NP (NN (change))(NN (level))(NN (cdk4)))(VP (MD (may))(NP (JJ (useful))(NN (biomarker))(NN (detection))(NN (HCC)))))))) |ET|  |BS| 104:C04.557.470.200.025.255 158:D23.101  |ES| 2:1 19:1 200:1 244:1 249:1 441:1 491:1 796:1 885:1 1023:1 1036:1 1284:1 1291:1  |EV| 
-0.00017208692559234073371499107452109  |BT| (S (NP (NN (Claudin-1))(NN (overexpression))(JJ (intestinal))(JJ (epithelial))(NN (cell)))(VP (VBZ (enhances))(NP (NN (susceptibility))(JJ (adenamatous))(NN (polyposis))(JJ (coli-mediated))(NN (colon))(NN (tumorigenesis))))) |ET|  |BS| 3:C04.557.470.035.215.100 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 47:A03.556.124 75:A11.436 401:C23.550.291.687 952:D12.776.543.984.200.100  |ES| 19:1 58:1 78:1 94:1 109:1 113:1 127:1 152:1 1353:1 1356:1 3333:1 3334:1 3335:1  |EV| 
0.00041788035725208173528158472898042  |BT| (FRAG (SBAR (IN (Although))(S (NP (JJ (incomplete))(JJ (intestinal))(NN (metaplasia)))(ADVP (RB (morphologically)))(VP (VBZ (resembles))(NP (NP (NN (colon)))(, (,))(NP (NN (CDX2))(NN (expression))))(NP (ADJP (RB (apparently))(JJR (lower)))(JJ (normal))(NN (colon))))))) |ET|  |BS| 46:A03.556.124.526.356 47:A03.556.124 48:C23.550.589  |ES| 2:1 19:1 107:1 108:1 109:1 110:1 111:1 112:1 113:1 114:1 115:1 116:1 117:1 118:1  |EV| 
-0.00023720369541715968786377288779477  |BT| (NP (NP (NP (JJ (Constitutive))(NN (activation))(NN (phosphoinositide))(NN (3-kinase)))(PRN (-LRB- (-LRB-))(NP (NN (PI3K)))(-RRB- (-RRB-))))(: (-))(S (NP (NN (Akt))(NN (pathway)))(VP (VBZ (transmits))(NP (NP (JJ (growth-regulatory))(NN (signal))(NN (play))(JJ (central))(NN (role)))(S (VP (VBG (promoting))(NP (NP (NN (survival)))(, (,))(NP (NN (proliferation)))(, (,))(NP (NN (angiogenesis))(JJ (human))(NN (prostate))(NN (cancer))(NN (cell)))))))))) |ET|  |BS| 15:F01.829.316.616 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693 96:I03.784 378:D08.811.913.696.620.682.700.755 578:D08.811.913.696.620.550  |ES| 2:1 10:1 14:1 18:1 19:1 31:1 36:1 77:1 94:1 225:1 238:1 274:1 299:1 383:1 859:1 881:1 2080:1 2502:1 3235:1 3394:1 3399:1 3400:1 3401:1 3402:1 3403:1  |EV| 
-0.00029605208126974591475999432077515  |BT| (S (NP (NN (Penta-1,2,3,4,6-O-galloyl-beta-D-glucose)))(VP (VP (VBZ (induces))(SBAR (S (NP (NN (p53)))(VP (VBZ (inhibits))(NP (NN (STAT3))(NN (prostate))(NN (cancer))(NN (cell))(NN (vitro)))))))(VP (VBZ (suppresses))(NP (NN (prostate))(NN (xenograft))(NN (tumor))(NN (growth)))(FW (vivo))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 41:A11 45:G07.700.320.249 82:D12.644.360.024.342.300 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 122:C14.280.383 202:C04.588.945.440.770  |ES| 7:1 12:1 18:1 19:1 77:1 94:1 102:1 214:1 216:1 251:1 265:1 378:1 615:1 685:1 686:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (NP (NP (NN (Characterization))(JJ (tumor-suppressive))(NN (function))(NN (SOX6))(JJ (human))(NN (esophageal))(JJ (squamous))(NN (cell))(NN (carcinoma)))) |ET|  |BS| 8:C04 55:B01.050.150.900.649.801.400.112.400.400  |ES| 19:1 33:1 36:1 94:1 177:1 304:1 1064:1 1065:1 1066:1 1067:1  |EV| 
0.00041788035725208173528158472898042  |BT| (S (NP (NN (Analysis))(JJ (colorectal))(NN (cancer))(NN (patient))(NN (cohort)))(VP (VBZ (establishes))(SBAR (S (NP (NN (HNF4alpha)))(ADVP (RB (significantly)))(VP (VBD (upregulated))(NP (VBN (compared))(NP (JJ (adjacent))(JJ (normal))(JJ (epithelial))(NN (resection))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 49:E05.318.760.500.750 50:M01.643  |ES| 17:1 18:1 19:1 50:1 118:1 119:1 120:1 121:1 122:1 123:1 124:1 125:1 126:1 127:1 128:1  |EV| 
-6.9412316450190303385170409455895e-08  |BT| (NP (NP (NN (Aspirin))(NN (use))(NN (survival))(NN (diagnosis))(JJ (colorectal))(NN (cancer)))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 96:I03.784 263:E01 670:D02.455.426.559.389.657.410.595.176  |ES| 17:1 18:1 19:1 274:1 1037:1 1659:1 2449:1  |EV| 
-0.00031414429248699526908694679150358  |BT| (NP (NP (NP (NN (Silencing))(NN (CXCR4))(VBG (impairing))(NN (MIF-CXCR4))(NN (signaling))(NN (pathway))(NN (ISO-1)))(, (,))(NP (NN (pAb))(NN (FL-115)))(, (,))(NP (NN (AMD-3100)))(, (,))(NP (JJ (monoclonal))(NN (antibody))(NN (12G5)))(, (,))(NP (NN (BIM-46187)))(VP (VBD (abolished))(NP (JJ (aggressive))(NN (phenotype)))))) |ET|  |BS| 80:G05.695 126:G02.111.087.800 162:F01.145.126.125 1204:D12.776.543.750.100.160.500.400 1420:D12.776.124.486.485.114.224 1421:D06.472.699.327.700.500  |ES| 2:1 19:1 195:1 236:1 383:1 538:1 722:1 775:1 1365:1 2611:1 4220:1 4582:1 5165:1 5166:1 5167:1 5168:1 5169:1 5170:1 5171:1  |EV| 
-0.0003062837069740254047900407385896  |BT| (S (ADVP (RB (Here)))(, (,))(VP (VBP (provide))(NP (NP (NP (NN (evidence))(NN (periostin))(, (,))(NN (protein))(JJ (structural))(NN (sequence))(NN (homology))(JJ (TGF-beta-inducible))(NN (gene)))(, (,))(NP (NN (beta))(NN (ig-h3)))(, (,)))(VP (VBN (upregulated))(NP (JJ (colorectal))(NN (cancer))(NN (liver))(NN (metastasis)))))(, (,))(VP (MD (may))(VP (VB (play))(NP (NN (role)))(S (VP (VBG (promoting))(NP (NN (growth))(NN (tumor))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 6:G05.360.340.024.340 8:C04 15:F01.829.316.616 45:G07.700.320.249 79:I03.450.642.693 112:D12.776.097.820 113:C04.697.650 242:A03.620 503:D12.644.276.374.687 1005:G02.111.810  |ES| 2:1 4:1 7:1 9:1 17:1 18:1 19:1 31:1 38:1 102:1 125:1 238:1 293:1 400:1 491:1 711:1 806:1 836:1 881:1 1972:1 3512:1 3513:1 3514:1 3515:1 3516:1  |EV| 
-0.00031019431798087748752834613696905  |BT| (S (NP (DT (The))(NN (effect))(NN (folate))(NN (transporter))(NN (gene))(NN (ablation))(NN (colon))(NN (carcinogenesis)))(VP (VBD (evaluated))(NP (NP (CD (8))(CD (38))(NN (week)))(JJ (post-azoxymethane))(NN (injection))(JJ (wild-type))(JJ (heterozygous))(NN (mouse))))) |ET|  |BS| 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 157:G05.380.383 224:D03.438.733.631.400 225:E05.337 226:E02.319.267.530 227:D12.776.157.530  |ES| 8:1 9:1 19:1 52:1 75:1 91:1 113:1 207:1 691:1 778:1 779:1 780:1 781:1 782:1 783:1 784:1 785:1 786:1  |EV| 
-0.0004082828858586740050640173649299  |BT| (S (NP (NN (Germ-line))(NN (mutation))(NN (APC))(NN (gene)))(VP (NN (cause))(SBAR (S (NP (NP (JJ (adenomatous))(NN (polyposis))(NN (coli))(PRN (-LRB- (-LRB-))(NP (NN (APC)))(-RRB- (-RRB-))))(, (,))(NP (NN (syndrome))(NN (patient))))(VP (VBP (develop))(NP (CD (hundred))(CD (thousand))(JJ (precancerous))(JJ (adenomatous))(JJ (colorectal))(NN (polyp)))))))) |ET|  |BS| 3:C04.557.470.035.215.100 6:G05.360.340.024.340 21:G05.360.340.024.340.375.249.050 50:M01.643 341:C04.834 551:C04.557.470.035.215 552:G05.365.590.350 553:C23.550.288.500  |ES| 2:1 9:1 10:1 11:1 14:1 17:1 19:1 34:1 57:1 58:1 59:1 120:1 647:1 648:1 1130:1 1779:1 1939:1 1940:1 1941:1 1942:1  |EV| 
-0.00035744048140495105186226210136624  |BT| (NP (NP (NN (AIM))(: (:)))(S (VP (TO (To))(VP (VB (define))(NP (NP (JJ (biological))(NN (contribution))(NNP (Hras))(NN (mouse))(NN (hepatocarcinogenesis)))(, (,))(VP (VBN (quantified))(S (FW (vivo))(NP (NN (interaction))(JJ (mutant))(NNP (Hras))(JJ (genetic))(NN (alteration)))(ADVP (RB (frequently)))(VP (VBN (associated))(NP (NP (NN (liver))(NN (cancer)))(, (,))(PP (VBG (including))(NP (NP (NN (overexpression))(NP (NN (transcription))(NN (factor))(NN (c-myc))(JJ (epidermal))(NN (growth))(NN (factor))(NN (receptor))(NN (ligand))(VBG (transforming))(NN (growth))(NN (factor))(NN (alpha))))(PRN (-LRB- (-LRB-))(NP (NN (TGFalpha)))(-RRB- (-RRB-)))))))))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 64:D08.811.913.696.620.682.725.400.009.300 167:H01.158.273 170:D27.720.470.480 521:D08.811.277.040.330.300.400.500.600 522:D12.644.276.382.750 523:D12.776.260.676  |ES| 2:1 10:1 14:1 18:1 19:1 52:1 102:1 104:1 152:1 169:1 184:1 185:1 186:1 378:1 440:1 455:1 487:1 561:1 618:1 698:1 811:1 828:1 836:1 864:1 900:1 951:1 959:1 1360:1 1772:1 1832:1 1833:1 1834:1 1835:1 1836:1 1837:1  |EV| 
-0.00010098796034342660821181425490067  |BT| (S (NP (NNS (RWPs)))(VP (VBD (reduced))(NP (SBAR (S (NP (NP (NN (expression))(NN (VEGF)))(, (,))(NP (NP (NP (NN (matrix))(NN (metalloproteinase)))(PRN (-LRB- (-LRB-))(NP (NN (MMP)))(-RRB- (-RRB-))))(CD (-2))(, (,))(NN (MMP-9))(, (,))(NN (cyclooxygenase-2))))(VP (VBD (increased))(NP (NN (expression))(NN (tumor))(NN (suppressor))(NN (gene))(NN (p16))(-LRB- (-LRB-))(NN (INK4A))(-RRB- (-RRB-))))))(, (,))(NP (NN (p53))(, (,))(NN (p73))(NN (tumor))(NN (cell)))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 8:C04 24:D08.811.600.720.750 41:A11 155:G05.355.310 203:G05.360.340.024.340.375.249.375 206:G05.360.340.024.340.375.249 586:D08.811.277.656.300.480.205.360 1417:D08.811.277.656.300.480.205.352  |ES| 2:1 7:1 9:1 10:1 12:1 14:1 19:1 47:1 61:1 94:1 115:1 452:1 700:1 1313:1 2066:1 2158:1 2892:1 3182:1 3491:1 5147:1 5148:1 5149:1 5150:1  |EV| 
-0.00010931532724710313342342260511941  |BT| (S (NP (PRP (We)))(ADVP (RB (previously)))(VP (VBD (reported))(SBAR (S (NP (NP (NN (dextran))(NN (sodium))(NN (sulfate)))(PRN (-LRB- (-LRB-))(NP (NN (DSS)))(-RRB- (-RRB-))))(ADVP (RB (strongly)))(VP (VBZ (enhances))(SBAR (S (NP (NP (NP (NN (colon))(NN (carcinogenesis))(NN (Apc)))(PRN (-LRB- (-LRB-))(NP (NN (Min)))(: (/))(CC (+))(-RRB- (-RRB-))))(NP (NP (NN (mouse))(NN (over-expression))(JJ (inducible))(JJ (nitric))(NN (oxide))(NN (synthase)))(PRN (-LRB- (-LRB-))(NP (NN (iNOS)))(-RRB- (-RRB-)))))(VP (VBZ (contributes))(NP (NN (enhancement))))))))))) |ET|  |BS| 3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 22:D08.811.682.664.500.772.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300  |ES| 10:1 14:1 19:1 52:1 63:1 64:1 65:1 66:1 67:1 113:1 207:1 280:1 406:1 407:1 635:1 705:1 843:1 845:1 993:1 1013:1 1356:1 1527:1 2278:1 3300:1 3306:1  |EV| 
-0.00012668098367711599916418663269724  |BT| (S (NP (JJ (Branched-chain))(NN (amino))(NN (acid))(-LRB- (-LRB-))(NN (BCAA))(-RRB- (-RRB-)))(, (,))(S (VP (VB (improve))(NP (NN (insulin))(NN (resistance)))))(, (,))(VP (VBD (inhibited))(NP (NP (JJ (obesity-related))(NN (colon))(NN (carcinogenesis))(JJ (rodent))(NN (model)))(, (,))(S (ADVP (RB (also)))(VP (VBD (reduced))(NP (NN (incidence))(JJ (hepatocellular))(NN (carcinoma))(JJ (obese))(NN (patient))(NN (liver))(NN (cirrhosis)))))))) |ET|  |BS| 33:C04.697.098 46:A03.556.124.526.356 50:M01.643 104:C04.557.470.200.025.255 122:C14.280.383 357:C06.552.630 434:E05.318.308.985.525.375 514:B01.050.150.900.649.865 564:C18.654.726.500 639:D12.125.070 678:C18.452.394.968.500  |ES| 2:1 5:1 10:1 14:1 19:1 72:1 113:1 120:1 207:1 303:1 304:1 365:1 452:1 836:1 1094:1 1199:1 1275:1 1511:1 2173:1 2189:1 2360:1 2364:1 2465:1 2466:1 2467:1 2468:1  |EV| 
-0.00011395820629475639229610806069104  |BT| (FRAG (SBAR (IN (Although))(NP (NP (NP (VBN (induced))(NN (cell))(NN (death)))(VBN (regarded))(JJ (major))(NN (component))(NN (p53))(JJ (tumor-suppressive))(NN (activity)))(, (,))(S (ADVP (RB (recently)))(VP (VBD (found))(SBAR (S (NP (JJ (sustained))(NN (p53))(NN (activation))(JJ (subsequent))(NN (DNA))(NN (damage)))(VP (VBZ (promotes))(NP (JJ (inflammation-associated))(NN (hepatocarcinogenesis))))))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 8:C04 134:G04.299.139 525:C23.550.470 526:G05.355.180  |ES| 2:1 12:1 19:1 37:1 94:1 107:1 177:1 225:1 298:1 399:1 411:1 412:1 462:1 666:1 772:1 900:1 1021:1 1319:1 1521:1 1847:1 1848:1 1849:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (S (NP (NN (miR-137))(NN (overexpression)))(VP (VBD (resulted))(NP (NP (NN (downregulation))(NN (CAR))(NN (protein))(NN (mRNA)))(PRN (-LRB- (-LRB-))(PP (IN (via))(NP (NN (mRNA))(NN (degradation))))(-RRB- (-RRB-))))))(: (;))(S (VBN (sensitized))(NP (JJ (doxorubicin-resistant))(NN (cell))(NN (doxorubicin)))(-LRB- (-LRB-))(VP (VP (VBN (shown))(S (VP (VBN (reduced))(NP (NN (proliferation))))))(, (,))(VP (VBD (increased))(NP (NN (apoptosis))))(VP (VBD (increased))(NP (JJ (G2-phase))(NN (cell))(NN (cycle))(NN (arrest))))(SINV (-RRB- (-RRB-))(NP (VBD (reduced))(FW (vivo))(NN (growth))(NN (rate))(NN (neuroblastoma))(NN (xenograft))))))) |ET|  |BS| 7:D12.776 39:G04.299.139.160 41:A11 45:G07.700.320.249 85:G02.111.087.225 92:E04.936.764 93:A01.941.875 111:D13.444.735.544 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 139:J01.937.500.100 177:G04.299.134.109.500 178:G02.111.780  |ES| 2:1 4:1 10:1 14:1 19:1 41:1 47:1 89:1 94:1 102:1 152:1 217:1 237:1 265:1 299:1 325:1 378:1 420:1 421:1 423:1 424:1 452:1 594:1 595:1 596:1 597:1 598:1 599:1 600:1 601:1 602:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (NP (NP (CD (Fifty-four)))(PRN (-LRB- (-LRB-))(NP (CD (73))(NN (%)))(-RRB- (-RRB-))))(NP (NP (CD (74))(NN (lesion))(NNS (metaplasias))(JJ (bronchiolar))(NN (epithelium)))(VP (VBN (obtained))(NP (NP (JJ (IPF))(NN (patient))(NN (lung))(NN (carcinoma))(CD (8)))(PRN (-LRB- (-LRB-))(NP (CD (17))(NN (%)))(-RRB- (-RRB-))))(NP (NP (CD (46))(NN (sample)))(VP (VBN (obtained))(NP (NP (JJ (IPF))(NN (patient)))(PP (IN (without))(NP (NN (lung))(NN (carcinoma))))))))))(VP (VBD (showed))(NP (NP (NNP (LOH))(NNP (FHIT))(NN (gene)))(PRN (-LRB- (-LRB-))(S (NP (NN (P)))(VP (JJR (<))(NP (CD (0.0001)))))(-RRB- (-RRB-)))))) |ET|  |BS| 6:G05.360.340.024.340 48:C23.550.589 50:M01.643 62:A10.272 182:A04.411 265:C04.557.470.200 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765 365:A04.411.125.500  |ES| 9:1 10:1 14:1 19:1 120:1 132:1 173:1 304:1 311:1 312:1 328:1 369:1 575:1 781:1 835:1 930:1 946:1 1004:1 1122:1 1131:1 1195:1 1220:1 1221:1 1222:1 1223:1 1224:1 1225:1 1226:1  |EV| 
-0.00032565104723844551237732503068401  |BT| (S (SBAR (IN (Because))(S (NP (NN (Notch))(NN (signaling))(VBN (implicated))(NN (colon))(NN (cancer))(NN (tumorigenesis)))(VP (VBZ (protects))(NP (NP (NN (cell))(NN (apoptosis)))(VP (VBG (inducing))(NP (JJ (prosurvival))(NN (target))))))))(, (,))(VP (VBD (hypothesized))(SBAR (S (NP (NP (NN (inhibition))(NN (Notch))(NN (signaling))(NN (gamma-secretase))(NN (inhibitor)))(PRN (-LRB- (-LRB-))(NP (NN (GSI)))(-RRB- (-RRB-))))(VP (MD (may))(NP (VB (enhance))(NP (NN (chemosensitivity))(NN (colon))(NN (cancer))(NN (cell))))))))) |ET|  |BS| 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 41:A11 43:F01.145.544 69:G02.111.087.800 125:D08.811.277.656.300.032  |ES| 2:1 10:1 14:1 18:1 19:1 78:1 89:1 94:1 103:1 113:1 160:1 195:1 256:1 380:1 386:1 491:1 977:1 1690:1 1750:1 1862:1 1863:1 1864:1 1865:1 1866:1 1867:1  |EV| 
-0.00024455783098385926177531501934936  |BT| (NP (NP (NP (JJ (Decorin-mediated))(NN (inhibition))(JJ (colorectal))(NN (cancer))(NN (growth))(NN (migration)))(NP (VBN (associated))(NN (E-cadherin))(NN (vitro))(NN (mouse))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 43:F01.145.544 45:G07.700.320.249 613:D12.776.395.550.200.200 708:D12.776.395.650.750.625  |ES| 17:1 18:1 19:1 52:1 102:1 103:1 169:1 216:1 514:1 2267:1 2557:1  |EV| 
-7.5677674375457942845812908672087e-05  |BT| (S (PP (IN (In))(NP (JJ (wild-type))(NN (mouse))))(, (,))(NP (CD (200))(NN (ppm))(NN (cyproconazole)))(VP (VBD (caused))(NP (NP (NP (NP (NN (liver))(NN (hypertrophy)))(, (,))(NP (VBD (increased))(NN (liver))(NN (weight))(NN (cell))(NN (proliferation)))(, (,)))(JJ (single-cell))(NN (necrosis))(JJ (fat))(NN (vacuolation)))(, (,))(NP (NP (NP (NN (effect)))(ADJP (RB (generally))(JJ (similar))))(VP (VBN (caused))(NP (CD (850))(NN (ppm))(NN (phenobarbital)))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 183:G04.299.233.750 242:A03.620 756:D03.383.742.698.253.650 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 1151:C06.552.416 1215:C23.888.144.243.926 1216:C23.550.717  |ES| 2:1 8:1 19:1 47:1 52:1 75:1 94:1 244:1 299:1 332:1 836:1 2399:1 2425:1 2506:1 2685:1 3233:1 3364:1 3992:1 4254:1 4255:1 4256:1 4257:1 4258:1 4259:1  |EV| 
-8.7076055697368759389576098328689e-06  |BT| (S (NP (NN (HOX))(NN (gene)))(ADVP (RB (frequently)))(VP (VBN (dysregulated))(NP (NP (JJ (human))(NN (leukaemia))(NN (gene))(NN (rearrangement))(JJ (mixed))(NN (lineage))(NN (leukaemia)))(PRN (-LRB- (-LRB-))(NP (NN (MLL)))(-RRB- (-RRB-))))(NP (NN (partner))(NN (gene))))) |ET|  |BS| 6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400 229:G05.360.340.024.340.230.500 361:C04.557.337 373:G05.355.330  |ES| 9:1 10:1 14:1 19:1 36:1 698:1 1204:1 1207:1 1259:1 1260:1 1261:1 1262:1 1263:1 1264:1  |EV| 
-0.00028586984316252483581677346080596  |BT| (S (NP (NN (p66))(NN (overexpression)))(ADVP (RB (also)))(VP (VBD (prevented))(NP (NP (NN (activation))(NN (luciferase))(NN (reporter))(NN (gene)))(VP (VBN (controlled))(NP (NN (SOD2))(NN (promoter)))))(, (,))(S (VP (VBG (indicating))(S (NP (NN (p66))(NN (repression))(NN (MnSOD)))(VP (VBZ (operates))(NP (JJ (transcriptional))(NN (level))))))))) |ET|  |BS| 208:F01.393.821 209:G02.111.087.847 264:G05.355.315.800 1375:D08.811.682.517 1403:D08.811.682.881  |ES| 2:1 5:1 9:1 19:1 83:1 152:1 225:1 249:1 288:1 559:1 706:1 1944:1 2236:1 4601:1 4604:1 4963:1 5094:1 5095:1 5096:1  |EV| 
-0.00019880297518487521912788906774949  |BT| (NP (NP (NP (NP (JJ (Ursodeoxycholic))(NN (acid)))(PRN (-LRB- (-LRB-))(NP (NN (UDCA)))(-RRB- (-RRB-))))(NP (NP (JJ (known))(NN (suppressor))(JJ (cholestatic))(NN (liver))(NN (disease)))(JJ (colorectal))(NN (cancer))(NN (development))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 650:C06.552 737:D04.808.105.225.272.962 879:C06.130.120.135  |ES| 10:1 14:1 17:1 18:1 19:1 35:1 556:1 700:1 836:1 998:1 1275:1 2631:1 3121:1 3122:1  |EV| 
-1.4797982621592153940071057149908e-05  |BT| (S (NP (NP (DT (The))(JJ (key))(NN (event))(JJ (responsible))(NN (mouse))(NN (liver))(NN (tumor)))(VP (VBD (induced))(NP (NP (NN (pesticide)))(PRN (-LRB- (-LRB-))(NP (NP (NN (viz.)))(, (,))(NP (NN (pronamide))))(-RRB- (-RRB-))))))(VP (VBD (investigated))(NP (S (NP (NN (series))(NN (study)))(VP (VBG (employing))(ADJP (ADJP (JJ (molecular)))(, (,))(ADJP (JJ (biochemical)))(, (,))(ADJP (JJ (cellular))))))(, (,))(NP (JJ (apical))(NN (endpoint)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 41:A11 515:C04.588.274.623 913:D27.720.031.700  |ES| 2:1 7:1 10:1 14:1 19:1 52:1 131:1 159:1 161:1 205:1 403:1 412:1 691:1 836:1 1689:1 1807:1 2132:1 3074:1 3214:1 3323:1 4010:1 4011:1 4012:1 4013:1  |EV| 
-1.3469827878192760020614748839307e-06  |BT| (S (NP (NN (Chemokine))(NN (gene))(NN (expression))(JJ (clonal))(NN (analysis))(NN (B))(NN (cell))(NN (tissue)))(VP (VBN (involved))(NP (JJ (lymphoid))(JJ (interstitial))(NN (pneumonitis))(JJ (HIV-infected))(JJ (pediatric))(NN (patient))))) |ET|  |BS| 50:M01.643 98:A10 155:G05.355.310 301:A11.251.353 310:A11.063.438 311:B04.820.650.589.650.350 312:C02.782.815.616.400.500 313:D12.644.276.374.200 314:C02.782.815.616.400 315:H02.403.670  |ES| 9:1 19:1 94:1 115:1 120:1 272:1 661:1 763:1 774:1 1068:1 1069:1 1070:1 1071:1 1072:1 1073:1 1074:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (NNS (METHODS))(: (:)))(NP (NP (JJ (Aberrant))(NN (methylation))(NN (status))(NN (p16))(NN (promoter))(NN (region)))(, (,))(NP (NN (expression))(NN (product)))(, (,))(NP (NP (NN (loss))(NN (heterozygosity)))(PRN (-LRB- (-LRB-))(NP (NN (LOH)))(-RRB- (-RRB-))))(NP (NN (9p21))))(VP (VBD (examined))(NP (NP (NP (ADJP (RB (surgically))(JJ (resected)))(NN (lung))(NN (specimen))(CD (57))(NN (patient)))(PRN (-LRB- (-LRB-))(NP (CD (28))(JJ (male))(CD (29))(NN (female)))(-RRB- (-RRB-))))(S (NP (JJ (peripheral-type))(NN (lung))(NN (adenocarcinoma)))(VP (VBG (measuring))(NP (ADVP (JJR (<))(: (/)))(NP (JJ (=))(CD (2))(NN (cm))(NN (diameter))))))))) |ET|  |BS| 36:G02.111.087.029.538 50:M01.643 115:E04 168:E05.581 182:A04.411 196:G02.111.570.080.689.675 203:G05.360.340.024.340.375.249.375 228:E05.978 290:G05.365.590.029.530  |ES| 2:1 10:1 14:1 19:1 32:1 80:1 81:1 83:1 104:1 115:1 120:1 148:1 255:1 312:1 324:1 326:1 328:1 416:1 528:1 565:1 667:1 675:1 1004:1 1154:1 1312:1 1313:1 1399:1 1400:1 1401:1 1402:1 1403:1 1404:1 1405:1 1406:1 1407:1 1408:1 1409:1  |EV| 
-0.00032984629175864649784644111463194  |BT| (S (NP (NNS (RESULTS)))(: (:))(S (NP (NN (Microarray))(NN (analysis)))(VP (VBD (revealed))(SBAR (S (NP (NP (NN (osteopontin)))(, (,))(NP (NN (marker))(NN (colon))(NN (cancer))(NN (progression)))(, (,)))(VP (VBD (down-regulated))(NP (NP (NP (NN (polyp))(NN (Apc)))(PRN (-LRB- (-LRB-))(NP (NN (Delta14)))(: (/))(CC (+))(-RRB- (-RRB-))))(NN (mouse))(VBN (given))(NN (parecoxib)))(NP (VBN (compared))(NN (control))))))))) |ET|  |BS| 3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 142:I01.880.604 158:D23.101 350:D12.644.276.374.625 351:A17.360 444:C23.300.825 718:E05.588.570  |ES| 2:1 10:1 14:1 18:1 19:1 29:1 48:1 50:1 52:1 104:1 113:1 275:1 280:1 281:1 289:1 534:1 647:1 661:1 710:1 1160:1 1283:1 3738:1 3739:1  |EV| 
-0.00012626535118648307687294618517626  |BT| (S (PP (IN (In))(NP (NP (NP (NN (mouse))(JJ (ovarian))(JJ (endometrioid))(NN (adenocarcinoma)))(PRN (-LRB- (-LRB-))(NP (NNS (OEAs)))(-RRB- (-RRB-))))(VP (VBG (arising))(NP (NN (Apc))))))(: (-))(NP (NP (NN (Pten-inactivation)))(, (,))(NP (NN (Ctnnb1))(JJ (hemizygous))(NN (dose))))(VP (VBD (affected))(NP (NP (NN (beta-catenin))(NN (level))(NN (beta-catenin/TCF))(NN (target))(NN (gene)))(, (,))(NP (NN (Myc))(NN (induction))))(VP (VBD (retained))(SBAR (S (NP (NNS (OEAs)))(VP (VBD (arose))(NP (NP (NN (fashion))(JJ (akin)))(VBN (seen))(JJ (intact))(NN (Ctnnb1))(NN (gene))(NN (dose))))))))) |ET|  |BS| 3:C04.557.470.035.215.100 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 213:F02.830.816.964 433:F01.470.047 1368:C04.557.470.200.025.240 1369:A05.360.319.114.630  |ES| 2:1 9:1 10:1 14:1 19:1 52:1 60:1 160:1 244:1 249:1 255:1 724:1 736:1 1577:1 1763:1 1786:1 2301:1 4032:1 4422:1 4722:1 4754:1 4906:1 4907:1 4908:1 4909:1 4910:1 4911:1 4912:1 4913:1 4914:1  |EV| 
-0.00029233898903674448987999312521424  |BT| (S (NP (NP (JJ (Antisense))(NNS (oligodeoxynucleotides))(JJ (human))(NN (superoxide))(NN (dismutase))(CD (2)))(CC (and/or))(NP (JJ (ectopic))(NN (bcl-2))(NN (overexpression))))(VP (VBD (avoided))(NP (NP (NNS (polyphenols)))(SBAR (S (NP (JJ (chemoradiotherapy-induced))(JJ (colorectal))(NN (cancer))(NN (elimination)))(VP (VBD (showed))(NP (NP (JJ (mangano-type))(NN (superoxide))(NN (dismutase))(NN (Bcl-2))(JJ (key))(NN (target))(JJ (molecular))(NN (mechanism)))(VP (VBN (activated))(NP (JJ (combined))(NN (application))(NN (t-PTER))(NNP (QUER))))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 56:D02.455.426.559.389.657.715 57:D13.695.578.424.450 58:D08.811.682.881 59:E02.186.079  |ES| 17:1 18:1 19:1 36:1 132:1 144:1 145:1 146:1 147:1 148:1 149:1 150:1 151:1 152:1 153:1 154:1 155:1 156:1 157:1 158:1 159:1 160:1 161:1 162:1 163:1 164:1 165:1 166:1 167:1  |EV| 
-0.00022798549321870198447470556857297  |BT| (S (S (NP (JJ (Ursolic))(NN (acid)))(VP (VBZ (inhibits))(NP (NP (NN (growth))(NN (metastasis))(JJ (human))(JJ (colorectal))(NN (cancer))(JJ (orthotopic))(JJ (nude))(NN (mouse))(NN (model)))(VP (VBG (targeting))(NP (JJ (multiple))(NN (cell))(NN (signaling))(NN (pathway)))))))(: (:))(NP (NN (chemosensitization))(NN (capecitabine)))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 113:C04.697.650 122:C14.280.383 126:G02.111.087.800 810:D03.383.742.680.245.500.425  |ES| 17:1 18:1 19:1 36:1 52:1 72:1 94:1 102:1 104:1 195:1 266:1 383:1 615:1 616:1 649:1 806:1 1275:1 2873:1 3740:1 3883:1 3884:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (JJ (Intestinal))(NN (cancer)))(VP (VBN (driven))(SBAR (S (NP (ADJP (RB (purely))(NN (PTEN-deficiency)))(JJ (transgenic))(NN (mouse)))(VP (VBD (developed))(NP (NP (NN (CM))(JJ (human))(NN (CRC)))(, (,))(NP (NP (NN (CM)))(VP (VBN (associated))(NP (NNP (PTEN))(NNP (PRKCZ))(NN (readout))))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 66:F01.658.293 87:C18.654.521 99:B01.050.050.136.500 101:C04.588.274.476.411  |ES| 2:1 18:1 19:1 36:1 52:1 169:1 204:1 245:1 285:1 920:1 1165:1 1936:1 2030:1 2031:1 2032:1 2033:1 2034:1  |EV| 
-0.00024052887698478020439551983145066  |BT| (S (PP (IN (In))(NP (NN (conclusion))))(, (,))(NP (NN (Folbp1))(NN (RFC1)))(ADVP (RB (genetically)))(VP (NP (VBN (modified))(NN (mouse))(NN (exhibit))(JJ (distinct))(NN (change))(NN (colonocyte))(NN (phenotype)))(ADVP (RB (therefore)))(SBAR (S (NP (NN (utility))(NN (model)))(VP (VBP (examine))(NP (NP (NN (role)))(JJ (folate))(NN (homeostasis))(NN (colon))(NN (cancer))(NN (development)))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 80:G05.695 152:G07.700.345 175:J01.897.280.500.269 224:D03.438.733.631.400  |ES| 2:1 18:1 19:1 31:1 35:1 52:1 72:1 113:1 200:1 218:1 236:1 244:1 500:1 587:1 778:1 898:1 960:1 1284:1 2026:1 2194:1 2335:1 3548:1 3549:1 3550:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (NN (Inhibition))(NN (STAT3))(NN (signaling))(NN (pathway))(NN (nitidine))(NN (chloride)))(VP (VBD (suppressed))(NP (NN (angiogenesis))(NN (growth))(JJ (human))(JJ (gastric))(NN (cancer))))) |ET|  |BS| 43:F01.145.544 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 82:D12.644.360.024.342.300 126:G02.111.087.800  |ES| 18:1 19:1 36:1 86:1 102:1 195:1 251:1 307:1 383:1 2502:1 2703:1 2788:1 3594:1  |EV| 
-0.00032972935328834385160234887734987  |BT| (NP (NP (NN (Overactivation))(NN (Wnt-beta-catenin))(NN (signaling)))(, (,))(PP (VBG (including))(NP (NP (NN (beta-catenin-TCF))(NN (target))(NN (gene))(NN (expression)))(, (,))(NP (NP (NN (hallmark))(JJ (colorectal))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (CRC)))(-RRB- (-RRB-))))(NP (NN (development)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 105:G02.149.115.800.925 155:G05.355.310  |ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 35:1 115:1 160:1 195:1 245:1 561:1 1427:1 1500:1 1501:1 1502:1  |EV| 
-4.8677241736258577338458154726286e-06  |BT| (NP (NP (DT (These))(S (VP (VBG (finding))(VP (VB (provide))(NP (NP (JJ (important))(NN (information))(NN (interaction)))(PP (IN (among))(NP (NP (VBG (transforming))(NN (growth))(NN (factor))(NN (beta)))(, (,))(NP (NN (BMP)))(, (,))(NP (NN (Wnt))(NN (signaling))(NN (pathway))(NN (progression))(NN (CRC))))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 16:C23.550.291.656 147:G02.149.115.800.925 503:D12.644.276.374.687 1099:D12.644.276.954.200  |ES| 2:1 19:1 48:1 102:1 185:1 195:1 245:1 383:1 618:1 711:1 792:1 877:1 902:1 927:1 1372:1 1772:1 1972:1 2338:1 3855:1  |EV| 
-0.00036687988597939496029920469766239  |BT| (S (ADVP (RB (Herein)))(, (,))(VP (VBD (found))(SBAR (IN (whereas))(S (VP (VBG (sparing))(NP (NP (JJ (normal))(NP (JJ (human))(NN (colon))(JJ (mucosal))(JJ (epithelial))(NN (cell))))(, (,))(NP (NN (EPLE))))(VP (ADVP (RB (selectively)))(VBD (inhibited))(NP (NN (proliferation))(NN (CRC))(NN (cell))(NN (line)))(ADVP (RB (well)))(NP (JJ (primary))(NN (tumor))(NN (cell))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 41:A11 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 75:A11.436 122:C14.280.383 183:G04.299.233.750 302:A10.615.550  |ES| 2:1 7:1 19:1 36:1 37:1 94:1 113:1 118:1 127:1 245:1 264:1 299:1 344:1 365:1 372:1 428:1 787:1 2489:1 3521:1 3522:1 3523:1  |EV| 
-0.00034273576997182961245691501517285  |BT| (S (NP (NP (NNS (Mice)))(VP (VBG (receiving))(NP (NN (NaTC)))))(VP (VBD (manifested))(NP (NP (VBN (increased))(JJ (intestinal))(NN (expression))(JJ (FXR-regulated))(NN (gene)))(, (,))(NP (NP (NNP (Shp)))(, (,))(NP (NNP (FGF15))(NNP (IBABP)))(, (,))(NP (JJ (concomitant))(NN (decrease))(NN (cyclin))(NN (D1))(NN (message))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 47:A03.556.124 142:I01.880.604 155:G05.355.310 215:D12.644.360.262.150.100  |ES| 2:1 9:1 19:1 47:1 109:1 115:1 295:1 548:1 583:1 743:1 744:1 1681:1 1928:1 4507:1 5006:1 5007:1 5008:1 5009:1 5010:1  |EV| 
-5.3021460039437418032548521296121e-05  |BT| (S (NP (PRP$ (Our))(NN (study)))(VP (VBZ (demonstrates))(NP (NP (NN (inhibition))(NN (cell))(NN (proliferation))(NN (regulation)))(SBAR (S (NP (JJ (inflammatory))(NN (marker)))(VP (MD (may))(, (,))(ADVP (JJS (least))(NN (part)))(, (,))(S (VP (VBG (underlying))(NP (NN (mechanism))(JJ (related))(NN (liver))(NN (tumor))(NN (inhibition))(NN (diosmin))))))))))) |ET|  |BS| 41:A11 43:F01.145.544 85:G02.111.087.225 158:D23.101 183:G04.299.233.750 515:C04.588.274.623 715:D03.383.663.283.266.450.260.222  |ES| 2:1 7:1 19:1 94:1 103:1 131:1 162:1 299:1 419:1 435:1 438:1 451:1 491:1 534:1 658:1 836:1 1331:1 2430:1 2541:1 2695:1  |EV| 
-0.00027725764767733140914174327917863  |BT| (S (NP (NN (Inhibition))(NN (autophagy)))(VP (VBZ (potentiates))(NP (JJ (antitumor))(NN (effect))(NN (multikinase))(NN (inhibitor))(NN (sorafenib))(JJ (hepatocellular))(NN (carcinoma))))) |ET|  |BS| 43:F01.145.544 104:C04.557.470.200.025.255 390:G04.299.139.399  |ES| 19:1 75:1 303:1 304:1 380:1 1317:1 2063:1 2244:1 2499:1 2703:1 3592:1  |EV| 
-0.00023234837111284212252115821684129  |BT| (S (NP (NN (ING5)))(VP (VP (VBZ (suppresses))(NP (NP (NN (proliferation)))(, (,))(NP (NN (apoptosis)))(, (,))(NP (NN (migration))(NN (invasion)))))(, (,))(VP (VBZ (induces))(NP (JJ (autophagy))(NN (differentiation))(JJ (gastric))(NN (cancer))(NN (cell))))(: (:))(NP (JJ (good))(NN (marker))(NN (carcinogenesis))(JJ (subsequent))(NN (progression))))) |ET|  |BS| 16:C23.550.291.656 33:C04.697.098 39:G04.299.139.160 74:G04.299.151 158:D23.101 390:G04.299.139.399  |ES| 2:1 18:1 19:1 48:1 86:1 89:1 94:1 104:1 207:1 214:1 215:1 299:1 514:1 534:1 620:1 686:1 1316:1 1317:1 1318:1 1319:1  |EV| 
-7.308001910360205355399187965304e-05  |BT| (S (ADVP (RB (Thus)))(, (,))(NP (NN (inactivation))(NN (TGF-beta))(NN (signaling))(NN (loss))(NN (PTEN)))(VP (VBP (cooperate))(NP (NP (NN (drive))(JJ (intestinal))(NN (cancer))(NN (formation))(NN (progression)))(VP (VBG (suppressing))(NP (NN (cell))(NN (cycle))(NN (inhibitor))))))) |ET|  |BS| 16:C23.550.291.656 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 66:F01.658.293 69:G02.111.087.800 101:C04.588.274.476.411 353:G04.299.134 503:D12.644.276.374.687  |ES| 2:1 18:1 19:1 32:1 43:1 48:1 94:1 109:1 181:1 195:1 380:1 474:1 601:1 1314:1 1691:1 1774:1 1936:1 2250:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (DT (These)))(VP (VBP (result))(VP (VBP (implicate))(S (NP (NN (SPARC))(NN (promoter))(NN (methylation))(JJ (important))(NN (factor))(NN (tumorigenesis))(JJ (gastric))(NN (carcinoma)))(VP (VB (provide))(NP (NP (JJ (new))(NN (insight))(JJ (potential))(NN (use)))(NP (NNP (SPARC))(JJ (novel))(NN (biomarker))(JJ (potential))(JJ (clinical))(NN (importance))(JJ (human))(JJ (gastric))(NN (cancer))))))))) |ET|  |BS| 32:C04.697.098.500 33:C04.697.098 36:G02.111.087.029.538 37:D12.776.157.125.715 55:B01.050.150.900.649.801.400.112.400.400 70:A03.556.875.875 158:D23.101 259:D12.776.395.240.150.500 265:C04.557.470.200  |ES| 18:1 19:1 36:1 78:1 81:1 82:1 83:1 84:1 86:1 101:1 185:1 304:1 711:1 712:1 792:1 827:1 885:1 891:1 902:1 1141:1 1658:1 1659:1 1660:1  |EV| 
-0.00012928521981782348237999258344644  |BT| (NP (NP (NN (Repression))(NN (MUC2))(NN (gene))(NN (expression))(NN (butyrate)))(, (,))(NP (JJ (physiological))(NN (regulator))(JJ (intestinal))(NN (cell))(NN (maturation)))) |ET|  |BS| 47:A03.556.124 155:G05.355.310 208:F01.393.821 230:G04 1307:D02.241.081.114.750 1309:D02.241.081.114  |ES| 2:1 9:1 19:1 94:1 109:1 115:1 212:1 235:1 3758:1 3762:1 5042:1 5131:1  |EV| 
-1.5053609938787959610095867901691e-05  |BT| (S (NP (NN (BACKGROUND))(: (:)))(NP (NP (JJ (Epidermal))(NN (growth))(NN (factor))(JJ (receptor-tyrosine))(NN (kinase))(NN (inhibitor)))(PRN (-LRB- (-LRB-))(NP (NN (EGFR-TKIs)))(-RRB- (-RRB-))))(VP (VBD (approved))(NP (NP (NN (patient)))(JJ (recurrent))(NP (NP (JJ (non-small))(NN (cell))(NN (lung))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (NSCLC)))(-RRB- (-RRB-))))))) |ET|  |BS| 50:M01.643 64:D08.811.913.696.620.682.725.400.009.300 110:C04.588.894.797.520.109.220.249 496:C23.550.291.937 634:D12.125.072.050.875  |ES| 10:1 14:1 18:1 19:1 94:1 102:1 104:1 120:1 185:1 328:1 329:1 380:1 470:1 694:1 1046:1 1753:1 2340:1 2343:1 3297:1 3298:1  |EV| 
-8.1050591238529534621193306520581e-10  |BT| (S (NP (NN (miR-137)))(VP (VBZ (regulates))(SBAR (S (NP (JJ (constitutive))(NN (androstane))(NN (receptor)))(VP (VBZ (modulates))(NP (NN (doxorubicin))(NN (sensitivity))(JJ (parental))(JJ (doxorubicin-resistant))(NN (neuroblastoma))(NN (cell)))))))) |ET|  |BS| 41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320  |ES| 19:1 94:1 186:1 420:1 422:1 423:1 424:1 599:1 603:1 604:1 605:1 606:1 607:1  |EV| 
-8.4018493468479560348782797518652e-06  |BT| (S (NP (NN (Down-regulation))(NN (Notch))(NN (signaling)))(ADVP (RB (also)))(VP (VBD (prevented))(NP (NP (NP (NN (induction)))(JJ (prosurvival))(NN (pathway)))(, (,))(NP (NP (ADJP (RB (notably))(JJ (phosphoinositide)))(NN (kinase-3)))(: (/))(NP (NNP (Akt))))(, (,))(NP (NN (oxaliplatin)))))) |ET|  |BS| 69:G02.111.087.800 85:G02.111.087.225 378:D08.811.913.696.620.682.700.755 578:D08.811.913.696.620.550  |ES| 2:1 5:1 19:1 195:1 256:1 383:1 736:1 1865:1 1944:1 2080:1 2543:1 3458:1 4758:1 4759:1  |EV| 
-0.00011271356220788480984040802468371  |BT| (S (NP (PRP$ (Our))(VBP (result)))(VP (VBP (indicate))(NP (S (NP (NN (miR-9))(NN (miR-197)))(VP (ADVP (RB (specifically)))(VBP (downregulate))(NP (NN (MTHFD1L))(NN (level))(NN (HEK293))(NN (MCF-7))(NN (cell))(NN (SNPrs7646)))(ADVP (RB (significantly)))(VP (VBP (affect))(NP (NP (NN (miR-197))(NN (binding))(NN (affinity))(NN (MTHFD1L))(CD (3)))('' ('))(NN (UTR)))(, (,))(S (VP (VBG (causing))(NP (NP (JJ (efficient))(JJ (posttranscriptional))(NN (gene))(NN (repression))(NN (presence))(NN (allele)))(VP (VBN (associated)))))))))(NP (VBD (increased))(NN (risk))(NNS (NTDs)))))) |ET|  |BS| 6:G05.360.340.024.340 61:E05.318.740.600.800 77:G05.360.340.024.340.030 208:F01.393.821 252:F02.784.692.351 411:C10.500.680 431:D13.444.735.544.875 432:A11.251.210.190.630 433:F01.470.047  |ES| 2:1 9:1 19:1 47:1 94:1 101:1 124:1 169:1 171:1 230:1 249:1 346:1 508:1 658:1 706:1 862:1 1279:1 1398:1 1479:1 1480:1 1481:1 1482:1 1483:1 1484:1 1485:1 1486:1 1487:1 1488:1 1489:1 1490:1 1491:1 1492:1 1493:1  |EV| 
-0.00023235768971605064159291487158043  |BT| (S (S (ADVP (RB (Hence)))(, (,))(NP (NN (agent)))(VP (VBD (prevented))(SBAR (S (NP (NN (colon))(NN (cancer)))(VP (VBD (decreased))(NP (NP (JJ (mitotic))(NN (index)))(NP (VBN (altered))(NN (expression))(NN (c-myc)))))))))(, (,))(NP (NN (p16))(NN (p27)))(VP (VBG (suggesting))(NP (NP (NN (modulation))(NN (expression))(NN (gene)))(JJ (potential))(NNS (biomarkers))(JJ (chemopreventive))(NN (activity))))) |ET|  |BS| 155:G05.355.310 158:D23.101 203:G05.360.340.024.340.375.249.375 212:E01.370.225.500.385.500  |ES| 2:1 9:1 18:1 19:1 113:1 115:1 202:1 399:1 455:1 693:1 720:1 721:1 728:1 827:1 1009:1 1124:1 1269:1 1313:1 1943:1 1944:1 1945:1 1946:1  |EV| 
-6.4409216283561887550490610010456e-05  |BT| (S (NP (NN (Histone))(NN (deacetylase))(NN (inhibitor)))(VP (VBP (suppress))(SBAR (S (NP (NN (thymidylate))(NN (synthase))(NN (gene))(NN (expression)))(VP (VBP (synergize))(NP (NNS (fluoropyrimidines))(NP (NN (colon))(NN (cancer))(NN (cell))))))))) |ET|  |BS| 41:A11 153:D27.505.519.389.360 155:G05.355.310 713:D08.811.913.555.500.862  |ES| 9:1 18:1 19:1 66:1 94:1 113:1 115:1 380:1 504:1 2441:1 2578:1 3528:1 4878:1 4879:1  |EV| 
-0.00015881851736104790617787330120336  |BT| (S (NP (DT (The))(NN (ability))(NN (PF-03084014)))(VP (VBP (inhibit))(NP (NP (NN (gamma-secretase))(NN (activity)))(VP (VBN (shown))(NP (NP (NP (NN (reduction))(JJ (endogenous))(NN (NICD))(NN (level))(NN (downregulation))(NN (Notch))(NN (target))(NN (gene))(NN (Hes-1))(NN (cMyc))(NN (T-cell))(JJ (acute))(JJ (lymphoblastic))(NN (leukemia)))(PRN (-LRB- (-LRB-))(NP (NN (T-ALL)))(-RRB- (-RRB-))))(NN (cell))(NN (line))(NN (HPB-ALL))))))) |ET|  |BS| 6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 85:G02.111.087.225 122:C14.280.383 125:D08.811.277.656.300.032 385:F02.784.629.131 1435:C04.557.337.428.600.620  |ES| 9:1 10:1 14:1 19:1 90:1 94:1 160:1 237:1 249:1 256:1 264:1 370:1 399:1 595:1 691:1 1300:1 1370:1 1866:1 2277:1 3870:1 5187:1 5200:1 5208:1 5209:1 5210:1 5211:1 5212:1 5213:1  |EV| 
-0.00020900669369800428318284524209503  |BT| (S (NP (NNP (LOH))(NNP (FHIT))(NN (locus)))(ADVP (RB (frequently)))(VP (VBN (found))(PP (IN (among))(NP (NN (lesion))(NNS (metaplasias))(JJ (bronchiolar))(NN (epithelium))(NN (patient))(NN (IPF))))(PRN (-LRB- (-LSB-))(NP (NP (CD (62))(PRN (-LRB- (-LRB-))(NP (CD (52))(NN (%)))(-RRB- (-RRB-))))(NP (CD (119))(JJ (informative))(NN (lesion))))(-RRB- (-RSB-))))) |ET|  |BS| 48:C23.550.589 50:M01.643 62:A10.272 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765 365:A04.411.125.500  |ES| 10:1 14:1 19:1 37:1 120:1 173:1 369:1 377:1 698:1 946:1 1004:1 1122:1 1131:1 1222:1 1223:1 1372:1 1373:1 1374:1 1375:1 1376:1 1377:1 1378:1  |EV| 
-8.8860465013440581572012888500467e-06  |BT| (NP (NP (ADVP (RB (Thus)))(, (,))(NP (NP (NN (inactivation))(NN (p16))(NN (gene))(JJ (common))(NN (event))(JJ (non-small))(NN (cell))(NN (lung))(NN (cancer)))(, (,))(NP (NN (mechanism))(NN (gene))(NN (alteration)))(VP (VBZ (differs))(NP (NN (smoker))(NN (nonsmoker))))))) |ET|  |BS| 18:G05.365.590 42:G05.355.315.203.374 110:C04.588.894.797.520.109.220.249 203:G05.360.340.024.340.375.249.375  |ES| 2:1 9:1 18:1 19:1 94:1 162:1 205:1 328:1 655:1 694:1 951:1 1313:1 1314:1 1315:1 1691:1 1692:1 1693:1  |EV| 
-1.6507974883599868531902643553622e-05  |BT| (S (NP (PP (TO (To))(NP (NN (knowledge))))(, (,))(JJ (first))(NN (study))(NN (report))(NN (change))(NN (lncRNA))(NN (expression))(NN (profile)))(VP (VBD (induced))(NP (NN (resveratrol))(NN (lung))(NN (cancer))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 479:G08.686.157.500 480:D13.444.735.790.375 481:D13.444.735.790.375 482:K01.468  |ES| 2:1 18:1 19:1 115:1 131:1 200:1 328:1 412:1 417:1 816:1 828:1 1709:1 1710:1 1711:1 1712:1  |EV| 
-0.00036009077597321621430626059634506  |BT| (NP (NP (NP (JJ (Anticancer))(NN (effect))(NN (wogonin))(NN (estrogen))(JJ (receptor-positive)))(: (-))(NP (JJ (negative))(JJ (human))(NN (breast))(NN (cancer))(NN (cell))(NN (line))(NN (vitro))(JJ (nude))(NN (mouse))(NN (xenograft))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 94:A11.251.210 936:D12.776.826.750.350  |ES| 18:1 19:1 23:1 36:1 52:1 75:1 94:1 216:1 264:1 265:1 266:1 2444:1 2446:1 3168:1 3285:1 3286:1  |EV| 
-4.5654822932745392494169323072128e-05  |BT| (S (NP (PRP (We)))(VP (VBD (investigated))(NP (NP (NP (NN (expression))(NN (leptin))(NN (receptor))(CD (171))(JJ (consecutive))(NN (patient)))(PRN (-LRB- (-LRB-))(NP (NP (CD (78))(JJ (female))(CD (93))(NN (male)))(: (;))(NP (CD (71))(NN (year))))(-RRB- (-RRB-))))(NN (CRC))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 642:M01.975 1124:D06.472.699.042.500  |ES| 10:1 14:1 19:1 115:1 120:1 186:1 217:1 245:1 403:1 843:1 1402:1 1404:1 1452:1 3206:1 3930:1 3931:1 3932:1 3933:1 3934:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (NP (NP (NNS (CONCLUSIONS))(: (:)))(S (NP (PRP$ (Our))(NN (result)))(VP (VB (identify))(NP (NP (NP (JJ (novel))(NN (candidate))(NN (mouse))(NN (gene)))(, (,))(NP (NN (Zfp277)))(, (,)))(SBAR (WHNP (WP$ (whose))(NN (expression))(NN (pattern)))(S (NP (JJ (compatible))(NN (role)))(VP (VBG (mediating))(NP (JJ (divergent))(NN (effect))(NN (Chrm3))(NN (Chrm1))(NN (gene))(NN (ablation))(JJ (murine))(JJ (intestinal))(NN (neoplasia)))))))))) |ET|  |BS| 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 47:A03.556.124 102:C04.588.274.476.411 259:D12.776.395.240.150.500 537:G05.360.340.024.340.375  |ES| 2:1 9:1 19:1 31:1 52:1 75:1 91:1 101:1 104:1 109:1 115:1 239:1 260:1 627:1 640:1 658:1 761:1 832:1 891:1 919:1 1243:1 1895:1 1896:1 1897:1 1898:1 1899:1  |EV| 
-0.00032401056265591449134788604169444  |BT| (FRAG (ADVP (RB (Here)))(, (,))(NP (NP (NN (report))(ADJP (RB (inversely))(JJ (related)))(NN (expression))(NN (miR-137))(NN (CAR))(JJ (parental))(JJ (doxorubicin-resistant))(NN (neuroblastoma))(NN (cell)))(, (,))(SBAR (WHADVP (WRB (wherein)))(S (NP (NN (miR-137)))(VP (VBD (downregulated))(NP (JJ (resistant))(NN (cell)))))))) |ET|  |BS| 41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320 139:J01.937.500.100  |ES| 2:1 19:1 94:1 115:1 400:1 417:1 418:1 419:1 420:1 421:1 422:1 423:1 424:1 425:1 426:1 427:1  |EV| 
-0.0003283509567895675357318552300967  |BT| (NP (NP (NN (INTERPRETATION)))(: (:))(S (S (NP (NN (Stimulation))(NN (survivin))(NN (expression))(NN (TCF/beta))(NN (catenin)))(VP (MD (might))(VP (VB (impose))(NP (NN (stem))(JJ (cell-like))(NN (phenotype)))(SBAR (S (NP (JJ (colonic))(NN (crypt))(NN (epithelium))(NN (coupling)))(VP (VBD (enhanced))(NP (NN (cell))(NN (proliferation))(NN (resistance))(NN (apoptosis)))))))))(, (,))(VP (VBP (contribute))(NP (JJ (molecular))(NN (pathogenesis))(JJ (colorectal))(NN (cancer)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 39:G04.299.139.160 46:A03.556.124.526.356 62:A10.272 80:G05.695 183:G04.299.233.750 308:A11.872  |ES| 2:1 17:1 18:1 19:1 89:1 94:1 104:1 115:1 161:1 173:1 236:1 299:1 385:1 450:1 501:1 677:1 798:1 1094:1 1106:1 2229:1 2913:1 3601:1 3602:1 3603:1 3604:1 3605:1 3606:1 3607:1  |EV| 
-8.2144689473859222594853690679884e-05  |BT| (NP (NP (NP (NN (BACKGROUND)))(CC (&))(NP (NNS (AIMS))))(: (:))(S (NP (NP (NN (p53))(NNS (Mutations)))(JJ (common))(NP (JJ (human))(JJ (hepatocellular))(NN (carcinoma)))(, (,))(NP (NN (induction))(JJ (hepatic))(NN (p53))(NN (expression))))(VP (VBP (cause))(SBAR (S (NP (NN (lysis)))(VP (VBD (implanted))(NP (NN (hepatoblastoma))(NN (cell))(JJ (chimeric))(NN (mouse))))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 41:A11 55:B01.050.150.900.649.801.400.112.400.400 73:N05.715.350.200 104:C04.557.470.200.025.255 504:C04.557.435.380 505:B05.200  |ES| 2:1 12:1 19:1 36:1 52:1 94:1 104:1 115:1 303:1 304:1 655:1 736:1 838:1 1046:1 1410:1 1777:1 1778:1 1779:1 1780:1 1781:1 1782:1 1783:1  |EV| 
-0.00018856700310729453129443555781108  |BT| (S (NP (PRP (We)))(VP (VBD (found))(FRAG (NP (NN (melatonin)))(ADVP (RB (significantly)))(NP (VBD (enhanced))(NP (JJ (5-FU-mediated))(NN (inhibition))(NN (cell))(NN (proliferation)))(, (,))(NP (NP (NN (colony))(NN (formation)))(, (,))(NP (NN (cell))(NN (migration))(NN (invasion))(NN (colon))(NN (cancer))(NN (cell)))))))) |ET|  |BS| 20:G03.495 41:A11 43:F01.145.544 109:I01.696.116 183:G04.299.233.750 560:D03.383.742.698.875.404 681:G04.299.283 707:D03.438.473.914.481  |ES| 2:1 18:1 19:1 37:1 43:1 94:1 103:1 113:1 124:1 299:1 314:1 385:1 514:1 620:1 843:1 2556:1 3903:1  |EV| 
-9.4434937005782870755865587852895e-06  |BT| (S (NP (NN (gamma-Secretase))(NN (inhibitor)))(VP (VBP (abrogate))(NP (NP (JJ (oxaliplatin-induced))(NN (activation))(NN (Notch-1))(NN (signaling))(NN (pathway))(NN (colon))(NN (cancer))(NN (cell)))(VP (VBG (resulting))(NP (VBN (enhanced))(NN (chemosensitivity))))))) |ET|  |BS| 41:A11 69:G02.111.087.800 125:D08.811.277.656.300.032 126:G02.111.087.800  |ES| 18:1 19:1 20:1 94:1 113:1 195:1 225:1 379:1 380:1 381:1 382:1 383:1 384:1 385:1 386:1  |EV| 
-3.9889229234764400633395098338951e-05  |BT| (FRAG (NP (NP (NP (NN (H)))(-LRB- (-LRB-))(CD (2))(-RRB- (-RRB-))(NP (NN (O))(-LRB- (-LRB-))(CD (2))(-RRB- (-RRB-))))(RRC (ADVP (RB (also)))(NP (VBN (stimulated))(NP (NN (expression))(NN (Gadd45b))(VBN (cultured))(NN (cell))))))) |ET|  |BS| 94:A11.251.210 1356:D01.268.406.500 1357:A11.251  |ES| 5:1 10:1 14:1 19:1 94:1 115:1 148:1 612:1 1232:1 4853:1 4854:1 4855:1  |EV| 
-1.5055057870021204546873150320607e-05  |BT| (S (NP (PRP (We)))(VP (VBD (analyzed))(SBAR (S (NP (NP (NN (matrilysin))(NN (expression))(JJ (benign))(JJ (intestinal))(NP (NN (tumor))(NN (mouse))(JJ (heterozygous))(NN (ApcMin))(NN (allele))))(PRN (-LRB- (-LRB-))(NP (NN (Min)))(: (/))(NP (CC (+)))(-RRB- (-RRB-))))(VP (VBD (found))(SBAR (S (NP (NN (mRNA)))(VP (VBD (induced))(NP (NP (NP (NN (majority)))(PRN (-LRB- (-LRB-))(NP (CD (88))(NN (%)))(-RRB- (-RRB-))))(NN (adenoma))))))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 17:C04.557.470.035 47:A03.556.124 77:G05.360.340.024.340.030 111:D13.444.735.544 157:G05.380.383 381:C04 937:D08.811.277.656.300.480.525.700.250  |ES| 7:1 10:1 14:1 19:1 37:1 42:1 52:1 109:1 115:1 198:1 230:1 325:1 369:1 412:1 705:1 786:1 843:1 1168:1 1194:1 1288:1 3289:1 5562:1  |EV| 
-0.00023781338418942367732289433490678  |BT| (S (NP (DT (These)))(VP (VBP (result))(SBAR (S (NP (VBN (demonstrated))(NNS (SK-Hep1-NIS)))(VP (MD (could))(VP (ADVP (RB (selectively)))(VBN (killed))(NP (JJ (induced))(NN (131I))(NN (188Re-perrhenate))(NN (accumulation))(NN (NIS))(NN (gene))(NN (expression))))))))) |ET|  |BS| 155:G05.355.310 1443:I01.198.240.470  |ES| 9:1 19:1 101:1 115:1 412:1 792:1 908:1 1175:1 2120:1 3523:1 5268:1 5269:1 5270:1 5271:1 5272:1  |EV| 
-0.00012303038405586663728286112018395  |BT| (S (NP (NN (miR-490-3p)))(VP (VBD (exerted))(NP (NP (NN (growth)))(: (-))(NP (NP (JJ (metastasis-suppressive))(NN (effect))(JJ (gastric))(NN (cancer))(NN (cell)))(VP (ADVP (RB (directly)))(VBG (targeting))(NP (NP (NN (SMARCD1)))(, (,))(NP (NP (NN (SWItch/Sucrose))(NN (NonFermentable)))(PRN (-LRB- (-LRB-))(NP (NN (SWI/SNF)))(-RRB- (-RRB-))))(NP (NN (chromatin))(NN (remodeling))(NN (complex))(NN (subunit))))))))) |ET|  |BS| 41:A11 45:G07.700.320.249 113:C04.697.650 582:D09.698.629.305.770 583:D12.776.813  |ES| 2:1 10:1 14:1 18:1 19:1 75:1 86:1 94:1 608:1 616:1 621:1 695:1 1346:1 2102:1 2103:1 2104:1 2105:1 2106:1 2107:1 2108:1 2109:1 2110:1  |EV| 
-0.00024499057949822766744318869314156  |BT| (S (ADVP (RB (Moreover)))(, (,))(NP (NN (miR-221))(NN (reduction)))(VP (VBD (resulted))(NP (NN (alteration))(JJ (EMT-associated))(NN (gene))(NN (E-cadherin))(NN (vimentin)))(NP (RB (well))(ADJP (RB (significantly))(JJR (slower)))(NN (xenograft))(NN (tumor))(NN (growth))(JJ (nude))(NN (mouse))))) |ET|  |BS| 8:C04 18:G05.365.590 45:G07.700.320.249 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 820:D12.776.395.550.200.200 1527:D05.750.078.593.900  |ES| 2:1 7:1 9:1 19:1 52:1 102:1 124:1 140:1 265:1 266:1 370:1 594:1 622:1 787:1 951:1 2267:1 5687:1 5688:1 5689:1  |EV| 
-0.00041788035725208173528158472898042  |BT| (S (NP (NN (Sugiol)))(VP (VBD (induced))(SBAR (S (NP (NN (cell))(NN (cycle))(NN (arrest)))(VP (VBD (decreased))(NP (NP (NP (NN (expression))(NN (level))(NN (STAT3))(NN (target))(NN (gene)))(, (,))(NP (NN (cyclin))(NN (D1))))(, (,))(NP (NN (cyclin))(NN (A)))(, (,))(NP (NN (survivin))))))))) |ET|  |BS| 82:D12.644.360.024.342.300 155:G05.355.310 215:D12.644.360.262.150.100 773:G04.299.134.109 1431:D12.644.360.262.100  |ES| 2:1 9:1 19:1 69:1 94:1 115:1 160:1 202:1 249:1 251:1 412:1 601:1 602:1 743:1 744:1 2229:1 5202:1  |EV| 
-2.4043111649153965647673913963445e-05  |BT| (S (NP (NN (Troglitazone)))(VP (VBZ (induces))(NP (JJ (p27Kip1-associated))(NP (JJ (cell-cycle))(NN (arrest))(JJ (down-regulating))(NN (Skp2))(JJ (human))(NN (hepatoma))(NN (cell)))))) |ET|  |BS| 41:A11 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 338:D12.644.360.225.600 351:A17.360 507:D12.776.157.743 515:C04.588.274.623 773:G04.299.134.109  |ES| 19:1 36:1 94:1 214:1 602:1 1785:1 3097:1 3116:1 3896:1 5313:1 5314:1  |EV| 
-5.6791591150210426336419899939756e-05  |BT| (S (NP (NN (Overexpression))(NN (Klotho)))(VP (VBZ (suppresses))(SBAR (S (NP (NN (liver))(NN (cancer))(NN (progression)))(VP (VBZ (induces))(S (NP (NN (cell))(NN (apoptosis)))(ADVP (RB (negatively)))(VP (VBG (regulating))(NP (JJ (wnt/beta-catenin))(NN (signaling))(NN (pathway)))))))))) |ET|  |BS| 16:C23.550.291.656 39:G04.299.139.160 41:A11 105:G02.149.115.800.925  |ES| 18:1 19:1 48:1 89:1 94:1 195:1 214:1 383:1 668:1 686:1 836:1 2867:1 2868:1 2869:1 2870:1  |EV| 
-0.00016027377035173059546813156828193  |BT| (S (SBAR (IN (Although))(S (NP (NN (study)))(VP (VBD (needed))(VP (VB (prove))(SBAR (S (NP (VBN (increased))(NN (expression))(NN (Egr-1))(NN (PTX-2)))(VP (ADVP (RB (directly)))(VBP (lead))(NP (NP (NN (NAG-1))(NN (induction))(NN (apoptosis))(NN (induction)))(NP (JJ (p53-deficient))(NN (Hep3B))(NN (cell)))))))))))(, (,))(VP (VBP (result))(SBAR (S (NP (NN (study)))(VP (VBP (suggest))(SBAR (S (NP (NN (PTX-2)))(VP (MD (may))(NP (JJ (good))(NN (candidate))(NN (development))(JJ (potential))(JJ (anti-tumorigenic))(NN (agent))(JJ (p53-deficient))(NN (tumor))))))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 41:A11 86:D01.268.556.435 284:N03.349.380.420 1272:D03.438.759.758.824.651.700  |ES| 2:1 7:1 19:1 35:1 47:1 89:1 94:1 101:1 107:1 115:1 131:1 254:1 491:1 621:1 728:1 736:1 796:1 827:1 981:1 1243:1 1318:1 1662:1 2669:1 4498:1 4502:1 4560:1 4561:1 4562:1  |EV| 
-2.0767288200728567515440659008163e-05  |BT| (S (PP (IN (As))(NP (NP (NN (Bim))(NN (expression))(JJ (critical))(NN (biomarker))(NN (response)))(NP (JJ (many))(VBN (targeted))(NN (therapy)))))(, (,))(NP (NN (PTK6))(NN (inhibition)))(VP (MD (may))(VP (VB (offer))(NP (NP (JJ (therapeutic))(NN (approach)))(VP (VBG (treating))(NP (NN (patient))(NN (Her2))(VBN (targeted))(JJ (therapy-resistant))(NN (breast))(NN (cancer)))))))) |ET|  |BS| 43:F01.145.544 50:M01.643 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 158:D23.101  |ES| 2:1 16:1 18:1 19:1 23:1 103:1 115:1 120:1 130:1 168:1 491:1 494:1 541:1 825:1 885:1 911:1 1039:1 1040:1 1041:1 1042:1 1043:1 1044:1 1045:1  |EV| 
-3.6655538988794589272401935886592e-05  |BT| (S (NP (PRP (We)))(ADVP (RB (also)))(VP (VBD (observed))(SBAR (S (NP (NN (flavokawain))(NN (B)))(VP (VBD (caused))(NP (NP (NP (NN (G2/M))(NN (phase))(NN (arrest))(JJ (mediated))(NN (reduction))(NN (level))(NN (cyclin))(NN (A)))(, (,))(NP (NN (cyclin))(NN (B1))))(, (,))(NP (NN (Cdc2))(NN (Cdc25C))(NN (increase))(NN (p21/WAF1)))(, (,))(NP (NN (Wee1))(NN (p53))(NN (level))))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 122:C14.280.383 979:D12.644.360.262.120.100 1431:D12.644.360.262.100 1453:G04.299.134.500.340  |ES| 2:1 5:1 12:1 19:1 40:1 69:1 249:1 261:1 370:1 437:1 602:1 743:1 763:1 843:1 2506:1 2528:1 2529:1 3455:1 5333:1 5334:1 5335:1 5336:1 5337:1  |EV| 
-7.9510143012998879888386660752531e-05  |BT| (NP (NP (NP (JJ (Mammary))(NN (tumour)))(NP (VBN (observed))(NN (EphB4))(JJ (transgenic))(NN (animal))))(: (;))(NP (ADVP (RB (however)))(, (,))(NP (NP (JJ (double))(JJ (transgenic))(NN (animal))(VBG (expressing))(NN (EphB4))(NN (neuT))(NN (gene)))(, (,))(NP (NN (tumour))(NN (appearance)))(S (S (ADVP (RB (significantly)))(VP (VBD (accelerated))))(, (,))(NP (NP (NN (contrast))(JJ (neuT-only))(NN (animal)))(, (,))(NP (NN (metastasis)))(NP (VBD (observed))(NN (lung)))))))) |ET|  |BS| 6:G05.360.340.024.340 8:C04 19:B01.050 113:C04.697.650 182:A04.411 352:B01.050.050.136 407:E01.370.225.812.735.550 408:C04.588.531  |ES| 2:1 9:1 19:1 46:1 124:1 217:1 261:1 285:1 328:1 806:1 810:1 1011:1 1379:1 1386:1 1387:1 1388:1 1389:1 1390:1 1391:1 1392:1 1393:1  |EV| 
-0.0002083100680843052998625353211537  |BT| (S (NP (NP (NN (Sodium))(NN (butyrate)))(PRN (-LRB- (-LRB-))(NP (NN (NaB)))(-RRB- (-RRB-))))(VP (VP (VBZ (inhibits))(NP (NN (proliferation))))(, (,))(VP (VBZ (stimulates))(NP (NN (apoptosis))))(, (,))(VP (VBZ (promotes))(NP (NN (differentiation))(JJ (human))(NN (colon))(NN (cancer))(NN (cell)))(PP (IN (along))(NP (JJ (absorptive))(NN (phenotype))))))) |ET|  |BS| 39:G04.299.139.160 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 80:G05.695 122:C14.280.383 1075:D02.241.081.114.750  |ES| 2:1 10:1 14:1 18:1 19:1 36:1 89:1 94:1 113:1 215:1 236:1 298:1 299:1 615:1 2666:1 2962:1 3758:1 3759:1 3760:1 3761:1  |EV| 
-0.00023025860084403826366639123079949  |BT| (S (PP (IN (In))(NP (JJ (intestinal))(JJ (epithelial))(NN (cell))(NN (IEC-6))(NN (colon))(NN (cancer))(NN (cell))(NN (HCT-116))))(, (,))(NP (NN (IL-6))(NN (expression))(NN (signaling)))(VP (VBN (assessed))(NP (NP (NNP (SHH))(NN (inhibitor))(NN (level))(JJ (inflammatory))(NN (mediator)))(, (,))(NP (NP (NN (proliferation)))(, (,))(NP (NN (apoptosis)))(, (,))(NP (NN (tumorsphere))(NN (formation))))(, (,))(NP (NP (NN (tumorigenesis)))(VP (ADVP (RB (also)))(VBN (measured))))))) |ET|  |BS| 20:G03.495 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 41:A11 47:A03.556.124 69:G02.111.087.800 75:A11.436 201:D12.644.276.374.465.224 228:E05.978 1523:E01.370.225.625.400 1524:E04.936.225.687.500  |ES| 2:1 5:1 18:1 19:1 43:1 78:1 89:1 94:1 109:1 113:1 115:1 127:1 195:1 244:1 249:1 299:1 380:1 738:1 789:1 2430:1 3148:1 3351:1 3823:1 5662:1 5663:1 5664:1  |EV| 
-1.7736495605547020204539876431227e-10  |BT| (NP (NP (JJ (Aberrant))(NN (methylation))(NN (histone))(NN (deacetylation))(NN (cyclooxygenase))(CD (2))(JJ (gastric))(NN (cancer)))) |ET|  |BS| 24:D08.811.600.720.750 36:G02.111.087.029.538 399:D12.776.660.470  |ES| 18:1 19:1 80:1 81:1 86:1 148:1 503:1 3180:1 3256:1  |EV| 
-0.00014199118064131543981432059808867  |BT| (S (NP (NP (NNP (DCA)))(, (,))(NP (NNP (TCA))(JJR (lesser))(NN (extent)))(NN (chloroform)))(VP (VBD (decreased))(SBAR (S (NP (NN (methylation)))(VP (VBD (increased))(NP (NN (mRNA))(NN (expression))(NN (c-myc))(NN (gene)))))))) |ET|  |BS| 36:G02.111.087.029.538 111:D13.444.735.544 155:G05.355.310 1196:D02.455.526.439.224 1331:C06.198.439 1332:Z01.107.084.900  |ES| 2:1 9:1 19:1 47:1 81:1 115:1 202:1 325:1 455:1 2805:1 4179:1 4180:1 4486:1 4746:1  |EV| 
-0.00020148205951488890042000434732472  |BT| (NP (NP (NNS (CONCLUSIONS))(: (:)))(S (NP (PRP$ (Our))(NN (result)))(VP (VBP (suggest))(SBAR (S (NP (NN (Raloxifene))(JJ (potent))(NN (IL-6))(: (/))(NN (GP130))(NN (inhibitor)))(VP (MD (may))(VP (VB (chemoprevention))(NP (NP (NN (agent))(NN (liver))(NN (cancer)))(VP (VBG (targeting))(NP (JJ (persistent))(NN (STAT3))(NN (signaling)))))))))))) |ET|  |BS| 69:G02.111.087.800 82:D12.644.360.024.342.300 201:D12.644.276.374.465.224 253:E02.319.162 964:D02.455.426.559.389.150.700.900.775  |ES| 18:1 19:1 22:1 101:1 104:1 195:1 239:1 251:1 380:1 491:1 616:1 658:1 728:1 796:1 836:1 870:1 3384:1 3385:1 3386:1  |EV| 
-6.6476551246474890888293884927407e-06  |BT| (S (NP (NNP (Thymoquinone)))(VP (VBZ (reduces))(SBAR (S (NP (NN (mouse))(NN (colon))(NN (tumor))(NN (cell))(NN (invasion)))(VP (VBZ (inhibits))(NP (NN (tumor))(NN (growth))(JJ (murine))(NN (colon))(NN (cancer))(NN (model)))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 41:A11 45:G07.700.320.249 51:C04.588.274.476.411.307.180 122:C14.280.383  |ES| 7:1 18:1 19:1 52:1 72:1 94:1 102:1 113:1 142:1 615:1 620:1 627:1 3087:1  |EV| 
-6.5690996287358360827823844374507e-05  |BT| (S (NP (DT (These))(NN (observation)))(VP (VBP (suggest))(SBAR (S (NP (JJR (safer))(JJ (efficacious))(NN (sulindac))(NN (derivative)))(VP (VBD (developed))(NP (NP (JJ (colorectal))(NN (cancer))(NN (chemoprevention)))(VP (VBG (targeting))(NP (NN (PDE5)))(VP (ADVP (RB (possibly)))(NP (JJ (cGMP-degrading))(NNS (isozymes))))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 251:D02.455.426.559.847.486.875 253:E02.319.162 429:N04.761.559.590.900 430:E05.581.249 993:D08.811.348 1100:D03.438.759.646.454.160 1101:N06.850.135.060.075  |ES| 17:1 18:1 19:1 190:1 616:1 792:1 796:1 869:1 870:1 1165:1 1477:1 1548:1 2813:1 3858:1 3859:1 3860:1 3861:1  |EV| 
-0.00021819627029600956961280511237078  |BT| (S (NP (VBN (Combined))(NN (lapatinib))(NN (panobinostat))(NN (treatment)))(VP (VBD (interacted))(ADVP (RB (synergistically)))(VP (VB (inhibit))(NP (NP (NN (proliferation))(NN (colony))(NN (formation))(NN (CRC))(NN (cell))(NN (line)))(VP (VBN (tested))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 94:A11.251.210 109:I01.696.116 122:C14.280.383  |ES| 19:1 43:1 94:1 245:1 264:1 299:1 314:1 546:1 741:1 1370:1 2488:1 2988:1 3347:1 3348:1 3349:1  |EV| 
-0.00010847113678230657640710887790192  |BT| (S (NP (NN (HNF4alpha))(NN (Cdx2)))(ADVP (RB (also)))(VP (VBD (exhibited))(NP (JJ (comparable))(VBN (deregulated))(NN (pattern))(JJ (human))(NN (CRC))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 175:J01.897.280.500.269  |ES| 5:1 19:1 36:1 123:1 213:1 245:1 260:1 609:1 1964:1 1965:1  |EV| 
-2.5248102040797970602170607890002e-05  |BT| (S (NP (PRP$ (Our))(NNS (data)))(VP (VBP (support))(NP (NP (NN (PGG))(JJ (multitargeting))(NN (agent))(NN (chemoprevention))(NN (therapy))(NN (prostate))(NN (cancer)))(VP (VBG (activating))(NP (NP (NN (p53))(NN (tumor))(NN (suppressor))(NN (pathway)))(VP (VBG (inhibiting))(NP (NN (STAT3))(JJ (oncogenic))(NN (signaling))))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 52:E02 69:G02.111.087.800 82:D12.644.360.024.342.300 122:C14.280.383 133:D01.248.497.158.685.750.744.600 253:E02.319.162 279:D27.888.569.100 1399:D12.776.260.820  |ES| 7:1 12:1 18:1 19:1 77:1 130:1 195:1 251:1 383:1 413:1 658:1 700:1 728:1 793:1 870:1 880:1 953:1 1364:1 1958:1 5082:1  |EV| 
-6.1734054536294455037270800801252e-05  |BT| (NP (NP (NP (JJ (Primary))(JJ (renal))(NN (neoplasm))(NN (ASPL-TFE3))(NN (gene))(NN (fusion))(JJ (alveolar))(JJ (soft))(NN (part))(NN (sarcoma)))(: (:))(S (NP (JJ (distinctive))(NN (tumor))(NN (entity)))(ADVP (RB (previously)))(VP (VBD (included))(PP (IN (among))(NP (JJ (renal))(NN (cell))(NN (carcinoma))(NN (child))))(ADVP (JJ (adolescent))))))) |ET|  |BS| 8:C04 274:C04.588.945.947.535 295:C04.557.470.200.025.390 359:G05.355.760.385 439:C04.557.450.590.775 440:M01.060.057 441:M01.060.406  |ES| 7:1 9:1 19:1 94:1 104:1 304:1 451:1 922:1 935:1 936:1 1117:1 1287:1 1372:1 1522:1 1523:1 1524:1 1525:1 1526:1 1527:1 1528:1 1529:1 1530:1  |EV| 
-4.6172669715405234569516323972493e-09  |BT| (S (S (NP (JJ (Ectopic))(NN (expression))(NN (miR-155)))(VP (VBD (promoted))(NP (NP (NP (NN (growth))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(NN (cell)))))(, (,))(IN (whereas))(S (NP (NN (depletion)))(VP (VBD (inhibited))(NP (NN (cell))(NN (growth)))))) |ET|  |BS| 41:A11 45:G07.700.320.249 104:C04.557.470.200.025.255 107:G05.355.315.202 122:C14.280.383  |ES| 2:1 10:1 14:1 19:1 94:1 102:1 115:1 303:1 304:1 305:1 365:1 372:1 441:1 1613:1 1911:1 1912:1  |EV| 
-7.2114418351048215245768790992997e-05  |BT| (NP (NP (NN (BACKGROUND)))(: (:))(S (NP (PRP (It)))(VP (VBD (suggested))(NP (NP (JJ (altered))(NN (iron))(NN (metabolism))(NN (liver))(NN (tumor)))(, (,))(NP (VBN (characterized))(JJ (iron-deficient))(NN (phenotype)))(, (,))(NP (NN (importance))(NN (tumor))(NN (growth))))))) |ET|  |BS| 8:C04 45:G07.700.320.249 80:G05.695 515:C04.588.274.623 895:D01.490.600 896:D01.268.556.412 897:Z01.252.245.500.375 898:G03.495  |ES| 2:1 7:1 19:1 102:1 104:1 236:1 693:1 836:1 925:1 985:1 1046:1 1327:1 1660:1 3162:1 3163:1 3164:1  |EV| 
-5.1554081365035031581101065967232e-05  |BT| (S (NP (NN (Detection)))(VP (VBN (methylated))(S (NP (NN (PAX5)))(VP (VBD (utilized))(NP (JJ (independent))(JJ (prognostic))(NN (factor))(NN (GC))))))) |ET|  |BS| 36:G02.111.087.029.538 243:D12.776.260.645.500  |ES| 19:1 185:1 554:1 846:1 883:1 884:1 1179:1 1180:1 1182:1  |EV| 
-0.00012522535072080100138069980175715  |BT| (NP (NP (NP (NP (JJ (Altered))(NN (expression))(JJ (human))(NN (enhancer))(NN (filamentation))(CD (1)))(PRN (-LRB- (-LRB-))(NP (NP (NN (HEF1)))(: (;))(NP (ADJP (RB (also))(VBN (known)))(NN (NEDD9))(NN (Cas-L))))(-RRB- (-RRB-))))(NP (VBN (implicated))(NN (progression))(NN (melanoma))(, (,))(NN (breast))(, (,))(NN (CRC))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 10:A01.236 16:C23.550.291.656 55:B01.050.150.900.649.801.400.112.400.400 282:C04.557.465.625.650.510  |ES| 2:1 5:1 10:1 14:1 19:1 23:1 36:1 48:1 98:1 115:1 217:1 245:1 556:1 971:1 972:1 973:1 974:1 975:1 976:1 977:1 978:1  |EV| 
-5.4319841656519374240019715216476e-06  |BT| (NP (NP (NNS (CONCLUSIONS))(: (:)))(S (NP (NN (Reduction))(NN (ING1b))(NN (gene))(NN (expression)))(VP (VBN (associated))(VP (VBD (reduced))(NP (NN (p21))(NN (bax))(NN (gene))(NN (expression))(NNS (NSCLCs))))))) |ET|  |BS| 110:C04.588.894.797.520.109.220.249 155:G05.355.310 342:D12.644.360.075.718.400  |ES| 9:1 19:1 104:1 115:1 169:1 239:1 452:1 1133:1 1134:1 1135:1 1136:1 1137:1  |EV| 
-9.5540027826654036480213960658148e-05  |BT| (S (PP (IN (In))(NP (NN (line))(NN (observation))))(, (,))(NP (JJR (lower))(NN (serum))(NN (level))(JJ (active))(NN (Caspase-3)))(VP (VBD (found))(SBAR (S (NP (NN (patient))(JJ (metastasised))(NN (CRC)))(VP (VBD (revealed))(NP (NP (JJ (stable))(NN (disease))(NN (tumour))(NN (regression)))(VBN (compared))(NN (disease))(NN (progression)))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 16:C23.550.291.656 50:M01.643 288:C23.550.288 429:N04.761.559.590.900 430:E05.581.249 782:A12.207.152.846 846:F01.393.784 906:D08.811.277.656.262.500.126.350.300  |ES| 2:1 19:1 37:1 48:1 50:1 117:1 120:1 197:1 244:1 245:1 249:1 264:1 275:1 360:1 998:1 1011:1 1477:1 2741:1 3002:1 3190:1 3191:1  |EV| 
-6.4904329740572697104994404071476e-12  |BT| (NP (NP (NNS (RESULTS))(: (:)))(S (NP (NN (MDR1))(NNS (GCS)))(ADVP (RB (coincidently)))(VP (VBN (overexpressed))(NP (NP (JJ (drug-resistant))(NN (breast)))(, (,))(NP (NN (ovary)))(, (,))(NP (JJ (cervical))(NN (colon))(NN (cancer))(NN (cell))))))(FRAG (: (;))(NP (NP (NN (silencing))(NNS (GCS)))(VP (VBG (using))(NP (NP (NP (JJ (novel))(NN (mixed-backbone))(NN (oligonucleotide)))(PRN (-LRB- (-LRB-))(NP (NN (MBO-asGCS)))(-RRB- (-RRB-))))(VP (VBN (sensitized))(NP (CD (four))(JJ (drug-resistant))(NN (cell))(NN (line))(NN (doxorubicin))))))))) |ET|  |BS| 10:A01.236 41:A11 67:D26 94:A11.251.210 136:D02.455.426.559.847.562.050.200.175 259:D12.776.395.240.150.500 575:V02.050 1369:A05.360.319.114.630 1411:D13.695.578.424 1412:A02.835.232.834 1413:A01.598  |ES| 2:1 10:1 14:1 18:1 19:1 23:1 25:1 94:1 100:1 104:1 113:1 217:1 264:1 350:1 453:1 598:1 599:1 710:1 891:1 3247:1 4188:1 4697:1 4761:1 5135:1 5136:1 5137:1 5138:1 5139:1  |EV| 
-0.00015026713394806785056845299664019  |BT| (S (NP (DT (This)))(VP (VBZ (indicates))(SBAR (S (S (NP (JJ (low))(NN (level))(JJ (active))(NN (Caspase-3)))(VP (MD (may))(VP (VB (represent))(S (NP (NP (JJ (new))(NN (predictor))(NN (CT))(NN (responsiveness)))(, (,))(NP (NN (inhibition))(NN (Caspase-3)))(, (,)))(VP (VBG (antagonising))(NP (JJ (downstream))(NN (effector))(NN (Caspase-3))(NN (paracrine))(NN (signalling))))))))(, (,))(NP (NN (COX-2)))(VP (MD (may))(VP (VB (improve))(NP (NP (NN (patient))(NN (outcome)))(VP (VBG (following))(SBAR (S (NP (NNP (CT)))(VP (VBD (advanced))(NP (NN (CRC)))))))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 50:M01.643 906:D08.811.277.656.262.500.126.350.300 1102:Z01.058.290.100.120 1103:G04.299.122.600  |ES| 2:1 19:1 76:1 103:1 120:1 197:1 245:1 249:1 491:1 531:1 547:1 560:1 570:1 628:1 712:1 799:1 807:1 997:1 2437:1 2466:1 3190:1 3510:1 3862:1 3863:1 3864:1 3865:1 3866:1  |EV| 
-8.7797709504060239549261268621194e-05  |BT| (S (NP (NN (Salinomycin)))(VP (VBZ (induces))(NP (NN (cell))(NN (death)))(PP (IN (via))(NP (NN (inactivation))(NN (Stat3))(NN (downregulation))(NN (Skp2)))))) |ET|  |BS| 82:D12.644.360.024.342.300 85:G02.111.087.225 134:G04.299.139 507:D12.776.157.743  |ES| 19:1 94:1 214:1 411:1 595:1 596:1 1314:1 1785:1 2646:1 5153:1  |EV| 
-0.00022645150395395052811409186688252  |BT| (NP (NP (NP (VBN (Reduced))(NN (expression))(NN (cyclooxygenase))(CD (2))(NN (protein))(JJ (hereditary))(JJ (nonpolyposis))(JJ (colorectal))(NN (cancer)))(JJ (relative))(JJ (sporadic))(NN (cancer)))) |ET|  |BS| 7:D12.776 24:D08.811.600.720.750 524:C04.588.274.476.411.307.190  |ES| 4:1 17:1 18:1 19:1 115:1 148:1 725:1 1531:1 1845:1 1846:1 3180:1 3734:1  |EV| 
-1.5159504992597050421210269632866e-06  |BT| (S (NP (NP (DT (The))(JJ (present))(NN (study)))(VP (VBN (undertaken))))(VBP (investigate))(NP (NP (NN (effect))(JJ (dietary))(NN (supplementation))(NN (nimesulide))(NN (eugenol))(NN (N-nitrosodiethylamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-))))(: (-))(VP (VBN (initiated))(NP (JJ (early))(NN (hepatocarcinogenesis))(NN (F344))(JJ (male))(NN (rat))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 554:D02.654.442.200 590:B01.050.050.199.520.760.200 595:G07.203.650.240 1165:D02.241.223.200.054.500  |ES| 10:1 14:1 19:1 75:1 131:1 459:1 691:1 849:1 900:1 1128:1 1307:1 1402:1 1875:1 2567:1 2594:1 2602:1 3185:1 3186:1 4022:1 4023:1 4024:1  |EV| 
-3.750480997258276438799384777667e-05  |BT| (NP (NP (DT (The))(NN (correlation))(NN (body))(NN (growth))(JJ (diethylnitrosamine-induced))(NN (hepatocarcinogenesis))(NN (relation))(NN (serum))(NN (insulin))(NN (somatomedin-C)))) |ET|  |BS| 45:G07.700.320.249 554:D02.654.442.200 598:D12.644.276.937.400 637:D06.472.699.587.200.500.625 782:A12.207.152.846 1246:I01.076.201.450.560  |ES| 19:1 102:1 691:1 900:1 1678:1 2364:1 2398:1 2732:1 2741:1 3544:1 4378:1  |EV| 
-5.301586574985028832429634348955e-05  |BT| (SINV (PP (IN (In))(NP (NN (study))))(, (,))(VBD (evaluated))(FRAG (NP (NN (susceptibility))(NNP (Vparp)))(: (-))(: (/))(: (-))(NP (NN (Tep1))(: (-))(: (/))(: (-))(NN (mouse))(JJ (dimethylhydrazine-induced))(NN (colon))(NN (tumorigenesis))(JJ (urethane-induced))(NN (lung))(NN (tumorigenesis))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 182:A04.411 225:E05.337 401:C23.550.291.687 1214:D02.241.081.251.944  |ES| 2:1 19:1 52:1 78:1 113:1 131:1 244:1 328:1 780:1 1353:1 4250:1 4251:1 4252:1 4253:1  |EV| 
-1.6427428172594016331231614458375e-05  |BT| (FRAG (SBAR (IN (Although))(S (NP (NN (CTCF)))(VP (VBD (described))(NP (NP (NP (ADJP (RB (significantly))(VBN (mutated)))(NN (gene))(JJ (endometrial))(NN (cancer))(NN (TCGA)))(, (,))(NP (NN (A))(-LRB- (-LRB-))(CD (7))(-RRB- (-RRB-))(NN (track))))(SBAR (S (NP (JJ (variant))(VBG (leading))(NN (T204))(NNS (frameshifts)))(VP (VBD (reported)))))))))) |ET|  |BS| 6:G05.360.340.024.340 86:D01.268.556.435 286:C04.588.945.418.948.585 287:G05.365.590.265  |ES| 2:1 9:1 10:1 14:1 18:1 19:1 69:1 107:1 124:1 229:1 276:1 634:1 639:1 986:1 987:1 988:1 989:1 990:1 991:1 992:1 993:1  |EV| 
-5.1573202927701622400036285398528e-06  |BT| (S (PP (IN (By))(NP (JJ (immunohistochemical))(NN (analysis))))(, (,))(NP (CD (20))(CD (38))(NN (case))(JJ (undifferentiated))(NN (type)))(VP (VBD (advanced))(NP (NP (NN (stomach))(NN (cancer))(NN (K-sam)))(JJ (positive)))(, (,))(PP (IN (whereas))(NP (NP (NN (none))(CD (11))(NN (case)))(SBAR (S (NP (VBN (differentiated))(JJ (intestinal))(NN (type)))(VP (VBD (revealed))(NP (NN (K-sam))(NN (staining)))))))))) |ET|  |BS| 47:A03.556.124 74:G04.299.151 232:D02.886.030.676.180  |ES| 2:1 18:1 19:1 109:1 233:1 275:1 372:1 543:1 661:1 782:1 801:1 803:1 804:1 934:1 997:1 1057:1 1167:1 1605:1 1868:1 1869:1 1870:1 1871:1  |EV| 
-8.959677538671441746065404743149e-06  |BT| (NP (NP (JJ (Seleno-cyclodextrin))(NNS (sensitises))(JJ (human))(NN (breast))(NN (cancer))(NN (cell))(JJ (TRAIL-induced))(NN (apoptosis))(NN (DR5))(NN (induction))(NN (NF-kappaB))(NN (suppression)))) |ET|  |BS| 39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 210:D12.776.260.600 1072:D04.345.103  |ES| 18:1 19:1 23:1 36:1 89:1 94:1 714:1 736:1 2453:1 3682:1 3753:1 3754:1 3755:1  |EV| 
-8.1545801793383998479214369581314e-06  |BT| (S (NP (NN (Survivin))(NN (overexpression)))(VP (VBN (associated))(NP (NP (JJ (poor))(NN (prognosis))(JJ (human))(JJ (gastric))(NN (cancer)))(, (,))(NP (NN (target))(JJ (gastric))(NN (cancer))(NN (therapy)))))) |ET|  |BS| 52:E02 55:B01.050.150.900.649.801.400.112.400.400 159:I01.880.735.634 163:E01.789  |ES| 2:1 18:1 19:1 36:1 86:1 130:1 152:1 160:1 169:1 544:1 545:1 3779:1  |EV| 
-1.3660727680713565922870911251152e-05  |BT| (FRAG (NP (NP (NP (NN (PhIP))(NN (diet)))(NP (ADJP (JJR (>))(ADJP (CD (43))(NN (week))))(NP (JJ (present))(NN (colon))(NN (tumor))(JJ (specific))(CD (-1))(NN (G))(NN (mutation)))))(PP (IN (within))(NP (QP (CD (5))('' (')))(: (-))(NN (GGGA-3))('' ('))(NN (sequence))(NN (APC))))(: (:)))(NP (NN (gene)))) |ET|  |BS| 3:C04.557.470.035.215.100 6:G05.360.340.024.340 18:G05.365.590 26:G02.111.570.080 51:C04.588.274.476.411.307.180 595:G07.203.650.240 596:E02.642.249  |ES| 7:1 9:1 11:1 19:1 34:1 104:1 113:1 293:1 540:1 783:1 1307:1 1466:1 1489:1 2122:1 2191:1 2641:1 5501:1 5502:1 5503:1  |EV| 
-2.9049386033885155056211146984424e-05  |BT| (PP (DT (These))(S (VP (VBG (finding))(S (VP (VBP (suggest))(SBAR (S (NP (NN (sulindac)))(VP (MD (may))(NP (NP (JJ (effective))(NN (agent))(NN (colon))(NN (cancer))(NN (prevention)))(NP (JJ (human))(JJ (low))(NN (15-PGDH)))))))))(, (,))(S (NP (NN (use)))(MD (may))(ADVP (RB (also)))(VP (VBN (associated))(NP (JJ (inflammatory))(NN (lesion))(NN (colon)))))))) |ET|  |BS| 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 251:D02.455.426.559.847.486.875  |ES| 2:1 5:1 18:1 19:1 36:1 113:1 133:1 169:1 491:1 531:1 728:1 792:1 796:1 869:1 927:1 1131:1 1474:1 1639:1 1659:1 2430:1  |EV| 
-0.00021253130176064616296827125552227  |BT| (SINV (S (VP (VBN (Taken))(ADVP (RB (together)))))(, (,))(S (VP (VBG (finding))(VP (VBP (demonstrate))(SBAR (S (NP (NN (pectolinarigenin)))(VP (MD (may))(NP (NP (NN (candidate))(NN (osteosarcoma))(NN (intervention)))(VP (VBN (linked))(NP (NP (NN (STAT3)))(NN (signaling))(JJ (inhibitory))(NN (activity)))))))))))) |ET|  |BS| 69:G02.111.087.800 82:D12.644.360.024.342.300 447:C04.557.450.565.575.650  |ES| 2:1 19:1 106:1 195:1 251:1 399:1 491:1 502:1 927:1 1243:1 1363:1 1537:1 1538:1 1562:1 2429:1 2785:1  |EV| 
-3.9561260714846002706224226130871e-05  |BT| (S (NP (JJ (Epidemiological))(NN (study)))(VP (VBP (indicate))(NP (JJ (adequate))(JJ (dietary))(NN (folate))(JJ (protective))(NN (colon))(NN (cancer)))(, (,))(SBAR (IN (although))(S (NP (NN (mechanism)))(VP (VBP (remain))(ADJP (RB (largely))(JJ (elusive)))))))) |ET|  |BS| 224:D03.438.733.631.400 595:G07.203.650.240 722:E05.318.760.500  |ES| 2:1 18:1 19:1 113:1 131:1 162:1 493:1 777:1 778:1 1479:1 1592:1 2181:1 2384:1 2593:1 2594:1 2595:1  |EV| 
-2.086733563722020790009992197156e-13  |BT| (S (PP (IN (Through))(NP (NN (combination))(NNS (data))(NN (mining))(JJ (biochemical))(NN (assay))))(, (,))(VP (VBD (identified))(NP (NP (NN (trophinin)))(, (,))(VP (MD (could))(VP (VB (enhance))(NP (NP (NN (cell))(NN (invasion)))(, (,))(NP (NP (JJ (novel))(JJ (prognostic))(NN (factor)))(JJ (early))(NN (stage))(NN (lung))(NN (cancer))))))))) |ET|  |BS| 41:A11 106:E05.091 182:A04.411 259:D12.776.395.240.150.500 472:L01.313.500.750.280.199 473:E01.789.625  |ES| 2:1 18:1 19:1 94:1 185:1 310:1 328:1 530:1 620:1 623:1 793:1 884:1 891:1 908:1 1128:1 1129:1 1266:1 1687:1 1688:1 1689:1 1690:1  |EV| 
-2.1262318662444712469294927359442e-05  |BT| (NP (NP (NNS (CONCLUSIONS))(: (:)))(S (NP (DT (The))(CD (two))(NN (library)))(ADVP (RB (differentially)))(VP (VBD (expressed))(SBAR (S (NP (NN (gene)))(VP (MD (may))(VP (VB (provide))(NP (NN (basis))(JJ (new))(NN (insight))(NN (clue))(NN (finding))(JJ (novel))(NN (lung))(JJ (cancer-related))(NN (gene)))))))))(: (;))(S (NP (JJ (several))(NN (gene)))(ADVP (RB (newly)))(VP (VBD (found))(NP (NP (NN (lung))(NN (cancer))(NN (ERGIC3)))(VP (VBG (seeming))(NP (JJ (novel))(NN (lung))(JJ (cancer-related))(NN (gene)))))))) |ET|  |BS| 9:G05.360.340.024.340.375.500 182:A04.411 259:D12.776.395.240.150.500 275:C23.888 343:G05.360.325 344:M01.438  |ES| 6:1 9:1 18:1 19:1 37:1 104:1 217:1 239:1 262:1 328:1 491:1 691:1 711:1 712:1 891:1 927:1 933:1 1138:1 1139:1 1140:1 1141:1 1142:1 1143:1 1144:1 1145:1 1146:1  |EV| 
-1.8497174364472211000043344597543e-06  |BT| (S (NP (NN (DNA))(NN (methylation))(NN (alteration)))(VP (VBD (detected))(SBAR (S (NP (NN (zebrafish))(NN (liver))(NN (tumor)))(VP (VBD (induced))(NP (NP (JJ (environmental))(NN (carcinogen))(CD (7)))(, (,))(NP (JJ (12-dimethylbenz))(-LRB- (-LRB-))(-RRB- (-RRB-))(NN (anthracene))))))))) |ET|  |BS| 366:G02.111.087.029.538.161 515:C04.588.274.623 572:B01.050.150.900.493.200.244.828 977:D27.888.569.100.125  |ES| 2:1 7:1 10:1 14:1 19:1 81:1 412:1 666:1 836:1 951:1 988:1 1007:1 2017:1 2125:1 3446:1 3447:1 3448:1  |EV| 
-1.7788512411798240719917885144241e-05  |BT| (S (NP (NN (Induction))(NN (SPARC)))(VP (VBD (demonstrated))(NP (NN (treatment))(JJ (demethylating))(NN (agent))(NN (5Aza-dC))(CD (5))(CD (7))(NN (cell))(NN (line))))) |ET|  |BS| 37:D12.776.157.125.715 94:A11.251.210 775:E02.760.058  |ES| 19:1 82:1 94:1 264:1 546:1 578:1 728:1 988:1 1175:1 2020:1 5446:1 5447:1  |EV| 
-7.5712280704529630673271789476075e-05  |BT| (S (NP (PRP (It)))(VP (VBD (suggested))(SBAR (S (NP (NN (ING5))(NN (expression)))(VP (MD (might))(VP (VP (VBN (employed))(S (NP (JJ (good))(NN (marker))(JJ (gastric))(NN (carcinogenesis))(JJ (subsequent))(NN (progression)))(VP (VBG (inhibiting))(NP (NN (proliferation))))))(, (,))(NP (NP (NN (growth)))(, (,))(NP (NN (migration)))(, (,))(NP (NN (invasion))(NN (metastasis)))))))))) |ET|  |BS| 16:C23.550.291.656 33:C04.697.098 45:G07.700.320.249 70:A03.556.875.875 113:C04.697.650 122:C14.280.383 158:D23.101  |ES| 2:1 19:1 48:1 86:1 102:1 115:1 207:1 299:1 514:1 534:1 620:1 798:1 806:1 880:1 925:1 1316:1 1318:1 1319:1 1327:1 1342:1  |EV| 
-9.7134444787936105591974467188265e-05  |BT| (NP (NP (NP (NN (Targeting))(NN (cyclooxygenase-2))(JJ (epidermal))(NN (growth))(NN (factor))(NN (receptor))(NN (prevention))(NN (treatment)))(JJ (intestinal))(NP (NN (cancer))))) |ET|  |BS| 24:D08.811.600.720.750 52:E02 64:D08.811.913.696.620.682.725.400.009.300 101:C04.588.274.476.411  |ES| 18:1 19:1 61:1 102:1 109:1 184:1 185:1 186:1 546:1 1474:1 2100:1  |EV| 
-9.9683818144402636107770376838744e-10  |BT| (S (S (VP (VBN (Taken))(ADVP (RB (together)))))(, (,))(VP (VBP (provide))(SBAR (S (NP (NP (NN (evidence))(NN (plant))(NN (flavonoid))(NN (fisetin)))(VP (VBP (induce))(NP (NN (apoptosis)))))(VP (VBP (suppress))(NP (NP (NN (growth))(NN (colon))(NN (cancer))(NN (cell))(NN (inhibition))(NN (COX2)))(: (-))(NP (NN (Wnt/EGFR/NF-kappaB-signaling))(NN (pathway))))))))) |ET|  |BS| 38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 41:A11 43:F01.145.544 45:G07.700.320.249 147:G02.149.115.800.925 210:D12.776.260.600 328:B01.650 534:D03.383.663.283.266.450  |ES| 2:1 18:1 19:1 38:1 89:1 94:1 102:1 103:1 113:1 243:1 383:1 711:1 1098:1 1537:1 1538:1 1886:1 2441:1 2978:1 2979:1 2980:1  |EV| 
-6.4899369444911068210979365744606e-07  |BT| (S (NP (NP (NP (NN (Overexpression))(NN (progastrin)))(, (,))(NP (JJ (nonamidated))(ADJP (RB (incompletely))(VBN (processed)))(NN (product))(NN (gastrin))(NN (gene)))(, (,)))(VP (VBN (shown))(VP (VBP (induce))(NP (JJ (colonic))(NN (hyperproliferation))))))(VP (VBP (promote))(NP (NP (JJ (colorectal))(NN (cancer))(NN (mouse)))(, (,))(NP (NP (NN (mechanism))(NN (pathogenesis)))(VP (VBN (defined))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 199:D06.472.317.413 200:D06.472.317.413  |ES| 2:1 9:1 17:1 18:1 19:1 52:1 162:1 237:1 243:1 501:1 668:1 671:1 672:1 673:1 674:1 675:1 676:1 677:1 678:1 679:1 680:1  |EV| 
-6.1675650558923322819282475393265e-09  |BT| (S (NP (PRP$ (Our))(NN (finding)))(VP (VBP (suggest))(SBAR (S (NP (NN (JNK/PTEN))(NN (NF-kappaB/PTEN))(NN (pathway)))(VP (VBP (play))(NP (JJ (critical))(NP (NN (role))(JJ (normal))(NP (JJ (intestinal))(NN (homeostasis))(NN (colon))(NN (carcinogenesis)))))))))) |ET|  |BS| 15:F01.829.316.616 33:C04.697.098 46:A03.556.124.526.356 47:A03.556.124 79:I03.450.642.693 152:G07.700.345 210:D12.776.260.600  |ES| 19:1 31:1 109:1 113:1 118:1 207:1 238:1 383:1 500:1 658:1 796:1 825:1 927:1 2145:1 2146:1  |EV| 
-1.0423530094616495489390217699111e-11  |BT| (NP (NP (JJ (EXPERIMENTAL))(NN (DESIGN)))(: (:))(S (PP (IN (In))(NP (JJ (present))(NN (study))))(, (,))(VP (VBD (investigated))(NP (NP (NP (NN (effect))(JJ (novel))(NN (farnesyltransferase))(NN (inhibitor)))(, (,))(NP (NN (ABT-100)))(, (,))(NP (JJ (human))(NN (liver))(NN (cancer))(NN (cell))(NN (line))))(, (,))(NP (NN (HepG2))(NN (Huh7)))(, (,))(NP (NN (animal))(NN (model))(NN (hepatocarcinogenesis))))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 204:E05.581.500 205:E05.581.500 259:D12.776.395.240.150.500 285:E05.598 988:D08.811.913.225.431 989:D08.811.913.225.437 990:C22.232  |ES| 2:1 18:1 19:1 36:1 46:1 72:1 75:1 94:1 104:1 131:1 244:1 264:1 380:1 403:1 689:1 690:1 836:1 891:1 900:1 1307:1 2538:1 3480:1 3481:1 3482:1  |EV| 
-3.2402703575851177220101817511022e-09  |BT| (S (S (NP (NN (Overexpression))(NN (NF-kappaB))(NN (superrepressor)))(VP (VBD (increased))(NP (NN (PTEN))(NN (expression))(NN (JNK))(NN (activity)))))(, (,))(IN (whereas))(S (NP (NN (overexpression))(NN (p65))(NN (NF-kappaB))(NN (subunit)))(VP (VBD (reduced))(NP (JJ (basal))(JJ (NaBT-mediated))(NN (JNK))(NN (activation))(NN (PTEN))(NN (expression)))))) |ET|  |BS| 210:D12.776.260.600 583:D12.776.813  |ES| 2:1 19:1 47:1 115:1 152:1 225:1 372:1 399:1 452:1 668:1 714:1 1936:1 2110:1 4184:1 4276:1 5016:1 5092:1 5093:1  |EV| 
-1.6862878219475740948496422788594e-07  |BT| (S (NP (NP (NN (Overexpression))(NN (cyclooxygenase))(CD (2)))(PRN (-LRB- (-LRB-))(NP (NN (COX-2)))(-RRB- (-RRB-))))(ADVP (RB (frequently)))(VP (VBD (found))(NP (JJ (early))(JJ (advanced))(NN (lung))(NN (cancer))))) |ET|  |BS| 24:D08.811.600.720.750  |ES| 10:1 14:1 18:1 19:1 37:1 76:1 148:1 328:1 668:1 698:1 997:1 1128:1 3180:1  |EV| 
-1.15375808272506026261328138105e-06  |BT| (NP (NP (NNP (UNLABELLED)))(: (:))(NP (NP (NP (NN (Loss))(NN (E-cadherin)))(PRN (-LRB- (-LRB-))(NP (NN (CDH1)))(-RRB- (-RRB-))))(, (,))(NP (NN (Smad4)))(, (,))(NP (NP (NN (p53))(VBN (shown))(NN (play))(JJ (integral))(NN (role)))(ADJP (JJ (gastric))))(, (,))(NP (JJ (intestinal))(, (,))(NN (breast))(NN (cancer))(NN (formation))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 12:Z01.542.049 15:F01.829.316.616 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 70:A03.556.875.875 79:I03.450.642.693 613:D12.776.395.550.200.200  |ES| 2:1 10:1 12:1 14:1 18:1 19:1 23:1 31:1 43:1 86:1 104:1 109:1 237:1 238:1 521:1 1788:1 2266:1 2267:1 2268:1 2269:1  |EV| 
